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THE IMPACT OF INFLAMMATORY AND IMMUNE RESPONSE-RELATED 
GENETIC VARIANTS ON PROSTATE CANCER RISK AMONG MEN OF 
AFRICAN DESCENT 
Dominique Zilpha Jones 
October 16, 2014 
Background: In the U.S., prostate cancer (PCA) metastasis is associated with a 5-yr 
survival rate of 29% and disproportionately affects men of African descent. Single 
nucleotide polymorphisms (SNPs) may serve as genetic markers to identify individuals at 
high risk of developing PCA.  
Methods: We examined main and joint effects of 119 inflammatory and immune 
response-associated SNPs among men of African descent (535 controls, 279 cases) via 
logistic regression (LR) and entropy-based-multi-factor dimensionality reduction (MDR) 
modeling. 
Results: MDR  yielded highly synergistic [(TLR10, TLR6 and IRF3), (TLR2, IRAK4), 
(IL1R2, IL10, IL10RA)] interaction models as the best predictors of PCA risk based upon 
informative information gain scores (p ≤ 0.003). Interestingly, CCL5 [rs2107538 (AA, 
GA+AA), rs3817655 (GA, AA)] SNPs were strongly associated with a 43-56% decrease 
in PCA risk. 
Conclusion: CCL5 (rs2107538 ,rs3817655) reduces PCA risk by > 50% and may serve 
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    INTRODUCTION 
Prostate cancer as a public health problem 
Prostate cancer (PCA) is a slow growing disease and one of the leading causes of 
cancer-related deaths among men in the U.S. and Caribbean (e.g., Jamaica). In the U.S., 1 
in 6 men will develop prostate cancer in their lifetime [1]. When the disease is detected at 
early and treatable stages, there is a 100% 5-year survival rate among U.S. men 
diagnosed with localized or regional disease [2]. However, the five-year survival rates 
drop drastically to 29% among U.S. men diagnosed with metastatic PCA. Among 
prostate cancer patients with metastatic disease, 90% and 65% of the cancer spreads to 
the bone and liver, respectively [3]. Metastatic PCA is aggressive and becomes non-
responsive to conventional treatments such as hormornal therapy [4, 5]. Among PCA 
patients who undergo a radical prostectomy, 20-40% of them will experience recurrent 
disease [6, 7]. Although, the 5-year survival rates for regional or distant prostate cancer 
among Jamaican men is unknown, the 74% five-year biochemical recurrence disease free 
survival rate for Jamaican men with clinically organ-confined prostate cancer (tumor 
stage 1-2) is comparable to rates found among African-American men [8]. In addition to 
poor disease prognosis attributed to detection of the disease at later stages and delays in 




expenditure for prostate cancer care was approximately $11.9 billion [9], according to the 
2010 U.S. National Cancer Institute (NCI) Cancer Trends Progress Report.  After 
diagnosis, the average medical cost for U.S. patients was $48,808, which included a 
direct cost of $29,417 for prostate cancer related procedures. Medical expenses for PCA 
patients with Medicare insurance were slightly lower than patients on other types of 
insurance within the U.S. Over a 4-year follow-up period, the average medical cost was 
$18,168 per prostate cancer patient on Medicare [10]. According to the PharMetrics 
database, patients who experienced watchful waiting care incurred a cost of $7,595; 
whereas, those who underwent treatment had a direct cost of $38,745[11, 12]. In 
particular, treatment options for prostate cancer patients 40 years or older between years 
2000 and 2005 incurred the following cost: $17,753 for chemotherapy, $29,984 for 
hormone therapy, $31,666 for surgery, and $42,554 for radiation therapy [11, 12].    
Determinants of Prostate Cancer 
 Although the pathogenesis of prostate cancer requires further elucidation, there 
are a number of established and plausible PCA risk factors. Established risk factors for 
prostate tumorigenesis, include age, family history of prostate cancer and race [1, 13].  
Naturally, as men become older their risk for PCA increases as well.  Race is a major 
determinant of prostate cancer as detailed in the “Prostate Cancer Health Disparities” 
section below. 
Plausible risk factors include: hormonal imbalances (e.g., androgen, testosterone); 
a sedentary lifestyle (e.g., obesity); environmental exposures (e.g., intake of red meat, 
high-fat dairy products, polyunsaturated fats); exposure to meats-derived carcinogens 
detected in meats prepared well done via grilling or pan-frying [14-18]; the inheritance of 




receptor, cytokine, chemokine); chronic inflammation [14, 19, 20]. In terms of chronic 
inflammation, it is estimated that approximately 20% of all human cancers, including 
prostate cancer (PCA), are associated with chronic inflammation [1, 21, 22].  In fact, 
epidemiological studies revealed a higher prostate cancer susceptibility among patients 
with a history of prostatic inflammation compared to those without a history [23, 24]. 
 Chronic inflammation is known to contribute to the various disease states leading 
to prostate cancer, including prostatic inflammation, proliferative inflammatory atrophy 
and prostatic intraepithelial neoplasia, as depicted in Figure 2. Prostatic inflammation 
may occur as the result of infection by microbial pathogens, chemical irritation caused by 
urine reflux, hormone imbalance, diet or environmental exposures, genetic alterations, 
age and autoimmunity.  
Prostatic inflammation is separated into four categories: (1) acute bacterial 
prostatitis; (2) chronic bacterial prostatitis; (3) chronic pelvic pain syndrome; and (4) 
asymptomatic inflammatory prostatitis [14]. Both acute and chronic bacterial prostatitis 
are caused by a bacterial infection of the prostate from Escherichia coli, Enterococcus 
spp. (species) or sexually transmitted infections (STIs). Symptoms of bacterial prostatitis 
include an increase in urination, pain in the genital area, fever, chills, and burning during 
urination [25]. Although, the cause of chronic pelvic pain syndrome is unknown, it is 
categorized as either non-inflammatory or inflammatory based on the absence or 
presence of white blood cells in prostatic fluid [26]. Asymptomatic inflammatory 












Figure 1. Progression of prostatic inflammation to prostate cancer. Chronic 
inflammation of the prostate may result from bacterial infection, age, hormonal 
imbalance, genetic alterations or environmental exposures (e.g., carcinogenic agents, 
diet). During inflammation, immune cells (e.g., mast cells, macrophages) travel to the 
site of inflammation and secrete cytokines and chemokines to recruit more immune cells. 
The accumulation of immune cells may lead to the formation of PIA lesions. PIA lesions 
may transition into PIN, which is characterized by epithelial cells with large nucleoli. 
High grade PIN occurs in 20-30% of prostate cancer and is regarded as a possible 





Prostate Cancer Health Disparities 
Men of African descent suffer disproportionately from PCA. African-American 
and Caribbean men have the highest prostate cancer incidence and mortality rates 
compared to their Caucasian counterparts [1, 8]. African-American men are 1.6 times 
more likely to receive a prostate cancer diagnosis and 2.4 times more likely to succumb 
to this disease than their European-American counterparts [27]. Similarly, Jamaican men 
have a high incidence rate of prostate cancer in comparison to European-American men 
[1, 13, 27, 28]. In a prostate cancer survey with more than 3,000 men on the island of 
Tobago in the Caribbean (i.e., ~60% of male population), the prevalence of prostate 
cancer among men over 59 years of age was 3 times higher than European-American men 
[29]. In a recent report on global patterns of prostate cancer, Rebbeck and co-workers 
(2013) observed that African-Americans had the highest incidence rate according to the 
age-standardized estimates for prostate cancer compared to Caribbean and African men 
[30]. However, the higher PCA mortality rates observed among Caribbean men relative 
to African-American men may be partially attributed to limited access to early PCA 
detection screening protocols as well as availability of medical care and treatment. 
Likewise, men from African countries such as South Africa and Senegal had the largest 
percentage of cancer with stage T3/T4 tumors, due to limited access to healthcare and 
treatment [30, 31]. Due to the limited availability of cancer statistics for African and 
Caribbean countries and misclassification of racial/ethnic background, some studies may 
not accurately depict the PCA incidence and mortality rates among men of African and 




 Differences in prostate cancer screening behavior, family history, access to health 
care, and cancer treatment regimens cannot fully explain the tumor burden that men of 
African descent suffer. Some studies speculate biological differences may help to explain 
the higher PCA incidence among African-American men relative to European 
Americans.  In a retrospective study, Eastham and colleagues (1998) observed that 
African-American men had significantly higher levels of serum PSA (p-value = 0.00003), 
PSA densities (p-value = 0.000009) and inflammation in the prostate than European-
American men [32]. Additionally, Winters and co-workers (1998) speculated higher 
levels of total testosterone and sex hormone binding globulin (SHBG) among young 
African-American men may predispose them to a higher risk of developing PCA than 
their Caucasian counter parts [33].  This increased risk may be attributed to enhanced 
cellular division in the prostate epithelium [33].  Moreover, increased apoptotic blockage 
via Bcl-2 expression, coupled with enhanced cellular proliferation may contribute to 
increased tumor volume and burden among African-American men relative to 
Caucasians.  In fact, deVere and colleagues (1998) showed a significant relationship 
between Bcl-2 immunopositivity and high proliferation among African American 
paraffin-embedded prostatic tumor tissue (p-value= 0.012)  but not European-Americans 
[34].  
 Our lab and other researchers have speculated that prostate cancer health 
disparities may be partially attributed to dysregulation within important biological 
pathways involved in inflammatory and immune response signaling [35-40]. The 
inflammatory and immune-response signaling pathway is triggered by the detection of 




Consequentially, production of cytokines and chemokines from immune cells via TLRs 
occur to recruit more immune cells to the site of infection or tissue damage.  In fact, 
Wallace and colleagues (2008) observed significant differences in the mRNA expression 
of chemokine-related genes in prostate tumor of African- and European-American men 
compared to surrounding non-tumor prostate tissue [41].  For instance, the mRNA 
expression of CXCR4, CCR7, and CCL5 were higher in prostate tumors collected from 
African-Americans compared to European-American men. Moreover, Reams and 
associates (2009) showed the gene expressions of CXCL2 and IRF4 were statistically 
under-expressed by 4-fold in African-American prostate tumor tissue compared to 
European-American tumors normalized to snap frozen non-tumor matched controls (p-
value ≤ 0.05) [42]. The differences shown in gene expression profiles between African- 
and European-American men may lead to an explanation for the PCA health disparity 
observed among men of African descent.  
Role of Inflammation and immune response in prostate cancer  
 Prostate tumorigenesis is largely driven by recurrent acute or chronic 
inflammation. During acute/chronic inflammation, inflammatory cells (e.g., mast cells, 
polymorphonuclear leukocytes, macrophages) produce pro- and anti-inflammatory 
cytokines and chemokines to launch an inflammatory response to repair tissue injury, 
remove pathogens and fight against infectious agents or foreign cells. Chemokines, 
function as chemoattractants that send signals to prostate cancer cells to migrate and 
metastasize to other organs in the body. In particular, the inflammatory response driven 
by recurrent acute or chronic inflammation can target malignant or tumor cells as 




regulation of pro- and anti-inflammatory signals. This imbalance may favor pro-
inflammatory signaling to trigger chronic inflammation of the prostate and ultimately 
lead to PCA development [43]. 
 Acute inflammation is the immediate response of the immune system triggered by 
the movement of plasma and leukocytes from blood to the site of inflammation to help 
clear pathogens in the body, as depicted in Figure 2a. Second, chronic inflammation is a 
state of prolonged inflammation where active inflammation, tissue injury and repair occur 
simultaneously, as depicted in Figure 2b. Following exposure to viral or chemical insults 
to normal prostate epithelium, viral or chemical carcinogens may induce somatic changes 
in normal prostate cells that introduce genomic alterations such as deletions mutations, 
and rearrangements of oncogenes and tumor suppressor genes. In response to these DNA 
changes, cellular death and repair mechanisms are initiated to fix damaged cells in DNA 
replication and cellular proliferation. These damaged cells may produce cytokines and 
chemokines to recruit inflammatory cells for their destruction leading to the onset of 
acute inflammation. Inflammatory cells serve as the frontline of defense for the immune 
system during inflammation and the release of factors (e.g.,VEGF) that enhance the 
angiogenic phenotype of tumors. During acute inflammation, inflammatory cells such as 
tumor associated macrophages (TAMs) release reactive oxygen and nitrogen species that 
induce oxidative DNA damage. Additionally, mast cells, neutrophils and leukocytes 
release cytokines and chemokines to recruit more inflammatory cells to the inflamed 
prostatic tissue (Figure 2a). In some cells, the damage may exceed the capacity of the 
cellular repair mechanism and these cells transition into permanently damaged cells with 




Tumor cells also produce cytokines and chemokines that attract inflammatory cells to 
their location. Inflammatory cells attempt to infiltrate inflamed prostatic tissue to destroy 
the tumor cells. Immature dendritic cells become activated and mature by engulfing 
antigens from the tumor cells. Mature dendritic cells travel to the lymph nodes to present 
tumor antigens and recruit lymphocytes to the inflamed prostatic tissue. Macrophages and 
lymphocytes express macrophage inhibitory factor (MIF), which is a potent cytokine that 
suppresses the transcriptional activity of p53. Persistent tissue damage and regeneration 
via reactive nitrogen and oxygen species released from inflammatory cells as well as the 
growing number of damaged cells leads to chronic inflammation.  
 During chronic inflammation, macrophages and lymphocytes such as T cells, B 
cells and natural killer (NK) cells are recruited to infiltrate inflamed prostatic tissue 
(Figure 2b). Moreover, chronic inflammation may lead to the accumulation of oncogenic 
mutations and promote prostate carcinoma. Unlike acute inflammation, chronic 
inflammation contributes to the development of an estimated 20% of adult cancers via 
bacterial infections, chronic non-infectious inflammatory diseases and environmental 






Figure 2a. Acute inflammation in prostate tumorigenesis. During acute inflammation, 
immune cells such mast cells, macrophages, neutrophils and leukocytes detect tumor 
cells through their TLRs, which recognize DAMPs (damage-associated molecular 
patterns) secreted from tumor cells. TLR signaling induces cytokine and chemokine 
production in the immune cells (e.g., mast cells, leukocytes, macrophages), which 
results in an increase recruitment of immune cells needed to target damaged prostatic 
cancer cells (tumor cells). Tumor associated macrophages secrete ROS and RNS to 
induce DNA damage. Immature dendritic cells engulf tumor cells to mature and travel to 






Figure 2b. Chronic Inflammation in Prostate Tumorigenesis. Primarily lymphocytes (B, T, 
NK cells) and macrophages are active in chronic inflammation. Cytokines and chemokines 




 Chronic inflammation of the prostate may lead to the development of PIA 
(proliferative inflammatory atrophic) followed by the progression of PIA to PIN 
(prostatic intraepithelial neoplasia) and ultimately the initiation of prostate cancer. PIA, 
attributed to repetitive tissue injury and damaged-induced cellular proliferation in 
prostate epithelium, is characterized by the formation of lesions in the peripheral zone of 
the prostate gland. The PIA lesions are related to increases in anti-apoptotic (e.g., Bcl-2) 
and proliferative signals as well as the population of mononuclear (e.g., lymphocyte, 
monocyte) and polymorphonuclear (e.g., neutrophils, mast cells) cells in the prostate 
epithelium and stromal tissue [44, 45]. IL17 positive monocytes/macrophages and other 
inflammatory cells accumulate in PIA lesions of radical human radical prostatectomy 
specimens [45]. The aforementioned immune cells exasperate PIA due to the 
overexpression of inflammatory cytokines. For instance, IL17 positive 
monocytes/macrophages accumulate in PIA lesions of human radical prostatectomy 
specimens [45]. IL17 plays a dual role in acute and chronic inflammation through the 
stimulation of IL6 (acute/chronic inflammation) and IL8 (acute inflammation) production 
[46]. As chronic inflammation persists in the prostate, PIA lesions can transition into 
PIN, a potential precursor of prostate cancer [44, 47]. High-grade PIN lesions contain 
abnormal cells with a large nucleus, detected in a number of prostate biopsies, and are 
associated with a 20-30% increase in the risk of prostate cancer development [47, 48].  
Innate and Adaptive Immunity Signal Pathways in Response to Pathogens 
 Chronic or recurrent exposure to pathogens or infectious agents can lead to 
prostatic inflammation followed by PIA, PIN and ultimately prostate carcinoma. In 




mechanisms, innate and adaptive immunity. Innate immunity immediately triggers the 
activation of macrophages. During innate immunity, macrophages and mast cells non-
specifically target pathogens through the recognition of their antigens. Next, these 
inflammatory cells secrete soluble inflammatory mediators such as cytokines, 
chemokines, matrix remodeling proteases and reactive oxygen species (ROS) that attract 
other inflammatory cells (e.g., epithelial cells, neutrophils, monocytes, natural killer (NK) 
cells, dendritic cells, basophils, eosinophils) to engage pathogens at the site of infection 
[49, 50]. Activated macrophages secrete cytokines (e.g., chemokines), which initiates the 
inflammatory response of the immune system. In addition, immature dendritic cells 
ingest pathogens and present receptors on their surface that recognize many common 
pathogens. Immature dendritic cells migrate through the lymph nodes to interact and 
activate lymphocytes. NK cells destroy certain groups of immature dendritic cells and 
promote the maturation of other dendritic cells [49]. During innate immunity, T- and B-
lymphocytes of adaptive immunity are exposed to foreign antigens via mature dendritic 
cells and develop receptors that are antigen-specific. Adaptive immunity is a complex 
antigen-specific defensive response to pathogens or infection and retains memory of 
specific antigens for future infections or invasion of pathogens. However, the effect of 
adaptive immunity is observed after approximately 4-7 days of infection [50]. Innate and 
adaptive immunity leads to the inflammatory response involved in pathogen or infectious 
agent induced prostate cancer development and progression. However, the focus of this 













Figure 3. Toll-like receptor signaling in innate immunity. TLRs play a critical role 
in innate immunity through their recognition of pathogen antigens. TLR signaling 
induces apoptosis, and elevate the expression of MMPs, cytokines and chemokines 
via the activation of NFκB and IRAK4. However, TOLLIP and IRAK3 can inhibit 





Role of TLRs, Cytokines and Chemokines in Inflammatory and Immune Response  
Toll-like receptors in relation to the inflammatory and immune response:  The pattern 
recognition receptor (PRR) family, which includes toll-like receptors (TLRs), plays an 
essential role in regulating innate immune responses against harmful pathogens, as 
depicted in Figure 3 [31]. With the assistance of extracellular accessory proteins (e.g., 
CD-14, MD-2), TLRs are activated through their recognition of pathogen-associated 
molecule patterns (PAMPs) of pathogens as well as damage-associated molecular 
patterns (DAMPs) released from injured epithelial cells [51]. Some human TLRs (e.g., 
TLR1, TLR2, TLR4, TLR5, and TLR6) are located on the cell surface and recognize 
lipid or protein ligands; whereas, others located within the intracellular compartments 
(e.g., TLR3, TLR7, and TLR9) recognize viral genetic material [31, 52].  
 Once activated, TLRs form complexes with adapter molecules (e.g., MyD88, 
TRIM, TRIF) to recruit downstream targets (e.g., IRAK4 and TRAF6), which lead to the 
activation of transcription factors [e.g., nuclear factor-κB (NF-κB) and interferon 
regulatory factors (IRFs)] via mitogen-activated protein kinase (MAPKs) signaling [31]. 
Overall, the TLR signaling cascade initiates local inflammation, which involves the 
secretion of inflammatory mediators, chemokines, cytokines, antibodies, major 
histocompatibility complex class II (MHCII) and interferons [31]. In addition, TLR 
signaling leads to the maturation of dendritic cells. Immature dendritic cells phagocytize 
pathogens and present fragments of the pathogen on its cell surface using MHC 
molecules. Mature dendritic cells induce the adaptive immune response, which is a more 





Chemokines in relation to the inflammatory and immune response:  Chemokines (e.g., 
CC, CXC, XCL, XC and CX3C), secreted via intracellular signaling through the TLR 
signaling pathway (i.e., TLR2/TLR4), play a pivotal role in chemotaxis, lymphocyte 
development, angiogenesis, host response to infection, chronic inflammation, trafficking 
of dendritic and lymphocytes and ultimately tumorigenesis [35]. These molecules 
mediate their actions through 7-transmembrane G-protein coupled receptors and serve 
three major physiological functions. First, chemokines are involved in the maturation and 
homeostasis of the immune system, as well as trafficking of memory T cells, 
lymphocytes, monocytes, and neutrophils to the inflammatory site.  Chemokines function 
in a chemotactic manner to attract lymphocytes, monocytes, and neutrophils to the site of 
infection and into pre-malignant tissue. Chemokine receptors located on the surface of 
innate immune cells include neutrophils (e.g., CXCR1, CXCR2), immature dendritic 
cells (e.g., CCR1, CCR5) and NK cells (e.g., CCR2, CCR4, CCR5, CCR7 and CCR8) 
and activated maturated dendritic cells (e.g., CCR7) [53, 54]. The occurrence of 
chemokine production in pre-malignant tissue may increase cell survival, tissue 
remodeling, and angiogenesis (e.g., CXCL1, 2, 3, 5, 6, 7) to contribute to tumor 
development [35].   
Cytokines in relation to the inflammatory and immune response:  Cytokines promote 
tissue repair or healing with anti-inflammatory activity and exacerbate inflammation via 
TLR signaling pathways. Several cytokines are associated with chronic inflammation, 
including IL1, IL2, IL3, IL4, IL5, IL6, IL7, IL9, IL10, IL12, IL13, IL17, interferon 
(IFN), TGFβ, and tumor necrosis factor (TNF) α and β [36, 46]. For innate immunity, 




IL17, IL18, IL22, IL23, IL25, and IFNα, to eliminate pathogens detected within the host 
[55]. The subset of cytokines involved in the adaptive immunity such as IL4, IL5, IL6, 
IL7, IL13 induce the production of antibodies from B-lymphocytes, which destroy 
microorganisms and restrict area of infection.  Moreover, many cytokines (e.g., IL1, IL2, 
IL3, IL4, IL7, IL9, IL10, IL12, interferon, transforming growth factor- β, tumor necrosis 
factor α and β) induce cellular responses, such as the mobilization of dendritic cells, 
monocytes, and T-lymphocytes, within adaptive immunity to eliminate pathogens [46, 
56]. Collectively, humoral and cellular responses play an integral role in chronic 
inflammation, which significantly contributes toward to prostate cancer development [14, 
24]. The dysregulation of inflammatory and immune response signaling pathways 
governed by the aforementioned toll-like receptors, chemokines, and cytokine contributes 
to inflammation and immune response via promotion of uncontrolled cellular 
proliferation, growth, invasion, and migration and ultimately leading to tumor 
development.  
Role of inflammatory and immune response pathways in relation to PCA 
TLR signaling pathway and  prostate cancer tumorigenesis:  TLRs are a family of 
transmembrane receptors that play a pivotal role in prostate cancer progression through 
its influence on the innate immune system via expression on immune cells and the 
induction of chemokine and cytokine production. In a gene expression study, human 
TLRs (TLR1-10) had detectable gene expression levels in normal prostate tissue [57]. In 
relation to prostate cancer, Varambally and co-workers (2005) observed down regulation 
of TLR1 gene expression in metastatic prostatic tissue compared to benign and primary 




Programs of Research Excellence (SPORE) [58]. Chin and colleagues (2010) observed 
suppression of prostate cancer tumor growth in IFNAR1 +/+ (type I interferon) and TLR3 
+/+ mice implanted with TRAMP C2 cells (i.e., transgenic mouse prostate cancer 
epithelial cells) compared to IFNAR1 -/- and TLR3 -/- mice, respectively [59]. Moreover, 
tumor suppression was observed after treatment with polyinosinic-polycytidylic acid 
(polyI:C), a natural agonist of TLR3 or immunostimulant, on orthotopic prostate tumors 
in mice. This lead to the recruitment of T-lymphocytes and NK cells via type I IFN-
dependent signaling. The study suggests that TLR3 agonists induce tumor suppression 
through the activation of the NF-κB, MAPK and IRF3 signaling pathways via TRIF 
(Toll/IL-1R domain-containing adaptor inducing IFN) in immune cells. These mediators 
bind to receptors on the immune cells and promote immune cells to target prostate tumor 
cells [59].  
 Galli and co-workers (2010) observed that TLR2, TLR3, TLR4, TLR5, and TLR6 
genes were expressed in PC3 cells (human metastatic prostate cancer cell line); however, 
both TLR3 and TLR5 gene and protein expression was present in LNCaP, Du-145, and 
PC3 cell lines (human metastatic prostate cancer cell lines) [52]. Nonetheless, TLR7, 
TLR8 and TLR9 genes were not expressed in PC3, Du-145 and LNCaP cell lines [52]. 
Unfortunately, this study fail to compare TLR expression in PCA cell lines to normal 
prostate cells. Stimulation of LNCaP and Du145 cells with poly (I:C) induce the 
production of chemokines (e.g., CXCL10, CCL5, CCL3 and IL8) via TLR3 and TLR5 
and recruitment of leukocytes. This demonstrates that TLR signaling plays a role in 
chemokine production in PCA cell lines. Gonzalez-Reyes and associates (2011) observed 




European men compared to benign tissue [60]. TLR3 and TLR9 mRNA expression had a 
significant positive association with prostate cancer biochemical recurrence (p = 0.039). 
The study speculates that elevated TLR3 and TLR9 mRNA expression in prostate cancer 
tissue may induce the production of cytokines and chemokines to recruit immune cells 
and stimulate the release of more cytokines. The continual stimulation of cytokine and 
chemokine production could feed into a state of immune tolerance and initiation of a 
tumor microenvironment.  
 Interestingly, the immunohistochemical staining for TLR4 was significantly lower 
in high gleason score (Gleason score 4-6) prostatic adenocarcinoma stromal epithelial 
cells compared to normal and low gleason score (Gleason score 7-10) tissue [61]. After 
activation of TLR4 with LPS treatment, the gene expression of NF-kB regulated pro-
inflammatory cytokines (e.g., IL1β) and chemokines (e.g., IL8) was up-regulated, which 
contributes to an inflammatory state in Du145 cells. Moreover TLR4 signaling may 
increase the risk of prostate cancer via chronic inflammation.  Pronounced TLR7 gene 
expression has been observed in normal prostate epithelial RWPE1 cells, but TLR7 
expression is absent in PC3 and Du145 cells [62]. Consisted with the in vitro findings, 
protein expression of TLR7 was decreased in high grade PIN and adenocarcinoma of 
mouse prostatic tissue compared to normal prostatic tissue in mice. 
 Downstream signaling in the TLR pathway also plays a role in prostate cancer. 
IRAK4 plays a critical role in the innate immune system by relaying signals from TLRs 
via recruitment of IRAK1, which activates NF-kB induce pro-inflammatory response and 
caspases induce apoptosis. IRAK4 expression was decreased in doxcetaxel resistant 




regulation of IRAK4 resulted in the resistance of U251 cells, a glioma cell line, to 
Temozolomide treatment [64]. Both studies suggest that IRAK4 expression modulates 
the sensitivity of cancer cells to chemotherapy and may serve as a good target for cancer 
treatments.  Zhu and co-workers (2012) demonstrated in HEK293T (human embryonic 
kidney epithelial cell line) cells that TOLLIP inhibits the TGF signaling pathway, a key 
biological pathway in prostate tumorigenesis [65]. In prostate cancer, TGF functions as 
a tumor suppressor in the early stages of prostate cancer via suppression of cycle 
dependent kinases and cMyc. However, in the advanced stages, TGF transitions into a 
tumor promoter via induction of VEGF expression to promote tumor progression[66-68]. 
Varambally and associates (2005) observed higher gene expression of TOLLIP in 
metastatic prostate tissue compared to benign tissue [58].  In another study, 
overexpression of TOLLIP was shown to accelerate the degradation of TGFβ receptor 
type 1 (TGFβR1) protein [65]. In addition, TOLLIP interacts with ubiquitinated TGFβR1 
via SMAD7, an inhibitory SMAD, which results in the suppression of TGF signaling. 
TOLLIP gene expression was observed in androgen sensitive (e.g., LNCaP, MDA-PCA-
2a) and insensitive (e.g., PC3, Du145) prostate cancer cell lines as well as prostatic 
cancer tissue [69]. TOLLIP may participate in the decrease of TGFβ receptor protein 
expression commonly seen in prostate cancer (i.e., LNCaP) and malignant prostate cancer 
archival tissue compared to benign tissue [70]. Collectively the aforementioned studies 
suggest that TOLLIP may play a central role in prostate tumorigenesis however, in vitro 
and in vivo studies are needed to determine its role.  However, no published reports have 
identified a strong relationship between the expression levels of TLR1 TLR6, TLR10 and 




Chemokines, their receptors and prostate cancer :  Chemokines are signaling molecules 
involved in the regulation of inflammation, trafficking of inflammatory cells (e.g., 
leukocytes, dendritic cells, neutrophils) and immune cell differentiation. These signaling 
molecules also play a role in cellular behaviors associated with prostate tumorigenesis. 
Kato and co-workers (2013) reported CCL5 treatment activates the ERK and Rac 
signaling pathways via one of its receptors (e.g., CCR1) in CCR1 knockdown paclitaxel-
resistant PC3 cells (PC3PR) compared to negative control transfected PC3PR [71]. The 
activation of CCR1 promotes cell invasion in PC3PR cells by increasing mRNA 
expression and secretion of matrix metalloproteinases, namely MMP2 and MMP9 [71].  
Matrix metalloproteinases degrade the extracellular matrix, which is an essential step of 
metastasis [72]. In another study, Vaday and colleagues (2006) observed high levels of 
pro-inflammatory chemokines CCL5 and CCR5 in radical prostatectomy specimens 
compared to invasive ductal breast carcinoma as a positive control [73]. In fact, 
overexpression of CCL5 and CCR5 is strongly associated with aggressive prostate 
cancer, presumably by triggering leukocyte production and promoting cell survival, 
proliferation, invasion and metastasis [22, 73, 74].  CCL5 also induced cell migration and 
proliferation in LNCaP cells through the activation of CCR5 [73]. Moreover, another 
study observed that CCL5 and CCR5 are highly expressed genes in prostate cancer tissue 
and may play a role in prostate tumorigenesis [75].  
 Its speculated that CCR7 gene/protein expression may mediate the cellular 
migration of tumor cells to the lymph nodes in various cancers including prostate cancer 
[76-79]. In addition to the CCL5-CCR1-CCR5 axes, some chemokines such as CXCL1 




Killian and colleagues (2012) observed that silencing these pro-inflammatory 
chemokines (i.e., CXCL1 and CXCL2) inhibits cell growth and induces apoptosis in PC-
3, a metastatic prostate cancer cell line [80]. Similarly, Benelli and associates (2013) 
showed that CXCL1 transfected TRAMP-C2 cells, a transgenic mouse epithelial prostatic 
cell line, inhibits tumor growth in mice compared to an empty vector [81]. This report 
further suggests that CXCL1 may induce senescence to inhibit tumor and cell growth via 
CXCR2 in TRAMP-C2 cells [81]. CXCR7, another pro-inflammatory chemokine that 
binds to CXCL11 and CXCL12 (SDF-1a), is elevated in various cancers, including 
prostate cancer [82-86]. Singh and Lokeshwar (2011) demonstrated high mRNA and 
protein expression levels of CXCR7 in PC-3 and LNCaP relative to RWPE1 cells 
(normal immortalized prostate epithelial cell line) [85]. In addition, this study showed 
that CXCR7 overexpression increased cell proliferation by 23% in RWPE1 cells. 
Depletion of CXCR7 in C4-2B cells, a derivative of the LNCaP cell line with androgen 
sensitivity, reduced tumor growth in nude mice and cell proliferation in PCA cell lines 
(e.g., PC3, LNCaP) [85-87]. CXCR7 promoted cell proliferation via phosphorylation of 
EGFR and Erk1/2 in RWCX7 cells, derivatives of RWPE1 cells that overexpress CXCR7 
[85]. Singh and co-workers (2004) showed that CCR9 mRNA levels were highly 
expressed in LNCaP and PC-3 cell lines in comparison to PrEC (normal prostate 
epithelial cell line) [88]. Treatment of LNCaP and PC-3 cells with CCL25, a known 
ligand of CCR9, resulted in an increase in cellular migration and invasion, as shown by 
flow cytometry. After CCL25 treatment, gene expression of metalloproteinases, MMP2 
and MMP13, was elevated in PC-3 and LNCaP cell lines compared to untreated PC-3 and 




essential to cellular invasion and migration in vitro. Chemokines contribute to prostate 
cancer phenotypes, including increased cellular proliferation, migration and invasion of 
prostate cancer cells.  
Cytokines and in prostate cancer:  The cytokine family, which includes chemokines, 
interleukins, interferons, and growth factors, plays an essential role in the development 
and progression of prostate cancer. Cytokines are soluble proteins, peptides or 
glycoproteins secreted from immune cells as signaling molecules in response to infection, 
foreign pathogens, and  tumor cells [89-91]. Several studies reveal pro-inflammatory 
cytokines, involved in chronic inflammation, participate in prostate cancer progression. 
Salman and colleagues (2012) observed elevated secretion of pro-inflammatory cytokines 
from peripheral blood mononuclear cells (PBMCs) incubated with PC-3 cells (IL1β, IL6, 
IL10) or LNCaP cells (IL6) compared to the incubation of PBMCs with no cancer cells 
[92]. The presence of prostate cancer cells induces the production of cytokines via the 
immune system. TGF-β1 is a highly expressed cytokine in tumor prostate epithelial cells 
that was significantly associated with high vascular density and bone metastasis in 
prostate cancer [93]. In particular, Wikstrom and associates (1998) observed that 
overexpression of TGFβ1 in 73 paraffin-embedded tumors was associated with short 
survival rates among European PCA patients who did not receive any treatment relative 
to normal prostatic tissue [93]. Rodriguez-Berriguete and colleagues (2013) revealed that 
high protein expression of cytokines in the tumor necrosis factor family [TNFα, TNFR1, 
TNF receptor-associated factor 2 (TRAF2)] were associated with high pathological 
prostatic tumor stage in prostatic tumor tissue relative to normal prostatic tissue [94]. In a 




cytokines, IL1β (HR = 0.431; 95% CI = 0.180-1.029) was marginally linked with a 57% 
decrease in biochemical progression [94]. IL6, a major cytokine, participates in chronic 
inflammation and prostate tumorigenesis. For instance, Chung and co-workers (1999) 
demonstrated a decrease in cell growth after treating hormone independent PCA cell lines 
(Du145, TSU and PC3) with a neutralizing polyclonal goat anti-human IL6 antibody 
compared with untreated cells [95]. Moreover, an independent study revealed that 
autocrine production of IL-6 induces a high gene and protein expression of IFR9, which 
is critical to the exertion of the IFNα2 anti-proliferative effect on prostate cancer cells 
(i.e., PC-3 and MDA PCA 2b cells) [96]. These studies confirm cytokines play a critical 
role in the progression of prostate cancer via cellular behaviors. In the aforementioned 
studies, inflammatory and immune response-associated genes and proteins were shown to 
participate in prostate tumorigenesis via promotion of cellular migration, proliferation 
and growth, which are critical biological pathways in prostate cancer.  
Epidemiology evidence of the relationship between variant inflammatory and 
immune response related sequence variants and prostate cancer  
 Over the past decade, many epidemiological studies have shown that genetic 
variants in inflammatory and immune response-related genes contribute to the 
dysregulation of critical biological pathways and ultimately leads to cancer development 
or disease progression. The inheritance of genetic variants in these mediators may impede 
their function to properly regulate the inflammatory and immune response. Some of the 
inflammatory and immune response-related sequence variants have been previously 
reported to play a role in several carcinomas, including carcinoma PCA. Although the 




published reports typically focus on men of Asian or European descent.  Little or no data 
addresses the impact of cytokine, chemokine and toll-like receptor-related sequence 
variants on PCA risk among men of African descent, even though this population suffers 
disproportionately from this disease [1, 14, 27, 100-102].  
TLR-associated sequence variants and PCA 
TLR-related sequence variants have been evaluated in relation inflammatory and 
immune response-related diseases including prostate cancer.  Stevens and co-workers 
(2008) showed that polymorphisms in TLR1 rs4833095 CC (OR = 0.64; 95% CI = 0.47-
0.86), TLR1 rs5743595 CC (OR= 0.63; 95% CI=0.42-0.93), TLR10 rs11096955 CC (OR 
= 0.78; 95% CI = 0.61-0.99), TLR10 rs11096957 CC (OR = 0.78; 95% CI = 0.61-0.99) 
and were linked with a 22-58% decrease in prostate cancer susceptibility among 1,414 
cases and 1,414 controls of Latin, European, and Asian descent (p-trend = 0.0022-0.011) 
[97].  In six observational studies, TLR4 (rs1927911 CC, rs2149356 TT), TLR10 
rs4274855 AG+AA were linked to a 1.12-6.68 fold increase in the risk of developing 
PCA among men of European and Asian descent [97, 98, 103-106].  In another study, 
inheritance of 1 copy of the risk allele for and TLR4 rs2149356 (OR = 0.66; 95% CI = 
0.51-0.86) was linked to a 13-34% reduction in PCA susceptibility among European 
Americans (700 cases, 700 matched controls) [107].  Unfortunately, there was no 
relationship between prostate cancer susceptibility and possession of variant TLR 
signaling associated alleles TLR4 (rs1927906), TLR6 (rs1039559, rs3821985, 
rs5743810), and IRAK4 rs4251545 with [97, 99, 103, 104, 106-109]. 
The relationship between innate immunity genetic anomalies and prostate cancer 




the recessive genetic model for TLR4 rs2149356 (i.e., TT vs.GG + GT), Chen and co-
workers (2005) observed a 36% decrease in risk of developing prostate cancer (OR = 
0.64; 95% CI = 0.45-0.91) among European men (700 cases, 700 matched controls) 
[107]; however, this relationship was insignificant in 3 other studies [103-105].   
Moreover, inheritance of the TLR4 rs1927911 CC genotype was linked with a 6.68-fold 
increase in the risk of developing prostate cancer but had a null effect in other studies 
[98, 103, 107].  Possession of the TLR10 rs11096955 CC, and TLR10 rs11096957 CC 
genotypes were associated with a 9-21% decrease in prostate cancer susceptibility in two 
studies but associated with 1.20-1.25-fold increase in prostate cancer risk in another 
report among men of European descent [97, 106, 109]. However, these findings were null 
in relation to prostate cancer risk with the exception of TLR10 rs11096955 CC genotype 
in one study [106]. In addition, several of the aforementioned studies that evaluated 
several SNPs simultaneously did not adjust their risk estimates for multiple hypotheses 
testing [98, 99, 107, 108].  Failure to adjust for multiple comparisons may lead to an over 
estimation of prostate cancer susceptibility among carriers of putative high-risk alleles. 
Moreover, a majority of the previously mentioned studies failed to include men of 
African descent, despite the fact that men of African descent suffer disproportionately 
from prostate cancer relative to men of European and Asian descent [98, 99, 103-105, 
107, 108]. In addition, some studies utilized different allelic discrimination assays such as 
Taqman, MassARRAY and multiplex PCR to genotype SNPs [104, 105, 107]. 
Furthermore, several of the aforementioned reports had evaluated different genotypes in 





In a recent published report from our lab, we addressed some of the 
aforementioned concerns that often plaque most genetic epidemiology studies. First, we 
evaluated the role of innate immunity sequence variants among a relatively large sub-
group of men of African descent (270 cases, 535 controls).  Our sample size enabled us to 
have adequate statistical power to observe reasonable protective (OR < 1.00) and risk 
(OR > 1.4) effects.  Lastly, all of our relationships were adjusted for multiple hypothesis 
testing using the false discovery rate (FDR), in order to adjust for false positive results.  
Our study was restricted to polymorphisms detected within the genes of TLRs (1, 4, 6, 
10), TOLLIP and IRAK4 genes among 814 men of African descent [31].  We revealed 
that TLR6 rs2381289 GA (OR=1.46; 95% CI=1.02-2.09) and TOLLIP rs5743899 AG 
(OR=1.59; 95% CI=1.06-2.38), AG+GG (OR=1.49; 95% CI=1.02-2.18) genotypes 
modestly modified PCA risk among men of African descent from the U.S. and Jamaica. 
However, these sequences variants did not survive multiple hypothesis testing (FDR > 
0.05). After stratification by racial/ethnic group and age-adjustment, six TLR-related 
sequence variants detected were modestly linked to PCA susceptibility among men of 
African descent from the U.S. Inheritance of IRAK4 (rs4251545 A and rs4251473 A) and 
TLR6 rs5743818 C variants were associated with a 40-66% reduction in PCA risk among 
U.S. men (χ
2
 p-value = 0.099). On the contrary, possession of both IRAK4 rs4251545 GG 
referent genotype and TLR1 CT+CC genotype was associated with a 1.36-fold increase 
(95% CI = 1.09-1.69) in prostate risk among men of European descent (p-value < 0.01) 
[108], but IRAK4 rs4251545 had a null finding in another report [110]. However, the 
TOLLIP rs5743899 recessive genetic model (GG vs. AA+AG)  was modestly associated 




Jamaicans, possession of TLR6 rs2381289 GA+AA (ORage-adj = 2.05; 95% CI = 1.10-
3.78) and TLR6 rs5743818 AC+CC (ORage-adj = 1.10; 95% CI = 1.06-1.14) genotypes was 
linked to a 1.10-2.05-fold increase of PCA development. In contrast, IRF3 rs2304206 GG 
genotype was related to a 68% reduction (OR = 0.32; 95% CI=0.11-0.98) in PCA 
susceptibility. Notably, inheritance of the variant innate immunity alleles  among 
Jamaicans (TLR6 rs2381289 A, IRF3 rs2304206 G) and U.S. men (IRAK4 rs4251545 A) 
for U.S. men did not survive multiple hypothesis testing (Bonferroni Correction p-value 
> 0.0016). 
Chemokine-associated sequence variants and PCA 
Genetic alterations in chemokines and their receptors have been linked to the 
susceptibility, development and progression of numerous cancers, including prostate 
cancer [111-115].  The CCL5 rs2107538 variant contributed to an increased susceptibility 
for different cancers [116-118]. In terms of PCA, CCL5 rs2107538 GA+AA genotype 
(OR=1.44; 95% CI=1.09-2.38) was associated with an increase in prostate cancer risk 
among European men  (296 cases, 311 controls) [116]. In a pilot study, the CXCL12 
rs1801157 (OR = 1.58; 95% CI = 1.03-2.43) GA+AA genotype was significantly 
associated with a 1.58-fold increase in prostate cancer risk among Japanese men (167 
cases and 167 matched controls) [112]. However, there are no published reports on the 
main effect of CCR7 (rs3136685, rs3136687) and CCR5 rs1799988 sequence variants in 
relation to PCA susceptibility.  Some of the aforementioned studies failed to adjust for 
multiple hypothesis testing [116-119], and perform power calculations to specific odd 
ratio detection limits [116-118, 120]. Furthermore, prior to our 2012 published report, 




sequence variants and PCA among African-American men. 
 Our lab showed that five chemokine-related sequence variants were significantly 
associated with prostate cancer development among men of African descent (279 cases 
and 535 controls) [35] . The inheritance of CCL5 (rs2107538 and rs3817655) GA, AA 
and GA+AA genotypes were linked with a 34-44% reduction in PCA risk in the age 
adjusted LR models among men of African descent [false discovery rate (FDR) ≤ 
0.0493].  However, the inheritance of the CCR5 rs1799988 (OR age adjusted =1.52; 95% 
CI=1.02-2.26) recessive genetic model, CCR7 rs3136685 (OR age adjusted =1.66; 95% 
CI=1.09-2.54) AG+GG, and CCR7 rs3136687 (OR age adjusted =1.14; 95% CI=1.12-1.16) 
AG+GG genotypes were associated with a significant 1.14-1.66 fold increase in PCA risk 
within the age adjusted LR models. The CCL5 (rs2107538, rs3817655) dominant (FDR 
p-value ≤ 0.015) and CCR5 rs1799988 recessive genetic models (FDR p-value = 0.049) 
remained significant even after adjusting for multiple hypothesis testing.  
In a stratified analysis, several chemokine-chemokine receptor markers were 
linked to PCA susceptibility among men of African descent from the U.S. Inheritance of 
the CCR5 rs1799988 GG locus under the recessive genetic model (OR unadjusted  = 1.62; 
95% CI = 1.04-2.42) and the CXCR7 rs1045879 AG+GG genotype (OR unadjusted  = 1.54; 
95% CI = 1.07-2.22) was associated with a 1.54-1.62-fold increase in PCA risk among 
unadjusted risk models. However, possession CCL5 rs2107538 GA+AA (OR unadjusted  = 
0.52; 95% CI=0.36-0.76), CCL5 rs2280789 AG+GG (OR unadjusted  = 0.60; 95% CI = 0.41-
0.89), CCL5 rs3817655 GA+AA (OR unadjusted  = 0.46; 95% CI = 0.32-0.68), CCL25 
rs2032887 AG+GG (OR unadjusted  = 0.66; 95% CI = 0.46-0.96) genotypes was linked with 




previously mentioned genotypes risk estimates for CCL5 (rs2107538, rs3817655) 
remained significant. However among Jamaican men, CCR5 rs1799987, CCR5 
rs1799988, CCR7 rs3136685 and CCR9 rs1488371 loci were linked with PCA risk. In 
unadjusted risk models, CCR5 rs1799987 AA (OR unadjusted  = 2.18; 95% CI = 1.04-4.58), 
CCR5 rs1799988 GG (OR unadjusted  = 2.25; 95% CI = 1.08-4.71) and CCR7 rs3136685 
AG+GG (OR unadjusted  = 2.30; 95% CI = 1.05-5.07) genotypes were linked with a 2-fold 
increase in PCA susceptibility (P-trend = 0.034-0.086). On the contrary, inheritance of 
CCR9 rs1488371 CA+AA (OR unadjusted  = 0.46; 95% CI = 0.23-0.94) genotype was 
associated with a 54% reduction in PCA risk among unadjusted risk models. After 
adjusting for age, the risk estimates of the previously mentioned genotypes for CCR5 
rs1799987, and CCR7 rs3136685 remained significant among men of African descent.  
However, only CCL5 (rs2107538, rs3817655) sequence variants survived multiple 
hypothesis testing among U.S. men of African descent (Bonferroni Correction p-value ≤ 
0.0012). Our study revealed strong associations between genetic variants in CCL5 among 
men of African descent that warrant further investigation in future studies.  
 Unfortunately, our findings were not in agreement with cancer-related published 
reports. We observed that the inheritance of CCL5 rs2107538 GA+AA genotype was 
associated with a 41-48% reduction in PCA susceptibility (OR = 0.59; 95% CI = 0.44-
0.80 and OR unadjusted  = 0.52; 95% CI = 0.36-0.76) among men of African descent; 
however, Saenz-Lopez (2008) observed that the CCL5 rs2107538 GA+AA genotype was 
associated with an increase in prostate cancer risk (OR = 1.44; 95% CI = 1.09-2.38) [116, 
118].  This variant was also an important predictor of pancreatic cancer risk (OR = 2.3; 




and oral cancer risk among Asians (OR = 2.23; 95% CI = 1.07-4.66) [116, 118] [117]. 
Moreover, we observed an increased PCA susceptibility affiliated with inheritance of the 
CCR7 (rs3136685 AG+GG, rs3136687 GA+AA) genotypes; however, a couple of studies 
reported a 60-62% reduction in cancer susceptibility for multiple myeloma and chronic 
lymphocytic leukemia, among individuals of European descent [119, 120]. However, 
majority of the  aforementioned studies in relation to prostate cancer susceptibility failed 
to include men of African descent and adjust risk estimates for multiple hypothesis 
testing [116, 118]. Furthermore, the discrepancies between our study and the 
aforementioned reports may be attributed to differences in cancer type evaluated in 
relation to innate immunity genetic variants, limited sample size, genotype frequency 
distribution, allelic discrimination assays (i.e., PCR–RFLP) and ethnic groups included in 
each study population sample size and ethnic group [116-120].  In addition, a couple of 
epidemiological studies evaluated SNPs in relation to cancer susceptibility in populations 
that included women as well [117, 120]. 
Cytokine-Associated Sequence Variants and PCA 
 The production of cytokines can be influenced by single nucleotide 
polymorphisms (SNPs) in pro- and anti-inflammatory genes. Observed differences in the 
spectrum of cytokines expressed in an inflammatory environment or level of antitumor 
response within an individual can be explained by genetic variations, which leads to high- 
or low-level production of a given cytokine [46]. Epidemiological studies evaluated the 
relationship between prostate cancer and several cytokine-associated gene variants, such 
as TNF rs1800629 (-308 G>A) among Indian men as well as IL10 rs1800871 (-819 C>T) 




(2012) showed that TNF rs1800629 AA genotype was associated with a 1.79-fold (95% 
CI = 1.29-2.49) increase in the risk of developing prostate cancer among North Indian 
men (150 cases, 150 BPH controls) [121]. In another study, TNF rs1800629 has also 
been implicated in several other carcinomas (e.g., lymphoma, cervical, gastric) [129-
132]. However, some studies have concluded that TNF rs1800629 was not associated 
with prostate cancer or other cancers among individuals of European, African and South 
American descent [101, 121, 133-135]. Kesarwani and associates (2009) observed that 
IL10 rs1800896 GA genotype (OR = 2.8; 95% CI = 1.26-6.14) was associated with a 2.8-
fold increase in PCA risk among North Indian men (259 cases, 159 controls) [126]. 
Possession of the IL1B rs1143627 CC genotype (OR = 0.54; 95% CI = 0.36-0.81) was 
linked with a 46% reduction in susceptibility of PCA recurrence among U.S. men (524 
matched case-control pairs) [122]. Zabaleta and associates (2008) observed IL10 
rs1800871 CT (OR = 0.72; 95% CI = 0.53-0.98), IL10 rs1800872 CA (OR = 0.70; 95% 
CI = 0.52-0.93) and CA+AA (OR = 0.74; 95% CI = 0.56-0.98) 26%-30 reduction in PCA 
risk among men of European descent (889 men) [101]. However in the same study, IL10 
rs1800871 TT (OR = 0.18; 95% CI = 0.05-0.72) genotype was associated with a 82% 
decrease in PCA susceptibility among men of African descent. However in a report from 
our lab, IL10 (rs1800871, rs1800872) and IL10 rs1800896 were found to have no 
association to PCA risk among U.S. men of African descent (193 cases and 666 controls) 
[40]. Inheritance of IL1A rs17561 (+4845 G>T) had a protective effect against ovarian 
cancer risk (OR = 0.90, 95% CI = 0.83–0.97) among European American women (930 
cases, 1,037 controls) [136]. In addition, Balasubramanian and colleagues (2006) also 




European American women (521 cases, 895 controls) as well (p-value = 0.05) [137]. 
Sequence variant, IL1A rs2856836, CT (OR = 2.88; 95% CI = 1.58-5.27) and CC (OR = 
8.17; 95% CI = 2.23-29.9) genotypes were associated with a ≥ 2.0-fold increase in breast 
cancer risk among Korean women (209 cases, 209 controls) [138]. Although the IL1A 
loci (rs17561, rs2856836) were associated with increased susceptibility to hormone-
related cancers among individuals of European and Asian descent, our lab did not 
observe a significant association between these markers and PCA risk among men of 
African descent. Furthermore, some of these studies fail to adjust for multiple hypothesis 
testing [121, 136 , 137], and perform power calculations [121, 136 , 137 , 138].  
Moreover in a recent published report, our lab observed modest associations 
between prostate cancer risk and the inheritance of IL1R2 rs11886877, IL8RB 
rs11574752, TNF (rs1800629 and rs673) among men of African descent (279 cases and 
535 controls) [36]. Among men of African descent, IL8RB rs11574752 AA (ORage-adjusted 
= 38.4; 95% CI = 3.86-382.8), IL1R2 rs11886877 AA (OR age-adjusted =1.92; 95% CI = 
1.11-3.32), TNF rs1800629 GA (OR age-adjusted = 1.54; 95% CI=1.06-2.24), and TNF rs673 
GA (OR age-adjusted =1.50; 95% CI= 1.04-2.16) genotypes in adjusted risk estimates were 
associated with PCA susceptibility.  However, these sequence variants did not survive 
multiple hypothesis testing according to the new significance level (α = 0.0011) 
(Bonferroni Correction p-value > 0.0011). Upon stratification, intronic IL1R2 
rs11886877 AA (OR age-adjusted =2.75; 95% CI =1.38-5.50), GA+AA (OR age-adjusted =1.82; 
95% CI = 1.14-2.88) genotypes and recessive genetic model (OR age-adjusted =2.05; 95% 
CI=1.10-3.80) among U.S. men were linked to a 1.82-2.75 fold increase in risk of 




rs12135247 AG genotype (OR age-adjusted = 2.10; 95% CI = 1.04-4.24) was associated with 
PCA susceptibility among Jamaican men. We adjusted all associations for multiple 
hypothesis testing and perform power calculations to determine odd ratio limits. Notably, 
none of the evaluated cytokine-associated sequence variants were associated with PCA 
risk (Bonferroni Correction p-value > 0.0011). Although we reported null findings, 
IL1R2 rs11886877 AA and GA+AA genotypes were associated with significant risk 
estimates among both the total population and U.S. men in age-adjusted LR models. The 
IL1R2 rs11886877 A allele may favor pro-inflammatory signals and mute the protective 
effect of this receptor against the tumorigenic activity of IL1α and IL1β. IL1R2 is a 68kD 
receptor pre-dominantly expressed on monocytes, B-lymphocytes, polymorphonuclear 
(PMN) leukocytes and prostatic tumor cells [139, 140]. Under normal conditions, this 
receptor functions in an anti-inflammatory or immunosuppressive manner by binding to 
IL1α or IL1β to lower pro-inflammatory cytokine production from immune cells (e.g., 
lymphocyte, macrophage), as shown in Figure 3 [139, 141, 142]. The pro-inflammatory 
signal of IL1 may be decreased, due to its binding to IL1R2. However, the introduction of 
a sequence variant such as rs11886877 within the IL1R2 gene may render the IL1R2 
protein non-functional due to instability of mRNA/protein expression. In addition, the 
pro-inflammatory signal of IL1 may be elevated via production of pro-inflammatory 
cytokines from immune cells leading to chronic inflammation (Figure 4). Furthermore, 
chronic inflammation may develop into PIA, which can transition to high grade PIN 
(HPIN) and ultimately initiate PCA development (Figure 4). Nonetheless, subsequent 
studies are needed to evaluate the influence of the aforementioned sequence variant on 




whether the IL1R2 rs11886877 AA genotype in normal prostate cells will inhibit the anti-
inflammatory and immunosuppressive activity of IL1R2 via IL1β or IL1α induction. 
Overexpression of IL1R2 or inheritance of the rs11886877 AA genotype in prostate 
cancer cell lines will provide information on whether or not IL1R2 is protective against 
cancer cells. These studies will provide more insight about the biological function of 
IL1R2 in prostate cells and whether IL1R2 may serve as a potential target for prostate 











Figure 4. The effect of IL1R2 on immune cells and prostate cancer. Inheritance of IL1R2 
rs11886877 reference allele G does not modify prostate cancer susceptibility among men 
of African descent. However, the inheritance of the IL1R2 rs11886877 A allele was 
associated with an increase in prostate cancer risk. We proposed that rs11886877 A allele 
will impede function of the IL1R2 as a decoy receptor for IL1 on immune cells and allow 
the IL1 pro-inflammatory signal to induce the production of cytokines. Eventually immune 
cells will infiltrate normal epithelial prostate cells to initiate chronic inflammation that 





 To further investigate the impact of these sequence variants on prostate cancer, 
we will examine the biological significance of variants through in vitro and in vivo 
studies in relation to prostate cancer therapies, cellular behavior (e.g., cellular 
proliferation, migration, invasion) and tumorigenesis. We will evaluate the gene and 
protein expression of CCL5, CCR5, CCR6, CCR7, CCR9, TLR2, TLR6, TLR10, IRF3, 
IRAK4 and IL1R2 in standard prostate cancer cell lines (e.g., PC3, Du-145, LNCaP). 
Next, we will evaluate the effect of target gene mimics or inhibitors on cellular behaviors 
in normal and cancer cell lines.  Lastly, we will perform functional studies for selected 
genes significantly impacted by sequence variants through knockout and knockin in vivo 
models.  Such studies will enable us toevaluate the effect of overexpression or inhibition 
of these genes on tumor growth in response to selected current prostate cancer therapies 
using state-of-art imaging techniques (e.g., Multispectral optoacoustic tomography).   
Combined effects and gene-gene interactions on prostate cancer susceptibility 
 Gene-gene interactions aid researchers to model the complex involvement of 
biological pathways, and environmental factors in the etiology of prostate cancer as well 
as identify susceptible genes. High order interactions are difficult to detect and may lead 
to countless contingency tables with inadequate observations, inaccurate risk estimates 
and extremely wide 95% CIs. Only 4 of these published reports focused on PCA. 
However, 3 of the gene-gene interaction studies used logistic regression to detect 
interactions, and failed to predict high order (e.g., >2) gene-gene interactions in relation 
to PCA cancer risk. Moreover, two of the PCA genetic epidemiology studies did not have 
adequate statistical power to observe associations. Statistical power is the probability to 




effect. High statistical power decreases the probability of type II error to occur, which is 
the detection of no effect when there is actually an effect. Linear modeling limits logistic 
regression to effectively model high-order interactions with ample statistical power.  
Therefore, many researchers including our lab evaluate gene-gene interactions using 
multi-locus prediction tools [e.g., multivariate adaptive regression spline (MARS Logit), 
classification and regression trees (CART), computational evolution system (CES), 
modified logistic regression, and multifactorial dimension reduction program (MDR)] to 
perform intensive data mining for multivariate analyses.  
Multi-locus prediction tools have both advantages and drawbacks. For instance, 
MARS Logit is a non-parametric method used to predict gene-gene interactions, but 
analyses are limited to large datasets with a bias toward the contribution of the additive 
genetic model to disease susceptibility [143]. CART is a nonparametric statistical method 
used to detect mutually exclusive and exhaustive subgroups based on common traits of a 
population [144]. Interestingly, CART is user friendly, provides 95% confidence 
intervals and the results are easy to interpret. However, the CART analysis is unable to 
estimate the effect of an independent variable, which may lead to data dredging and 
multi-level classification trees that are difficult to interpret. CES (computational 
evolution system) models are biologically sound nonlinear interactions of high-
dimensional genetic data in 3D; however the interactions are governed by conventional 
mathematical models [145].  MDR is an intensive non-parametric method that randomly 
shuffles data to detect unbiased 1-4 factor interaction models on disease 
susceptibility[146]. This technique provides a cross validation consistency (CVC), and 




testing p-values to adjust for multiple hypothesis testing.  In addition, the current version 
of MDR does not require an equal number cases and controls to predict high order 
interactions. Unlike CART, MARS Logit, logistic regression, and CES, MDR is able to 
adjust analyses for multiple hypothesis testing. However, MDR does not provide risk 
estimates and associated 95% confidence intervals. 
Among peer-reviewed articles discussed in this report, 20% (9 out of 45) of the 
published reports evaluated gene-gene interactions among inflammatory and immune-
related sequence variants in relation to cancer susceptibility [40, 101, 102, 108, 112, 118, 
147-149]. Genetic variants within inflammatory and immune response-related genes in 
relation to prostate cancer have been observed in various gene-gene interaction studies 
(Table 1). For instance, Sun and associates (2006) showed that the gene-gene interaction 
involving IRAK4 polymorphisms and TLR1 CT+CC genotype had a 1.37-9.68 fold 
increase in risk of developing prostate cancer among Swedish men using logistic 
regression [108]. Xu and colleagues (2005) reported a statistically significant four-factor 
gene-gene interaction model between IL10, IL1RN, TIRAP and TLR5 linked with 
prostate cancer risk among Sweden men (Permutation testing p-value = 0.019) using 
MDR [147]. Although this study controlled for multiple hypothesis testing, Xu and 
associates only evaluated gene-gene interactions among men of European descent. In the 
literature, a report by Duell and co-authors (2006) was one of the few studies on cytokine 
gene-gene interactions (e.g., CCL5-CCR5, CCL5-TNFα, CCR5- TNFα) [118]. 
Unfortunately, these gene-gene interactions were in relation to pancreatic cancer and not 
prostate cancer.  Zabaleta and colleagues (2008) observed a significant two-factor gene-




increase in prostate cancer risk among African-Americans using MARS Logit [101]. In 
another study, Zabaleta and colleagues (2009) showed an increase of prostate cancer risk 
among individuals who possessed both the IL-1B CC and IL-10 GG genotypes (OR=3.38; 
95% CI=1.70–6.71) among European American men using MARS Logit [102]. However, 
the authors were unable to determine gene-gene interactions in relation to prostate cancer 
risk among African-Americans due to limited sample size. Most of the previous studies 
evaluated gene-gene interaction models among men of European and Asian descent, and 




















Table 1. Inflammatory and Immune related gene-gene interactions in Prostate cancer 
Gene Cases/ 
Controls 




















1,444/866 Swedish Prostate cancer MDR; p=0.019 Xu, 2005[147] 
IRAK4, 
TLR1 


























































To overcome the challenges and gaps of the aforementioned studies, our lab 
evaluated complex interactions among 119 inflammatory and immune response sequence 
variants in relation to PCA among men of African descent. We evaluated 1-, 2- and 3-
factor gene-gene interaction models among 119 inflammatory and immune response-
related sequence variants using a supercomputer with 24 computer processing units 
(CPUs). Gene-gene interactions were examined using MDR to identify interaction 
models with high cross validation consistency values, ranging between 80-100%, and 
accurate prediction scores (e.g., ATA ≥ 50%). As previously reported, our lab used 
multifactor-dimensionality reduction coupled with entropy graphs to identify, validate 
and visualize joint effects of inflammatory and immune response sequence variants as 
PCA predictors. MDR is a non-parametric method designed to detect higher order gene-
gene interactions involving 2 or more loci with relatively small sample sizes (≥200 cases, 
≥200 controls) for case-control studies, which is beyond the capacity of LR. It also has 
adequate statistical power to detect significant 2-4-factor gene-gene interactions in the 
presence of small sizes (200 cases, 200 controls). MDR analyses can be adjusted for 
multiple hypothesis testing using permutation testing, which minimizes spurious findings 
due to chance. In addition, this non-parametric method has the capacity to adjust for co-
founders (e.g., age) and utilizes entropy graphs to interpret the effect of gene-gene 
interactions. Entropy graphs indicate which factors within a gene-gene interaction is 
synergistic or not through connecting color-coded lines between each SNP. The color 
scheme is as follows: red (highly synergistic), orange (moderately synergistic), green 





The current version of MDR does not require an equal number cases and controls 
to predict high order interactions. For instance, our lab reported on gene-gene interactions 
among inflammatory and immune response-related sequence variants among men of 
African descent [31]. We observed that the age-adjusted three-factor (TLR10 rs11096957, 
TLR6 rs2381289, IRF3 rs2304206) interaction model was the best predictor of prostate 
cancer risk due to its high prediction accuracy score (ATA) of 65% and cross validation 
value (CVC) of 100% among men of African descent from the U.S. and Jamaica 
(Permutation testing p-value = 0.001) [31]. The synergy of this three-factor model was 
primarily driven by the information gain scores of TLR6 rs2381289 (IG = 1.71%) and the 
pairwise interaction between TLR10 rs11096957 and IRF3 rs2304206 (IG = 1.75%) (see 
Chapter 3 Results). However when MDR analysis was restricted to U.S. men, the age-
adjusted 2-factor model, IRAK4 rs4251545 and TLR2 rs1898830, was found to be the 
best predictor of prostate cancer risk based upon 100% CVC and 62% ATA values 
(Permutation testing p-value = 0.001). The MDR-based entropy graph displayed a highly 
synergistic pairwise interaction between IRAK4 rs4251545 and TLR2 rs1898830 with an 
information gain (IG) score of 2.33%. Due to the information score exceeding the mutual 
information gain scores of each loci, this information gain score was regarded as 
informative. For the Jamaican men, only the one-factor model of TLR6 rs2381289 
survived multiple hypothesis testing and therefore selected as the best predictor of PCA 
susceptibility. MDR analysis for chemokine-associated sequence variants showed that the 
age-adjusted three-factor model (CCR7 rs3136685, CCL5 rs3817655, CCR9 rs41289608) 
was selected as the best interaction model based upon 100% CVC and 67% ATA values 




the MDR entropy-based graph revealed no strong synergistic interaction due to none of 
the pairwise interactions yielding informative information information gain scores. 
Similarly, the age-adjusted three-factor model (CCR6 rs3093024, CCL5 rs3817655, 
CCR9 rs41289608) among U.S. men were statistically significant with 69% ATA score 
and 100% CVC value in relation to prostate cancer (Permutation testing p-value = 0.001). 
Moreover, the age-adjusted three-factor model (CCR6 rs3093024, CCR4 rs6550178, 
CXCR7 rs7559855) was associated with a 90% CVC value and 70% ATA score among 
Jamaican men (Permutation p-value = 0.017).  Within this interaction, the MDR entropy-
based graph showed a moderately synergistic interaction between SNPs in CCR6 and 
CXCR7 with an informative pairwise interaction IG score of 3.41% and CCR4 
rs6550178 with the highest individual IG score of 8.2%.  
Among the cytokine-associated gene-gene interactions, a three-factor model 
(IL1R2 rs11886877, IL10 rs1800896, IL10RA rs4252243) was selected as the best 
predictor of PCA risk among men of African descent based upon a 61% ATA score 
(Permutation testing p-value = 0.003) (see Chapter 5 Results). This model displayed a 
highly synergistic interaction with an informative IG score of 0.86% for the pairwise 
interaction between IL1R2 rs11886877 and IL10 rs1800896. MDR analysis restricted to 
U.S. men showed a significant three-factor interaction model (IL1B rs1143627, IL1A 
rs1800587, IL1RN rs315951) with a 100% CVC value and 67% ATA score (Permutation 
testing p-value = 0.001). The synergy of this three-factor interaction model was based 
upon an informative mutual information gain score for IL1B rs1143627 and IL1A 
rs1800587 pairwise interaction (IG = 1.93%) (Data not shown).  Among Jamaican men, 




predictor of PCA risk with a 100% CVC value, 65% ATA score, permutation testing p-
value of 0.008 and informative pairwise mutual information gain score of 4.77% (Data 
not shown). However, interaction models predicted in relation to prostate cancer for 
Jamaican men must be further validated due to limited sample size of Jamaican 
population. 
Gene-gene interactions among genetic variants are essential to understanding the 
complex genetic architecture of prostate cancer. Further investigation of these 
interactions using a pooled multi-center study may lead to the identification of 
polymorphisms related to PCA risk within racially/ethnically diverse subgroups and 
disease progression. Such efforts may lead to the detection of validation of SNP 
signatures that may help to explain the higher PCA tumor burden among men of African 
descent relative to their Caucasian counterparts. To further investigate whether 
modification of a combination of gene targets (e.g., CCL5, CCR5) may impact PCA 
behavior (e.g., cell migration, proliferation, invasion, metastasis) using appropriate in 
vitro and in vivo studies. Moreover, it will also be very valuable to assess the effect of 
altered expression (i.e., overexpression or knockout) of inflammatory and immune 
response associated gene products (e.g., TLR, chemokine, cytokine) in prostate 
tumorigenesis. For instance silencing of CXCL1 and CXCL2 inhibits cell growth and 
induces apoptosis in PC3 cells [80]. Ultimately, the investigation of inflammatory and 








Currently, physicians diagnose patients with prostate cancer based upon tumor 
biopsies (e.g., needle or TUR), pathological analyses of tumor traits (e.g., tumor size, 
grade, stage), a blood test (e.g., PSA levels) and digital rectal exams. However, these 
standard methods fail to accurately distinguish between non-aggressive and aggressive 
disease. The inability of physicians to determine which patients should receive a biopsy 
and aggressive therapy will lead to unnecessary and costly clinical management of 
prostate cancer. The identification of high-risk alleles associated with inflammatory and 
immune-response genetic variants may help to improve early detection of PCA and 
ultimately aggressive disease. In addition, genetic variants may be used to develop a 
genetic kit, which consist of a high risk SNP panel, to identify high-risk individuals who 
should receive aggressive prostate cancer therapy. The development of genetic kits will 
be very marketable for translational medicine and may prove to replace or enhance 
current diagnostic techniques. In addition, scientists will want to understand the effect of 
conventional drugs on people with high-risk alleles. Ultimately, genetic kits may help 
reduce the use of invasive diagnostic techniques (e.g., tissue biopsy) for cancer diagnosis, 
improve the decisions of physician about treatment options for patients, and guide the 
discovery of new therapeutic targets. 
Over the years, cancer researchers have utilized genetic alterations associated 
with inflammatory and immune response genes to identify potential therapeutic agents 
and treatment strategies for cancer. Drug agonists and antagonists of toll-like receptors, 
chemokines, and cytokines are being evaluated in various clinical trials as potential anti-
cancer therapeutic strategies, as summarized in Table 2. TLR signaling plays a critical 




agonists have been studied as anti-tumor drugs in relation to tumorigenesis. For instance, 
Sohn and associates (2014) observed that TLR7 agonist, imiquimod, induces apoptosis in 
the squamous cell carcinoma cell line, SCC12, through the suppression of A20 protein 
expression and activation of JNK [151]. TLR7 agonists, imiquimod and loxoribine, 
stimulate pro-inflammatory cytokine (IL6) and chemokine (CXCL1, CXCL2, CCL2) 
production in TRAMP-C2 cells (mouse prostate cancer cell line) via elevation of TLR7 
gene and protein expression [62]. In particular, loxoribine was shown to inhibit the 
growth of TRAMP-C2 cells primarily through TLR7 signaling. Thus, TLR7 agonists may 
possess anti-tumorigenic activity against prostate cancer tumorigenesis. TLR9 is a 
member of the innate immune system, which makes it a great target for candidate anti-
cancer therapeutic agents. Wakayama Medical University conducted a Phase I and II 
clinical trial to treat advanced recurrent esophageal cancer patients with a combination of 
novel tumor specific epitope peptides and TLR9 agonist, CpG7909 (Trial #: 
NCT00669292). Several studies have shown elevated TLR9 protein expression in poorly 
differentiated prostatic tumors and strongly associated with poor prognosis of prostate 
cancer [152, 153]. Moreover, the TLR9 agonist, CpG-ODN, stimulates PC3 cells to 
secrete immunosuppressive cytokines, IL8 and TGFβ1[154].  
The National Center of Tumor Diseases in Heidelberg, Germany has a Phase I 
clinical trial in progress studying the effect of CCR5 blockage on tumor cells in 
colorectal metastases. CCR5 inhibitor, maraviroc, is used to treat colorectal cancer 
metastasis in 12 patients with an 8-week follow-up time (Trial #: NCT01736813). Ochoa 
and co-workers (2013) demonstrated that maraviroc reduces liver injury, weight loss and 




Velasco and colleagues (2012) observed that CCR5 antagonists (maraviroc and 
vicriviroc) decreased both cellular invasion and tumor metastases on the lung in breast 
cancer metastasis in vivo using NOD/SCID mice [156]. In a non-randomized Phase I/II 
clinical trial completed in 2010, Biokine Therapeutics Ltd evaluated a CXCR4 
antagonist, BKT-140, as a novel treatment against multiple myeloma (Trial# 
NCT01010880). BKT-140 has a synergistic effect with Granulocyte-colony stimulating 
factor (G-CSF) to mobilize white blood cells and reduce anemic episodes.  
Expansion of the knowledge on the role of inflammatory and immune response-
related genes in prostate cancer tumorigenesis will provide guidance in the design of 
personalized medicine for cancer patients. Nonetheless, observational studies must 
evaluate all possible inflammatory and immune response signaling pathway targets. 
Further investigation of the inflammatory and immune-response signaling pathway may 
lead to the identification of novel and more effective targets to improve clinical 















Table 2. Current Inflammatory and Immune Response Gene Selective Drugs in Clinical 
Trials  
Target Compound Company Status Trial # 
CCR5 Maraviroc National Center for Tumor 
Diseases, Heidelberg 
Phase I NCT01736813 
CXCR4 BKT140 Biokine Therapeutics Ltd Phase I/II NCT01010880 
TLR gp100, R848 
gel, MAGE-3 
M.D. Anderson Cancer 
Center 
Phase II NCT00960752 
TLR7 Imiquimod New York University School 
of Medicine 
Phase I/II NCT01421017 
TLR8 VTX-2337 University of Washington Phase I NCT01334177 
TLR9 CpG7909 Wakayama Medical 
University 
Phase I/II NCT00669292 
IL15 IL15 National Institutes of Health 
Clinical Center, National 
Cancer Institute  















The following sections of this master’s thesis will be organized into chapters 2 
through 6. Chapter 2 describes the methods used to analyze main and joint effects of 
inflammatory and immune response related sequence variants. Next, research findings 
will be divided into 3 separate chapters for each signaling pathway. Chapter 3 describes 
the key logistic regression modeling and MDR analysis findings for the toll-like receptor 
signaling pathway. Chapter 4 highlights the key logistic regression and MDR analysis 
findings for the chemokine signaling pathway. Chapter 5 describes the key logistic 
regression modeling and MDR analysis findings for the cytokine signaling pathway.  
Lastly, Chapter 6 consists of the master’s thesis summary, conclusion and clinical 

















Research Hypothesis  
The proposed research hypothesizes that the inheritance of one or more high-risk 
alleles in inflammatory and immune response genes involved in the toll-like receptor, 
chemokine and cytokine signaling pathways will modify prostate cancer susceptibility 























Specific Aims  
      The following two specific aims will test the proposed research hypothesis: 
Specific Aim1: Determine main effects of inflammatory and immune response related 
sequence variants on prostate cancer susceptibility among men of African descent. 
Sequence variants within inflammatory and immune response genes may influence 
the interaction among the toll-like receptor, cytokine-cytokine receptor and 
chemokine-chemokine receptor signaling pathways. These variants may impact toll-
like receptor surveillance in innate immunity, chemokine and cytokine production 
during chronic inflammation and mobilization of inflammatory immune cells within 
the inflammatory and immune response signaling pathway. Regulation of the toll-like 
receptor, chemokine and cytokine signaling pathways are pivotal to the balance 
between anti- and pro-inflammatory signals released from immune cells. Genetic 
alterations that interfere with the operation of the inflammatory and immune response 
pathways may elevate pro-inflammatory signals leading to chronic prostatitis (chronic 
inflammation) and initiation of prostate cancer development. 
Specific Aim 2: Evaluate gene-gene interactions among inflammatory and immune 
response related sequence variants among U.S. and Jamaican men. The effect of 
single sequence variants may not fully explain the role of inflammatory and immune 
response-related genes in prostate cancer development and progression.  Therefore, 
the investigation of multiple sequence variants is needed to identify important PCA 
predictors. Multi-locus tools such as MDR can detect high order (≥2) interactions 
among sequence variants to elucidate the complexity of the roles these pathways and 




genes within the inflammatory and immune response pathway will provide insight to 
the complex mechanisms that feed into prostate cancer development. Gene-gene 
interactions can negatively or positively influence the translation of protein product 
and expression on various cell types. Immune cells (e.g., macrophages, leukocytes) 
express toll-like receptors on the extracellular membrane to detect bacterial infection 
and pathogens. Cytokine and chemokine receptors are also expressed on immune 
cells and utilized to detect their respective ligands and direct cell-cell 
communications. The inheritance of sequence variants within inflammatory and 


















Study Population  
The current study consisted of two independent case-control study sets with participants 
from the Prostate Cancer Clinical Outcome (PC
2
O) Study and the Prostate Cancer Case-
Control study (Table 3, 4, and 5). Among all 814 men of African descent, germ-line 
DNA samples were collected for 279 PCA cases and 535 disease-free men, as shown in 
Table 1.  In the PC
2
O Study, 603 unrelated men of African descent were recruited from 
Columbia, South Carolina and Howard University Hospital (HUH) Division of Urology 
in Washington, D.C. or related PCA screening programs between 2001 and 2005. This 
population of men of African descent (i.e., self-reported African Americans, East African 
Americans, West African Americans, and Afro-Caribbean Americans) consisted of 170 
incident PCA cases and 433 controls (Table 4).  Between March 2005 and July 2007, 
two hundred twenty-one unrelated Jamaican men were recruited and consecutively 
enrolled into a prostate cancer case-control study (109 prostate cancer cases, 102 
controls) during their first time visit at urology clinics (Table 5).  Details on case and 
control ascertainment and inclusion criteria for both sub-populations have ben detailed 






Table 3.  Study population characteristics among men of African descent from the U.S. 
and Jamaica. 
Characteristics Cases Controls p value
a
 
Number of Participants, n 279 535 --- 
Age at enrollment (yrs), 
Median (range) 
67 (45-91) 53 (27-89) <0.0001 
Family History of Prostate 
Cancer
b
, n (%) 
      Yes 
      No   
      Missing 
 
 












PSA (ng/ml), median (range) 11.7 (0.01-10,000) 0.9 (0.0-4.0) <0.0001 
PSA
b
 (ng/ml), n (%) 
      < 4 
      ≥ 4 
      Missing 
 
 37 (13.8) 
231 (86.2) 
 11 (0.04) 
 
517 (99.8) 
 1 (0.2) 





, n (%) 
      4 
      5 
      6 
      7 
      8 
      9 
      10 




 74 (34.2) 
 70 (32.4) 
18 (8.3) 
  22 (10.2) 
 6 (2.8) 










0.79 (0.25-0.94) 0.767 (0.25-0.95) 0.107 
Abbreviations:  PSA, prostate specific antigen; WAA, West African Ancestry; 
a
Chi-square test of 
homogeneity was used to determine whether the prevalence of family history or high PSA levels 
(PSA ≥ 4 ng/mL) vary between cases and controls; 
b
Wilcoxon Sum Rank Test was used to 
examine whether differences exist within the median age (yrs), PSA (ng/ml) and Global WAA 




















Table 4.  Baseline Characteristics among men of African Descent from the U.S. 
Characteristics Cases Controls p value
a
 
Number of Participants, n 170 433 --- 
Age at diagnosis (yrs), Median (range) 65 (45-91) 51 (27-89) <0.0001 
Family History of Prostate Cancer
b
, n (%) 
      Yes 
      No   







  9 (13.6) 
57 (86.4) 





 (ng/ml), median (range) 7.0 (0.01-5,000) 0.9 (0.0-3.9) <0.0001 
PSA (ng/ml), n (%) 
      < 4 
      ≥ 4 
      Missing 
 











, n (%) 
      4 
      5 
      6 
      7 
      8 
      9 
      10 














, mean (SD) 0.79 (0.25-0.94) 0.77 (0.25-0.94) 0.107 
Abbreviations:  PSA, prostate specific antigen; 
a
Differences in frequencies were  
tested by a Chi-square test of homogeneity or Fisher’s Exact Test; 
b
Differences in median  


























Table 5. Baseline Characteristics among men from Jamaica 
Characteristics Cases Controls p value
a
 
Number of Participants, n 109 102 --- 
Age at diagnosis (yrs), Median (range) 70 (49-80) 60 (40-80) <0.0001 
Family History of Prostate Cancer
b
, n (%) 
      Yes 
      No   






  12 (11.8) 
 90 (88.2) 





 (ng/ml), median (range) 35.0 (4.0-10,000) 1.2 (0.2-4.0) <0.0001 
PSA (ng/ml), n (%) 
      < 4 
      ≥ 4 
      Missing 
 











, n (%) 
      4 
      5 
      6 
      7 
      8 
      9 
      10 




  45 (41.7) 
  38 (35.2) 
  13 (12.0) 
10 (9.3) 
  2 (1.8) 
    1 (0.01) 
  
  
Abbreviations:  PSA, prostate specific antigen; 
a
Differences in frequencies were  
tested by a Chi-square test of homogeneity or Fisher’s Exact Test; 
b
Differences in median  
















Criteria for Inflammatory and Immune Response Gene and SNP selection 
 Inflammatory and immune response-associated genes and SNPs were selected 
using one or more of following criteria:  (1) epidemiological or molecular biological 
evidence from published reports indicating a relationship between the SNP/gene with 
cancer or inflammatory/immune response related diseases; (2) commonly studied loci; (3) 
marked disparities in genotype frequency comparing men of African descent to their 
Caucasian counterparts (i.e., ±10% change); (4) evidence demonstrating a link between 
the SNPs and alterations in mRNA expression/stability or protein expression/structure or 
function using in silico tools (e.g., SNPinfo) or published reports 
(http://snpinfo.niehs.nih.gov/snpfunc.htm); and (5) a minor allele frequency ≥1% 
reported in the National Center for Biotechnology Information (NCBI) Entrez SNP, 
(www.ncbi.nlm.nih.gov).  On average, a majority of the SNPs had minor allele 
frequencies ranging from 22-27%. However, eight SNPs with allele frequencies greater 
than 1% but less than 5% were included in the analysis to explore whether rare SNPs 
would lead to substantial gains in effect sizes (i.e., 2-3 fold increases in risk) and 
contribute to the missing genetic heritability [159, 160].  The SNPinfo webserver enabled 
us to annotate and/or predict the functional consequence of inflammatory and immune 
response associated sequence variants on altered alleles relative to referent alleles, as 
summarized in the Functional Consequence Tables 6-8.   
Quality Control Assurance and Data Management of Genotype data 
 At the onset of the project, allelic discrimination focused on inflammatory and 
immune response associated SNPs among men of African Descent. To minimize 




participants.  Each batch of up to 96 samples included four non-DNA template controls 
and eight duplicate samples, which enabled us to calculate the percent contamination 
(i.e., 0%) and concordance rates (i.e., 100%) per batch and for the entire data set, 
respectively.  Genotype call rates were calculated separately for each SNP and study 
participant.  Lastly, we tested whether the distribution of the genotypes among disease-
free individuals had significant departures from the Hardy-Weinberg equilibrium (HWE). 
 Prior to performing marker statistics, we excluded subjects who had genotype call 
rates that were <90%. To ensure high quality data, nine SNPs were excluded from the 
final analysis if:  the distribution of the genotypes among controls deviated substantially 
from the Hardy-Weinberg Equilibrium, using a conservative significance level cut-off 
value of P ≤ 0.005; they had a minor allele frequency that was  < 1%; or the genotype call 
rates fell below 95%.  Following data clean up, 119 inflammatory and immune-related 
SNPs were included in the final analysis consisting of 814 men of African descent (279 
cases, 535 controls).  All quality control analyses and data management was performed 
using Golden Helix’s SNP Variation Software 7.0 (Bozeman, MT).  
Genetic Analysis of Variant Inflammatory and Immune Response-Associated SNPs 
De-identified germ-line DNA was obtained from incident PCA male cases (n = 
279) and controls (n = 535). SNPs detected in TLRs (1, 2, 4, 6, and 10), IRAK4, TOLLIP, 
IRF3, CCLs (1,2,5,7,11,17,21,24,25, and 26), CCRs (4,5,6, 7, and 9), CXCL12, CXCRs (5 
and 7), ILs (1, 8, 10), TNF, RNASEL were genotyped using Illumina’s GoldenGate 
genotyping assay system combined with Veracode Technology (Illumina, Inc., San 
Diego, CA). Allelic discrimination was performed using a BeadXpress Reader (Illumina, 










dbSNPID   






















IRAK4   
rs4251467    
Intron 3 C/T 12 C>T 
 
 
T C 0.932 0.926 0.062 0.058 0.078 
IRAK4   
rs4251473    
Intron 5 A/C 12 A>C 
 
 
C A 0.951 0.76 0.202 0.204 0.195 
IRAK4   
rs4251520    
Intron 9 C/T 12 C>T 
 
 
T C 0.88 0.812 0.184 0.176 0.220 
IRAK4   
rs4251545    
Exon 8 A/G 12 A>G Ala>Thr 
Splice Site 
benign G A 0.937 0.625 0.300 0.304 0.282 
IRF3  







0.727 0.421 0.384 0.388 0.368 
IRF3   
rs968457    
Near Gene’5 T/C 19 T>C 
 
Splice Site 
nsSNP, benign C T 1 0.85 0.080 0.070 0.123 
TLR1  
rs3923647   
Exon 1 T/A 4 T>A 
 nsSNP 
probably 
damaging T A 0.913 0.917 0.068 0.058 0.109 
TLR1  
rs4624663   
3'UTR T/C 4 T>C 
 
 
T C 0.973 0.938 0.068 0.064 0.089 
TLR1  
rs4833095   
Exon 1 C/T 4 C>T 
 
nsSNP C T 0.273 0.646 0.198 0.208 0.152 
TLR1  
rs5743595   
Intron 2 G/A 4 G>A 
 
 
A G 0.753 0.958 0.029 0.033 0.010 
TLR1  
rs5743604   
Intron 3 G/A 4 G>A 
 
 
A G 0.729 0.542 0.450 0.470 0.368 
TLR2  
rs1898830   
Intron 1 A/G 4 A>G 
 
 
A G 0.628 0.833 0.136 0.359 0.327 
TLR2  
rs3804099   
Exon 1 C/T 4 C>T 
 
 
C T 0.586 0.354 0.382 0.256 0.181 
TLR2  
rs7656411   
Near Gene’3 G/T 4 G>T 
 
 
G T 0.792 -- 0.423 0.017 0.015 
    
 







dbSNPID   























rs7656411   
Near Gene’3 G/T 4 G>T 
 
 
G T 0.792 -- 0.423 0.017 0.015 
TLR4 





   
0.707 0.304 0.242 0.370 0.340 
TLR4  
rs1927906     
Near Gene’3 T/C 9 T>C 
 
 
T C 0.94 0.604 0.449 0.191 0.186 
TLR4  
rs1927911   
Intron 1 G/A 9 G>A 
 
 
G A 0.743 0.542 0.353 0.256 0.196 
TLR4  
rs4986791   
Exon 3 C/T 9 C>T 
 nsSNP 
possibly 
damaging C T 0.959 0.938 0.017 0.070 0.083 
TLR4  
rs5030710   
Exon 3 C/T 9 C>T 
 
Splice Site T C 1.000 0.729 0.149 0.097 0.025 
TLR6  
rs1039559   
Intron 1 G/A 4 G>A 
 
TFBS A G 0.513 0.771 0.190 0.227 0.255 
TLR6  
rs2381289    
3’UTR G/A 4 G>A 
 
 
G A 0.587 0.771 0.245 0.494 0.435 
TLR6  
rs3821985   
Exon 1 G/C 4 G>C 
 
 
C G 0.722 0.423 0.364 0.493 0.436 
TLR6  
rs5743810   
Exon 1 G/A 4 G>A 
 
nsSNP 
benign G A 0.588 0.907 0.072 0.031 0.015 
TLR6  
rs5743818   
Exon 1 C/A 4 C>A 
 
 
A C 0.761 0.839 0.083 0.032 0.025 
TLR10 
rs10776483      
Exon 1 G/A 4 G>A 
 
 
A G 0.707 -- 0.232 0.134 0.142 
TLR10 
rs11096955      
Exon 1 T/G 4 T>G 
 
nsSNP 
benign T G 0.408 -- 0.492 0.382 0.382 
TLR10 
rs11096957      
Exon 1 T/G 4 T>G 
 nsSNP 
possibly 
damaging G T 0.408 -- 0.493 0.424 0.421 
TLR10 
rs11466640     
Intron 1 G/A 4 G>A 
 
 







dbSNPID   























rs4274855   
5’UTR T/C 4 T>C 
 
 
C T 0.747 0.958 0.031 0.455 0.425 
TOLLIP 
rs3168046    
3’UTR G/A 11 G>A 
 
miRNA G A 0.568 0.568 0.422 0.428 0.397 
TOLLIP 
rs5743867   
Intron  1 G/A 11 G>A 
 
 
A G 0.92 0.854 0.201 0.202 0.197 
TOLLIP 
rs5743899   
Intron 1 T/C 11 T>C 
 
  T C 0.892 0.652 0.428 0.419 0.465 
Abbreviations: Chr, chromosome; UTR, untranslated region; TFBS, transcription factor binding site, miRNA, micro RNA; 
nsSNP, nonsynonymous SNP; EA, European-American; AA, African-American; 
a
TLR-related SNPs were analyzed among men 


















Consequence Current Study MAF 
CCR6 
rs1012656 6 5’UTR     TFBS C=19.5 
CCL2 
rs1024611 17 Near gene 5’     TFBS C=19.7 
CXCR7 
rs1045879 2 Exon 1 T>C Leu266Leu   G=30.7 
CCL17 
rs11076191 16 Intron 1     TFBS A=2.3 
CCL21 
rs11574914 9 Near gene 5’     TFBS A=9.1 
CCL21 
rs11574915 9 5’UTR     TFBS, Splicing C=10.6 
CCL21 
rs11574916 9 3’UTR     TFBS, miRNA A=5.5 
CCR9 
rs12721497 3 Exon 3 G>A Met284Val nsSNP, benign G=1.9 
CCR9 
rs1488371 3 Intron 2       A=15.6 
CCR6 
rs1556413 6 Near gene 5’     TFBS A=20.2 
CCL7 
rs17809012 17 Near gene 5’     TFBS G=34.6 
CXCL12 
rs17880777 10 Near gene 5’     TFBS C=17.4 
CCR5 
rs1799987 3 Intron 1     TFBS A=40.3 
CCR5 
rs1799988 3 5’UTR     TFBS G=41.9 
CCR5 
rs1800024 3 Intron 2     TFBS A=19.8 
CXCL12 
rs1801157 10 3’UTR     miRNA A=6.3 
CCR6 
rs2023305 6 Near gene 5’     TFBS A=16.8 






































Current Study MAF 
CCL25 





rs2107538 17 Near gene 5’     TFBS A=46.6 
CCR5 
rs2227010 3 Near gene 5’     TFBS G=19.8 
CCL17 
rs223895 16 Intron 1       A=29.9 
CCL5 
rs2280789 17 Intron 1     TFBS G=22.3 
CCL1 
rs2282691 17 Intron 2       A=46.2 
CCR9 
rs2286486 3 Near gene 5’     TFBS G=25.9 
CCL24 
rs2302004 7 Intron 1     TFBS G=41.9 
CCL26 
rs2302009 7 3’UTR     miRNA C=40.7 
CXCL12 
rs266093 10 3’UTR     miRNA G=42.9 
CCL21 
rs2812378 9 Near gene 5’     TFBS G=41.9 
CXCL12 
rs2839685 10 Near gene 5’     TFBS A=31.4 
CXCL12 
rs2839695 10 3’UTR     miRNA G=17.5 
CCR6 
rs3093023 6 Near gene 5’       A=13.8 
CCR6 
rs3093024 6 Intron 1       A=32.3 
CCR7 
rs3136685 17 Intron 1       G=49.5 














Consequence Current Study MAF 
CCR7 
rs3136687 17 Intron 1        A=44.4 
CCL5 
rs3817655 17 Intron 2     TFBS A=46.5 
CCR9 
rs41289608 3 5’UTR     TFBS, Splicing A=36 
CCL11 
rs4795896 17 Near gene 5’     TFBS G=4.8 
CXCR5 
rs523604 11 Intron 1       A=34.9 
CCR4 
rs6550178 3 Intron 1     TFBS A=17.2 
CCL25 
rs7259568 19 Near gene 5’     TFBS A=9.3 
CXCR7 
rs7559855 2 Intron 1       A=38.5 
CCR9 
rs7613548 3 Near gene 5’     TFBS A=44 
CCR4 
rs7632357 3 Near gene 5’     TFBS C=41.6 
Abbreviations: Chr, chromosome; UTR, untranslated region; TFBS, transcription factor binding site, miRNA, micro RNA; 
nsSNP, nonsynonymous SNP; 
a
Forty-three chemokine-related SNPs were analyzed among men of African Descent. SNPs 
denoted in bold had significant risk estimates associated with PCA risk in the total population. Italicized SNPs were 
significantly associated with PCA risk in the Jamaican population. Columns shaded in gray symbolize SNPs that were 



















 AA  
MAF 
(%) 

























 p-value                                    







3’UTR    
miRNA  
G>A A=37.9   26 (42.0) 
25 (40.3) 
11 (17.7) 





rs1071676*   
3’UTR    
miRNA 
(miRanda  and 
Sanger) 
G>C C=14.6 19 (79.2) 
3 (12.5) 
2 (8.30) 





rs11123902*     
Intron 1 
A>C C=31.8 10 (45.5) 
10(45.5) 
2 (9.10) 





rs1126579*   
3’UTR   
miRNA  
C>T T=14.5  46 (74.2) 










 Near gene 5'  
TFBS 





















rs11574752*   
3’UTR      
miRNA  
G>A A=10.4 19 (79.2) 
5 (20.8) 
0 (0.00) 































 AA  
MAF 
(%) 
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3’UTR       
TFBS, miRNA  
 












Near gene 5'    
TFBS 











3’UTR         
miRNA  
A>G G=39.6   8 (33.3) 
13 (54.2) 
  3 (12.5) 






Near gene 5'  
TFBS 
A>G G=39.0          18 (30.5) 
36 (61.0) 
5 (8.50) 






Exon 4   
Splicing (ESE or 
ESS), nsSNP, 
benign 
G>T T=15.3 44 (71.0) 
17 (27.4) 
  1 (1.60) 
C>A
†






Near gene 5'  
TFBS 











5’UTR       
TFBS, Splicing 
(ESE or ESS) 



























 AA  
MAF 
(%) 

























 p-value                                    







Near gene 5’ 
TFBS 
G>A A=13.7 46 (74.2) 
15 (24.2) 
1 (1.60) 



















Near gene 5’ 
TFBS 
C>A A=38.8     19 (38.8) 
22 (44.9) 
8 (16.3) 






Near gene 5’ 
TFBS 
G>A A=37.1     22 (35.5) 
34 (54.8) 
6 (9.70) 






Near gene 5’ 
TFBS 
A>G G=40.5     7 (33.3) 
11 (52.4) 
3 (14.3) 






Near gene 5’ 
TFBS 
A>C C=4.80 56 (90.3) 
6 (9.70) 
0 (0.00) 






Near gene 5' 
TFBS 











5’UTR       
TFBS, Splicing 
(ESE or ESS) 


























 AA  
MAF 
(%) 

























 p-value                                    









A>C C=8.70 19 (82.6) 
4 (17.4) 
0 (0.00) 






Exon 7    
nsSNP, probably 
damaging 
G>A A=20.5 14 (63.7) 
7 (31.8) 
1 (4.50) 






Exon 2  
Splicing (ESE or 
ESS), nsSNP, 
benign 
A>G G=16.9 44 (71.0) 
15 (24.2) 
3 (4.80) 






3’UTR     
miRNA  











Exon 5  
Splicing (ESE or 
ESS), nsSNP, 
benign 
A>G G=2.10 23 (95.8) 
1 (4.20) 
0 (0.00) 






3’UTR   
miRNA  
C>G G=47.9     8 (33.3) 
9 (37.5) 
7 (29.2) 








(ESE or ESS) 


























 AA  
MAF 
(%) 

























 p-value                                    







Near gene 5'  
TFBS 
A>G G=12.3     49 (80.3) 
9 (14.8) 
3 (4.90) 
A>G G=9.10 438 (81.9) 





Near gene 5'  
TFBS 
A>T T=26.6      34 (54.8) 
23 (37.1) 
5 (8.10) 






Near gene 5' 
TFBS 











Near gene 5'  
TFBS 











Near gene 5'  
TFBS 











Near gene 5'  
TFBS 
G>A A=25.0    14 (58.3) 
8 (33.3) 
2 (8.30) 






5’UTR       
TFBS 
A>G G=23.9    12 (52.2) 
11 (47.8) 
0 (0.00) 






Exon 1  
nsSNP, benign 
G>A A=16.7 16 (66.7) 
8 (33.3) 
0 (0.00) 





















 AA  
MAF 
(%) 

























 p-value                                    







Near gene 5'  
TFBS 










Near gene 5'  
TFBS 
G>A A=13.7  45 (72.6) 
17 (27.4) 
0 (0.00) 






Near gene 5'  
TFBS 











Near gene 5'  
TFBS 
G>A A=31.1 31 (50.8) 
22 (36.1) 
8 (13.1) 






3’UTR   
miRNA  
A>G G=41.9   20 (32.3) 
32 (51.6) 
10 (16.1) 






Near gene 5'  
TFBS 










The nucleotide change may vary relative to that reported in NCBI depending on whether the genotyping was performed using the sense or anti-
sense DNA strand. 
††
The chi-square test was used to assess differences in the overall genotype frequencies comparing men of African descent as reported in NCBI 
to those in the total population from the current study. P-values generated from the Fisher's exact test (in italics) were used when expected 
genotype counts were < 5 for either cases or controls. Abbreviations:  UTR, untranslated region; TFBS, transcription factor binding site; nsSNP, 
non-synonymous coding SNP; miRNA, microRNA binding site;; MAF, Minor Allele Frequency NCBI, National Center for Biotechnology 
Information Entrez SNP 
*NCBI AFR1 or African American Population Panel 





Cases and controls were genotyped with a set of 100 genome-wide ancestry 
informative markers to correct for potential population stratification among our admixed 
population of self-reported African-Americans, West African-Americans, East African-
Americans, Afro-Caribbean-Americans, as previously described [162, 163].  Individual 
genetic ancestry was determined using 100 ancestry identification markers (AIMs) for 
West African and European genetic ancestry as well as genotype data using the Bayesian 
Markov Chain-Monte Carlo method implemented in the STRUCTURE 2.1 program [162, 
164]. Study participants were grouped from lowest to highest genetic West African 
Ancestry, with scores ranging from 0-100%.  These 100 markers were assembled using 
DNA from self-identified African-Americans (Coriell Institute for Medical Research, n = 
96), Yoruban West Africans (HapMap, n = 60), West Africans (Bantu and Nilo Saharan 
speakers, n = 72), Europeans (New York City, n = 24), and CEPH Europeans (HapMap 
Panel, n = 60), as previously reported [163]. Individuals with a West African ancestry 
(WAA) score ≥25% and available inflammatory and immune response associated 
sequence variants were included in the final analysis. 
Statistical Analysis for Single Gene Effects 
Logistic regression (LR) modeling analyses were used to evaluate the relationship 
between 119 inflammatory and immune response SNPs among men of African descent 
and PCA risk.  For each SNP, we examined the frequency differences in the distribution 
of homozygous major, heterozygous, or homozygous minor genotypes between cases and 
controls using the chi-square (χ
2
) test of homogeneity. Odds ratios (OR) and 




inflammatory and immune response-related SNPs were estimated using unconditional 
multivariate after adjusting for potential confounders (e.g., age, PSA, WAA). 
Confounders were kept in the LR model if they significantly changed the risk estimates 
by ± 20% compared to the unadjusted model. LR analyses for genetic variants and PCA 
risk were conducted using the major or common genotype as the referent category. Chi-
square test and LR analyses were performed using SAS 9.3 (SAS Institute Inc., Cary, 
NC) and SVS software 7.0 (Golden Helix, Inc., Bozeman, MT). Adjustment for multiple 
hypothesis testing was achieved using false discovery rate (FDR) or Bonferroni 
Correction with a significance level of 0.05 and 0.001, respectively.  
Statistical Power for Single Gene Effects  
We calculated the odds of developing PCA among carriers of at least one or more 
minor allele among 119 inflammatory and immune response-associated sequence variants 
based on the average MAF 22-27%, a PCA disease prevalence of 0.740%, a significance 
level (α) of 5%, and 100% linkage disequilibrium (LD) between the casual and 
predisposing variant.  We assumed the causal SNP was in complete linkage 
disequilibrium with the predisposing variant (r
2
 = 1.0) and a co-dominant genetic model 
with 1 degree of freedom (df).  According to our sample size for the combined population 
(279 cases, 535 controls), U.S. (170 cases, 433 controls) and Jamaican men (109 cases, 
102 controls), we had >80% power to detect odds ratios (ORs) of ≥1.4, ≥1.6, ≥1.9 for 
TLRs, ≥1.5, ≥1.55, ≥2.0 for chemokines and ≥1.4, ≥1.6, ≥1.8 for cytokines in relation to 
PCA risk, respectively.  Statistical power calculations were performed using Power for 





Analysis of Gene-Gene Interactions Using Multi-factor Dimensionality Reduction  
 To evaluate the single- and joint- modifying effects of 119 candidate 
inflammatory and immune response sequence variants within a large dataset is 
computationally challenging. In order to overcome this problem, open source and freely 
available Multi-factor Dimensionality Reduction (MDR) 2.0 was used to detect and 
characterize all possible one-, two-, and three-way interaction models in relation to PCA 
(http://www.epistasis.org/) [166]. To reduce computation time needed to process 
thousands of SNP combinations in relation to PCA risk, we distributed MDR on a 
workstation with 12 hyper-threaded cores across two central processing units (total of 24 
simultaneous threads of execution) and 24 GB of RAM. Although MDR has been 
described elsewhere, for convenience we provide a brief summary. With MDR, genetic 
information is reduced to a one-dimensional multi-locus genotype variable shown in 
Figure 5 [167, 168]. Information from various disease loci were grouped and labeled as 
“high risk” or “low risk” based on whether or not the control ratio met or exceeded a 
particular threshold.  Subsequently, the resulting one-dimensional multi-locus genotype 
variable was examined for its capacity to categorize and predict disease outcome through 
cross-validation and permutation testing procedures. A 10-fold cross-validation was 
achieved by dividing the entire dataset into a training set and an independent testing set. 
The training set involved 9/10
ths
 of the data; the remaining 1/10
th
, known as the 
independent testing set, was evaluated against the training set. Evaluation of each 
independent testing set predicted average testing accuracy values for each MDR model. 
The greatest cross validation consistency (i.e., CVC ≥ 8/10) and highest prediction 




predictors of disease outcome. Sensitivity and specificity were determined as functions of 
true negatives (TN), false positives (FP), and false negatives (FN). Sensitivity, specificity 
and balanced accuracy values were calculated as follows: sensitivity = (TP)/(TP+FN); 
specificity = (TN)/(FP + TN); and balanced accuracy = (sensitivity + specificity)/2. 
ATAs were averaged across all 10 pieces of the data, in order to provide an estimate of 
the predictive ability of the loci in relation to the outcome of interest. We used cross-
validation consistency (CVC) to determine the degree to which the same best MDR 
model was selected across the 10 divisions of the data. Models with a CVC of ≥8/10 
using a 10-fold cross-validation were considered more carefully. CVCs and ATAs were 
calculated across 1,000 random seeds to ensure reproducibility in model selection. If the 
MDR model met the CVC criteria, we selected models that had the highest ATAs. 
Multiple hypothesis testing was controlled by CVC in combination with permutation 
testing.  Permutation testing results ≤ 0.05, generated using random seed 500, were 
considered statistically significant. Age-group covariate effects were removed by 























Figure 5. Graphical model of gene-gene interactions. MDR analysis reduces genetic data 
into a one-dimensional variable. The graphical model is an example of a 1-, 2- and 3-factor 
interaction graphical models using Random Seed 500. For each model, the major/major 
homozygous genotype (0), heterozygous genotype (1) and minor/minor homozygous 
genotypes (2) are shown. In each square, darker gray bars represent cases and lighter gray 






Visualization of Interaction Models Using Hierarchical Interaction Entropy Graphs 
            Hierarchical interaction entropy graphs, based on information theory, were used 
to visualize and interpret complex interactions among selected SNPs and PCA risk [169-
172]. With this approach, individual and all possible pairwise loci are assigned a joint or 
mutual information percentage score based on disease risk, respectively. Joint mutual 
information and mutual information gain scores are based on a number system, ranging 
from 0-100%.  However, these scores rarely exceed 5-6%.  When the pairwise or joint 
mutual information exceeds the mutual information gain scores, then the pairwise 
interaction is considered more informative in relation to prostate cancer risk when 
compared to each locus considered separately.  Potential interactions are assessed using 
interaction entropy graphs, which uses a color-coding system to depict redundant or 
synergistic interactions. Within the entropy graph, lines depicted between SNP pairs that 
are color-coded red, orange, green, blue, and gold represent highly synergistic, 
moderately synergistic, moderately redundant, highly redundant, and neither 
synergistic/redundant pairwise interaction models, respectively, as depicted in Figure 6. 










Figure 6. Entropy graph of gene-gene interactions. MDR analysis produce an entropy 
graph to demonstrate if a gene-gene interaction has a synergistic effect or not. The lines 
between SNPs display a pairwise mutual information gain score representative of the 
interaction and are color-coded in the following manner: red (highly synergistic), orange 
(moderately synergistic), green (moderately redundant), blue (highly redundant), and gold 
(neither synergistic/redundant). Each SNP displays the mutual information gain score 






TOLL-LIKE RECEPTOR-ASSOCIATED SEQUENCE VARIANTS AND PROSTATE 
CANCER RISK AMONG MEN OF AFRICAN DESCENT                                                                                                                                                                                                                                           
 Among inflammatory and immune response regulators, toll-like receptors (TLRs) 
have a critical role in innate immune responses against chronic/recurrent inflammation, a 
major contributor to PCA development. However, it remains unclear whether sequence 
variants within TLR genes influence PCA risk among men of African descent. Therefore, 
we evaluated the impact of 32 TLR associated single-nucleotide polymorphisms (SNPs) 
on PCA risk among African Americans and Jamaicans. SNP profiles of 814 subjects were 
evaluated using Illumina’s Veracode genotyping platform. Single and combined effects 
of SNPs in relation to PCA risk were assessed using age-adjusted logistic regression and 
entropy-based multifactor dimensionality reduction (MDR) models. Seven sequence 
variants detected in TLR6, TOLLIP (Toll-interacting protein), IRAK4 (interleukin-1 
receptor-associated kinase 4) and IRF3 (interferon regulatory factor 3) were marginally 
associated with PCA [31]. However, none of these effects remained significant after 
adjusting for multiple hypothesis testing. Nevertheless, MDR modeling revealed a 
complex interaction between IRAK4 rs4251545 and TLR2 rs1898830 as a significant 
predictor of PCA risk among US men (Permutation testing p-value = 0.001). However, 
these genetic susceptibilities detected within the TLR signaling pathway require further 
assessment and validation to provide a better understanding of their influence on PCA 






Population Description  
 The demographic and other pertinent characteristics of cases and controls for the 
entire study population and each study center are summarized in Table 3-5.  Overall, men 
diagnosed with prostate cancer were 14 years older and had higher PSA levels than 
controls (P < 0.0001).  Among controls, Jamaican men were about 9 years older and had 
higher PSA levels (P < 0.0001) and as well as higher median Gleason scores (P = 0.018) 
than U.S. men. As summarized in Table 3, there were no significant differences in family 
history of PCA with respect to the following: (1) cases to controls from the total 
population (P = 0.316) (Table 3), U.S. alone (P = 0.592) (Table 4), or Jamaica alone (P = 
0.272) (Table 5), and (2) controls (P = 0.757) or cases (P = 0.830) comparing the two 
study centers (data not shown).  Among African-Americans, the degree of West African 
ancestry did not vary by disease-status, as shown in Table 4 [162-164]; however, no such 
data was collected for the Jamaican men.  
Minor allele and genotype frequency among men of African descent from the U.S. and 
Jamaica  
           Overall, the average minor allele frequency (MAF) for TLR-associated SNPs 
among disease-free U.S. and Jamaican men combined was 23.3% [standard deviation 
(SD) = 15.8]. When stratified by study site, the MAFs for U.S. and Jamaican men were 
23.3% (SD = 16.1) and 21.9% (SD = 14.9), respectively. When the TLR-associated SNPs 
among the total population (i.e., U.S. and Jamaican men combined) were analyzed, 





Association between TLR-associated sequence variants and prostate cancer risk 
Three TLR-associated markers (TLR6 rs2381289, TOLLIP rs3168046, and 
TOLLIP rs5743899) were modestly linked with PCA susceptibility for the total 
population under the age-adjusted LR models, as shown in Table 9a. In particular, 
possession of the TLR6 rs2381289 GA or TOLLIP rs5743899 AG+GG genotypes was 
associated with a 1.46-1.49 fold increase in the risk of developing PCA. In contrast, 
TOLLIP rs3168046 AA carriers had a significant 42% reduction in PCA susceptibility 
(ORage-adjusted = 0.58; 95%CI = 0.35, 0.98).  However, none of these markers remained 
significant after adjusting for multiple hypothesis testing (FDR p-value > 0.05).  
 Upon stratification by study center, six of the 32 candidate TLR-associated SNPs 
were identified as modestly significant determinants of PCA risk after adjusting for age, 
as shown in Table 9b. Within the U.S. population, a nominal 40-66% reduction in PCA 
susceptibility was observed among men who possessed one or more IRAK4 (rs4251545 A 
and rs4251473 A) or TLR6 rs5743818 C minor alleles; however, the relationship was 
strongest for carriers of the IRAK4 rs4251545 AA genotype (ORage-adjusted = 0.34; 95%CI 
= 0.13, 0.91). Moreover, the TOLLIP rs5743899 locus, under the recessive genetic model 
(GG versus AG+AA), was modestly associated with a 1.14 fold increase in the risk of 
developing PCA (ORage-adjusted = 1.14; 95%CI = 1.12, 1.18). Among Jamaican men, IRF3 
rs2304206, TLR6 rs2381289, and TLR6 rs5743818 were marginally associated with PCA 
risk. For instance, inheritance of the IRF3 rs2304206 GG genotype (ORage-adjusted = 0.32; 
95%CI = 0.10, 0.98) was linked to a modestly significant 68% reduction in PCA 
susceptibility. On the other hand, there was a 1.10-2.0-fold increase in PCA risk 




1.10, 3.78) or TLR6 rs5743818 AC+CC GA (ORage-adjusted = 1.10; 95%CI = 1.06, 1.14) 
genotypes. Notably, additive genetic models for IRF3 rs2304206 and TLR6 rs2381289 
were significantly related to prostate cancer risk, which was modestly suggestive of a 
significant dose-response effect in relation to the number of inherited minor alleles (P-
trend ≥ 0.0193).  According to the new significance level (α=0.0016), these modest 
associations did not persist after adjustments for multiple hypothesis testing among U.S. 














Cases         
n (%) 
Controls         
n(%)               
Unadjusted 
OR (95% CI) 
Age Adjusted 
OR (95% CI) 
Chi-square (χ
2
)                       
p-value* 
p-trend 





GG 140 (50.4) 302 (56.7) 1.00 (referent) 1.00 (referent) 0.164 0.198 1.000 
GA 124 (44.6) 200 (37.7) 1.33 (0.98, 1.80) 1.46 (1.02, 2.09) 0.062   
AA   14 (5.04)   30 (5.63) 1.00 (0.52, 1.96) 1.20 (0.52, 2.76) 0.984   
GA+AA 138 (49.64) 230 (43.33) 1.28 (0.96, 1.72) 1.43 (1.00, 2.00) 0.088  1.000 






GG 104 (37.3) 189 (35.4) 1.00 (referent) 1.00 (referent) 0.363 0.261 0.798 
GA 131 (46.9) 239 (44.8) 1.00 (0.72, 1.40) 0.85 (0.58, 1.25) 0.981   
AA   44 (15.8) 106 (19.9) 0.75 (0.49, 1.15) 0.58 (0.35, 0.98) 0.194   
GA+AA 175 (62.7) 345 (64.7) 0.92 (0.68, 1.24) 0.76 (0.54,1.10) 0.596  1.000 
AA vs (GG+AG)   0.76 (0.51, 1.11) 0.64 (0.40, 1.02) 0.155  1.000 
TOLLIP   
rs5743899  
Intron 1 
AA   85 (30.8) 187 (35.2) 1.00 (referent) 1.00 (referent) 0.208 0.686 1.000 
AG 140 (50.7) 235 (44.2) 1.31 (0.94, 1.82) 1.59 (1.06, 2.38) 0.109   
GG   51 (18.5) 110 (20.7) 1.02 (0.67, 1.55) 1.29 (0.78, 2.14) 0.926   
AG+GG 191 (69.2) 345 (64.9) 1.22 (0.89, 1.66) 1.49 (1.02, 2.18) 0.215  0.884 
GG vs (AA+AG)   0.87 (0.60, 1.26) 0.98 (0.64, 1.53) 0.458  0.756 
The chi-square (χ
2
) test p-values were used to determine the difference in the genotype frequencies between cases and controls. *Fisher’s p-values were 
calculated when expected genotype counts were <5 for either cases and controls. Significant odd ratios (ORs) and 95% confidence interval (CI) are indicated 
in boldface. Abbreviations: UTR, untranslated region; miRNA, microRNA binding site; FDR, false discovery rate. 













































CC 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.270* 0.101 1.000* 0.955 
CA 0.76 (0.51, 1.14) 1.02 (0.55, 1.88) 0.61 (0.38, 0.99) 0.92 (0.47, 1.79) 0.181   0.950   
AA 0.57 (0.21, 1.56) 0.92 (0.28, 2.98) 0.34 (0.09, 1.21) 1.42 (0.32, 6.31) 0.274   0.887   
CA+AA 0.74 (0.50, 1.08) 1.00 (0.56, 1.78) 0.58 (0.36, 0.92) 0.97 (0.52, 1.84) 0.119   0.997   
AA vs (CC+CA) 0.62 (0.22, 1.68) 0.91 (0.28, 2.92) 0.40 (0.11, 1.40) 1.46 (0.34, 6.38) 0.347   0.878   
IRAK4 GG 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.072 0.023 0.685 0.473 
rs4251545 GA 0.71 (0.48, 1.04) 1.04 (0.58, 1.86) 0.60 (0.38, 0.94) 1.07 (0.56, 2.04) 0.076   0.909   
Exon 15  AA 0.50 (0.23, 1.08) 1.47 (0.60, 3.56) 0.34 (0.13, 0.91) 1.97 (0.70, 5.52) 0.079   0.391   
Splicing GA+AA 0.68 (0.47, 0.96) 1.13 (0.66, 1.94) 0.56 (0.36, 0.86) 1.22 (0.67, 2.24) 0.033   0.663  
(ESEor ESS) AA vs (GG+GA) 0.58 (0.28, 1.23) 1.45 (0.62, 3.40)     0.158   0.390  
IRF3 AA 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.767 0.558 0.079 0.037 
rs2304206 AG 1.15 (0.78, 1.70) 0.74 (0.42, 1.32) 1.22 (0.76, 1.97) 0.65 (0.34, 1.22) 0.475   0.314   
Intron 1 GG 1.12 (0.65, 1.94) 0.32 (0.11, 0.90) 1.30 (0.68, 2.49) 0.32 (0.10, 0.98) 0.666   0.031   
TFBS AG+GG 1.14 (0.80, 1.66) 0.65 (0.38, 1.12) 1.24 (0.80, 1.95) 0.57 (0.31, 1.06) 0.470   0.120   
 GG vs (AA+AG) 1.04 (0.63, 1.70) 0.37 (0.14, 1.00) 1.15 (0.64, 2.07) 0.40 (0.13, 1.16) 0.881   0.051   
IRF3 
rs968457 




GG 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.699* 0.485 0.133* 0.069 
GA+AA 0.92 (0.53, 1.58) 0.68 (0.30, 1.54) 0.85 (0.43, 1.67) 0.62 (0.25, 1.54) 0.750   0.359   
GA+AA 0.86 (0.50, 1.49) 0.56 (0.26, 1.18) 0.77 (0.40, 1.51) 0.50 (0.22, 1.18) 0.609   0.128   
AA vs (GG+GA) 
 
0.18 (0.02, 1.56) 
 
0.14 (0.01, 1.60) 0.987   0.120   
 
                
TLR6  
rs2381289 
3’ UTR                                                                                                                     
  
  
GG 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.770* 0.801 0.043* 0.019 
GA 1.13 (0.78, 1.64) 1.98 (1.12, 3.50) 1.28 (0.82, 2.00) 2.00 (1.06, 3.76) 0.510   0.017   
AA 0.88 (0.40, 1.96) 2.12 (0.48, 9.30) 0.92 (0.34, 2.50) 2.57 (0.50, 13.2) 0.768   0.318   
GA+AA 1.10 (0.76, 1.56) 1.99 (1.51, 3.46) 1.23 (0.80, 1.90) 2.05 (1.10, 3.78) 0.607   0.014   




AA 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.170* 0.176 0.056* 0.077 






GG 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.326 0.166 0.220 0.811 
GA 0.77 (0.52, 1.14) 1.56 (0.85, 2.83) 0.73 (0.45, 1.18) 1.15 (0.58, 2.26) 0.201   0.149   
AA 0.73 (0.44, 1.20) 0.89 (0.38, 2.06) 0.63 (0.34, 1.16) 0.56 (0.21, 1.46) 0.220   0.789   
GA+AA 0.76 (0.52, 1.10) 1.37 (0.80, 2.41) 0.70 (0.45, 1.08) 0.99 (0.52, 1.88) 0.139   0.283   
AA vs (GG+AG) 0.84 (0.53, 1.32) 0.69 (0.32, 1.46) 0.74 (0.42, 1.30) 0.52 (0.22, 1.22) 0.449   0.333   
TOLLIP 
rs5743899 
Intron 1  
  
  
AA 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.239 0.490 0.559 0.534 
AG 1.40 (0.93, 2.10) 1.11 (0.59, 2.08) 1.67 (1.02, 2.73) 1.35 (0.66, 2.74) 0.103   0.740   
GG 1.10 (0.66, 1.86) 0.75 (0.35, 1.61) 1.30 (0.69, 2.41) 1.12 (0.47, 2.66) 0.697   0.465   
AG+GG 1.31 (0.89, 1.92) 0.98 (0.54, 1.76) 1.55 (0.98, 2.46) 1.28 (0.66, 2.48) 0.166   0.952   




test p-values were used to determine the difference in the genotype frequencies between cases and controls. *Fisher’s p-values were calculated 
when expected genotype counts were <5 for either cases and controls. Significant odd ratios (ORs) and 95% confidence interval (CI) are indicated in boldface. 
Abbreviations: UTR, untranslated region; TFBS, transcription factor binding site; ESE exonic splicing enhancer; ESS, exonic splicing silencers; miRNA, 




Analysis of gene-gene interactions using Multi-factor Dimensionality Reduction    
MDR modeling was used to efficiently assess and validate age-adjusted gene-
gene interactions in relation to PCA risk for the total population, U.S. men alone, and 
Jamaican men alone [31]. The top one-, two-, and three-way interaction models for the 
total population, involving U.S. and Jamaican men combined, displayed 100% cross 
validation consistency (CVC) values, 57-65% average testing accuracy (ATA) scores, 
and permutation p-values = 0.001 (Table 10a). However, the three-way interaction 
among TLR6 rs2381289, TLR10 rs11096957, and IRF3 rs2304206 was selected as the 
best PCA predictor for men of African descent, since this model had the highest average 
testing accuracy (ATA = 0.6505). This three-way interaction was primarily driven by a 
highly synergistic relationship between TL10 rs11096957 and IRF3 rs2304206 due to its 
pairwise mutual information gain score (IG = 1.32%), which was higher than the mutual 
IG scores for each variant (Figure 7).  
CVC and ATA scores for all 1-, 2-, and 3-factor models among U.S. men were 
significant and characterized as 90-100% and 57-62%, respectively, as described in 
Tables 10b. However, interaction between TLR2 rs1898830 and IRAK4 rs4251545 was 
chosen as the best PCA predictor, based on a stronger CVC (100%) value as well as ATA 
(61.94%) score and lower permutation testing value (Permutation testing p-value = 
0.001) relative to the best three-factor model (Permutation p-value = 0.015). Moreover, 
the two-way interaction was highly synergistic since the pairwise mutual information 
gain score (2.33%) exceeded the mutual information gain scores for TLR2 rs1898830 




For the Jamaican population, the one-way model containing the TLR6 rs2381289 
loci was the best PCA-related MDR model based on a 62.7% prediction accuracy score 
(Permutation testing p-value  = 0.018). Although the three- factor model had high CVC 













































Table 10a. Interactions and main effects of TLR-associated SNPs as predictors of PCA 





























































*Analysis was restricted to 279 cases and 535 controls. Interaction models were 

















Figure 7. Entropy graph of TLR gene-gene interactions among U.S. and 
Jamaican men of African Descent. MDR analysis revealed a significant 
three-factor interaction (TLR10, TLR6 and IRF3) model with a pairwise 
mutual information gain score of 3.57%, 100% CVC and 65% ATA values 
(Permutation p-value=0.001). A highly synergistic relationship was 
observed for TLR6 rs2381289-TLR10 rs1109657 and TLR10 rs1109657-




Table 10b. Interactions and main effects of TLR-associated SNPs as predictors of PCA 

























Two Factor  






































*Analysis was restricted to 279 cases and 535 controls. Interaction models were 
















Figure 8. Entropy graph of TLR gene-gene interactions among U.S. men of 
African Descent. MDR analysis revealed a significant and highly synergistic (red 
line) two-factor interaction (TLR2 and IRAK4) model with a pairwise 
information gain score of 2.33%, 100% CVC and 61.9 % ATA values. The three-
factor interaction between TLR6 rs3821985, TLR4 rs1927906 and TLR2 
rs3804099 was shown as a good predictor of prostate cancer risk with a 90% and 




Table 10c. Interactions and main effects of TLR-associated SNPs as predictors of PCA 












Testing        
p-value 
One Factor     
TLR6 rs2381289 32 10/10  0.627 0.018 
Two Factor     
TLR6 rs2381289 496 7/10 0.646 0.203 
TOLLIP rs3168046        
Three Factor     
TLR10 rs11096955 4960 10/10  0.639 0.174 
TLR4 rs1927911        













*Analysis was restricted to 279 cases and 535 controls. Interaction models were 














Figure 9. Entropy graph of TLR gene-gene interactions among Jamaican 
men of African Descent. MDR analysis revealed a significant one-factor 
(TLR6) model with a mutual information gain score of 5.08%, 100% CVC 
and 62.7 % ATA values. However, two- and three- factor interaction models 





Dysregulation and genetic alterations in immune system function are linked to 
many cancers. In particular, it is estimated that approximately 20% of all human cancers, 
including prostate cancer (PCA), are associated with chronic inflammation [174, 175]. 
TLR activation, a key initiator of inflammation and dysregulation of TLR-responsive 
pathways, has been associated with cancer susceptibility. Consequently, we evaluated 32 
TLR-associated sequence variants to determine their individual and joint modifying 
effects on PCA risk among 279 cases and 535 disease free men of African descent [31]. 
We evaluated the impact of select polymorphic TLR-related genes (i.e., TLR1, TLR 2, 
TLR 4,TLR 6,TLR10, IRAK4, IRF3, and TOLLIP) on PCA susceptibility among men of 
African descent. Out of the 32 minor variant alleles, 3 loci (TLR6 rs2381289, TLR6 
rs5743818, TOLLIP rs5743899) displayed a 1.14-2.05 fold increase in PCA risk after 
adjusting for age; whereas, 4 markers (TOLLIP rs3168046, IRAK4 rs4251473, IRAK4 
rs4251545, IRF3 rs2304206) were linked to a 39-68% reduction in PCA risk. Among 
U.S. men, there was a nominal 40-66% reduction in PCA susceptibility among those who 
possessed one or more IRAK4 (rs4251545 A, rs4251473 A) or TLR6 rs5743818 C minor 
alleles. Similar to the total population, the TOLLIP rs5743899 SNP under the recessive 
genetic model (GG versus AG+AA) was modestly associated with a 1.14 fold increase in 
the risk of developing PCA (OR age-adjusted = 1.14; 95% CI = 1.12, 1.18) among men of 
African descent from the U.S. The TOLLIP rs3168046 GA was unique to the total 
population; whereas, 3 markers [IRAK4 rs4251473 (CA, CA+AA), IRAK4 rs4251545 
(GA, AA GA+AA), TLR6 rs2381289 (GA, GA+AA)] were unique to the U.S. men. 




under the additive genetic model. IRF3 rs2304206 GG genotype was linked to a 68% 
reduction (OR age-adjusted =0.32; 95%CI=0.10, 0.98) in PCA risk among Jamaican men 
(Table 9b). In addition, inheritance of TLR6 rs2381289 GA and GA+AA genotypes were 
associated to a 2-fold increase in PCA susceptibility among Jamaican men (χ
2
 p-value = 
0.014-0.017). However, TLR6 (rs2381289, rs5743818), IRAK4 rs4251473, TOLLIP 
(rs3168046, rs5743899), and IRF3 (rs2304206, rs968457) have never been studied in 
relation to cancer in the literature. Nonetheless, selected TLR-related sequence variants in 
the current study did not survive multiple hypothesis testing according to the new 
significance level (α = 0.0016) (Bonferroni Correction p-value > 0.0016). 
Collectively, 10 studies evaluated 14 out of the 32 SNPs examined in our study 
[97-99, 103-109].  In the Cancer of the Prostate Study (CAPS), inheritance of one or 
more TLR1 rs4833095 (OR = 1.28; 95% CI = 1.12-1.44) and TLR10 rs11096955 (OR = 
1.16; 95% CI = 1.02-1.30), TLR10 rs11096957 (OR = 1.16; 95% CI = 1.02-1.30) minor 
alleles were associated with an increase in prostate cancer risk among European 
Americans [99, 105]. However, the American Cancer Society Cancer Prevention II 
Nutrition Cohort (CPS-II) study reported protective effects for TLR1 rs4833095 CC (OR 
= 0.64; 95% CI = 0.47-0.86), TLR10 rs11096955 CC (OR = 0.78; 95% CI = 0.61-0.99) 
and TLR10 rs11096957 CC (OR = 0.78; 95% CI = 0.61-0.99) genotypes [97]. In the 
Health Professionals Follow-up Study (HPFS) [99, 109], and Prostate, Lung, Colon and 
Ovarian Cancer Screening Trial (PLCO) Study [99], inheritance of TLR10 (rs11096955, 
rs11096957) had no association with PCA risk among European Americans. However, 
there were null findings for TLR1 rs4833095, TLR10 (rs11096955, rs11096957) in 




Consistent with our study, five independent studies reported null findings in relation to 
prostate cancer risk and possession of TLR1 rs46224663 and TLR6 (rs5743814, 
rs5743810, rs1039559, rs3821985) variant alleles [97, 99, 106, 109]. Inheritance of one 
or more minor alleles was associated with either an increase [TLR1 rs5743604 (OR = 
1.28; 95% CI = 1.12-1.44), TLR10 rs4274855 (OR = 1.21; 95% CI = 1.03-1.39)] [99, 
106] or decrease [TLR1 rs5743595 CC (OR = 0.63; 95% CI = 0.42-0.93), TLR1 
rs2149356 (OR = 0.83; 95% CI = 0.67-0.99), TLR4 rs1927911 (OR = 0.79; 95% CI = 
0.62-0.96)] [97, 99, 107] in the risk of developing prostate cancer among Caucasians in 
three separate observational studies.  However, several studies including our study found 
that the previously mentioned sequence variants were not significantly related to prostate 
cancer among men of African and European descent [99, 103 , 105 , 109]. Song and 
associates (2009) observed that the TLR4 rs1927911 CC genotype was linked to an 
increase in prostate cancer risk in a Korean population case-control study (143 controls, 
157 cases) [98]; whereas, another study did not reveal a statistically significant 
relationship among Korean men (223 controls, 240 cases) [104]. Discrepant findings for 
these two studies may be attributed to differences in methods used for allelic 
discrimination [98, 104]. For instance, the RFLP-PCR method used in the 2009 study 
[98] may not have the same capacity to discern between homozygous and heterozygous 
genotypes, relative to fluorescence polarization detection, a more advance method used 
by Kim and co-workers (2012) [104]. Other explanations for differences in prostate 
cancer risk estimates for the aforementioned TLR-related SNPs may include: inadequate 
statistical power to detect significant differences between prostate cancer cases and 




99, 104-109]; and unknown environmental exposures/lifestyle factors (e.g., pathogens, 
environmental toxins, antioxidants) [97-99, 103-109].  
The functional impact and biological activity of TLR genes are greatly affected by 
the inheritance of their associated sequence variants. For instance, TLR6 rs2381289 
located in 3’UTR and TLR2 rs1898830 located in intron 1 may affect transcriptional 
regulation of TLR genes. TLRs 2 and 6 are controlled by the master regulatory 
transcription factor p53 [176]. TLR-associated SNPs may alter p53 interactions with TLR 
genes. In silico tools revealed that IRAK4 rs4251545 codes for a change from Ala to Thr 
in mRNA splicing, which in turn may influence mRNA stability of IRAK4 kinase 
activity, as well as TLR signaling protein-protein interactions.  Such alterations may lead 
to biochemical conditions that favor cell death, decreases in matrix metalloproteinases 
linked to cell migration, decreases in pro-inflammatory cytokines/chemokines and 
ultimately abrogation of tumor growth. Yeyeodu and associates (2013) identified that 
IRAK4 rs4251545 resides in a transcription enhancer/silencer region and codes for a 
phosphorylation site and non-synonymous mutation at position 428 [177]. It was 
speculated inheritance of the IRAK4 rs4251545 TT genotype was associated with a 4.5 
fold increase in breast cancer susceptibility among African-American women  relative to 
those with the referent genotype[177].  In addition,  this high susceptibility may have 
been attributed to alteration of IRAK4 phosphorylation.  This change may influence the 
transcriptional level of IRAK4 and impair TLR3 regulated apoptosis in breast cancer 
cells [177].    
 Lastly, we examined the combined effects of TLR-associated SNPs as predictors 




interaction models. In the total population, MDR analysis revealed a significant three-
factor (TLR10 rs11096957-TLR6 rs2381289-IRF3 rs2304206) interaction model as a 
good predictor of PCA risk (Permutation testing p-value = 0.001). Among U.S. men of 
African descent, the best predictor of PCA risk was the two-factor gene-gene interaction 
model between IRAK4 rs4251545 and TLR2 rs1898830 (Permutation testing p-value = 
0.001). However, only the TLR6 rs2381289 SNP for the Jamaican population remained 
statistically significant after adjusting for age and multiple hypothesis testing 
(Permutation testing p-value = 0.018).  However, there are no published reports on the 
TLR-associated sequence variants observed in our gene-gene interaction study.  
The strengths and limitations of our approach were considered in our research 
findings. Although nominal relationships between TLR-associated SNPs and PCA risk 
were observed, we cannot rule out the possibility that other TLR sequence variants within 
the innate immune pathway may still influence PCA risk and disease prognosis. 
Consequently, future studies will enable us to evaluate the relationship between TLR 
SNPs and Gleason score, tumor stage, biochemical/disease recurrence, as well as 
overall/disease specific mortality. Multi-center pooled genetic studies with thousands of 
cases and controls may enable us to confirm and validate our findings. Moreover, PCA 
susceptibility may also be influenced by polymorphisms of some genes even further 
downstream of the TLR signaling pathway, including caspases (CASP 3, 7, 8, and 10), 
mitogen-activated protein kinases (MAPKs), inflammatory cytokines, and chemokines. In 
fact, selected cytokine- and chemokine-associated sequence variants have been evaluated 
in relation to PCA susceptibility among men of African descent in published reports by 




Future studies will assess whether selected TLR-related SNPs may alter TLR 
signaling, miRNA and/or protein expression or relative expression activity of 
downstream targets. The genetic admixture among African-American men, as 
documented by other published reports, may modify the relationship between TLR SNPs 
and prostate cancer risk. Adjustment of our risk models for West African Ancestry 
ultimately had no significant bearing on calculated risk estimates among African-
American men. Our gene-gene interaction analyses were controlled for multiple 
hypothesis testing with permutation testing.  Given the high prediction accuracy (i.e., 
61.9%) between TLR2 and IRAK4, our study findings require replication within 
independent study sets.  However, recent simulation studies demonstrate that even 
modest disparities in genotype frequencies among study participants of independent study 
sets may interfere with the capacity to replicate complex interactions [178].  
Consequently, to replicate our findings, it is critical that future replicate studies have the 
same genetic architecture (i.e., ancestry identification markers and TLR SNPs) as the 
African-Americans in the current study. Caution is recommended in the interpretation of 
our study findings due to a modest marginal effect between TLR signaling sequence 
variants and PCA risk.  However, enthusiasm for the relationship between PCA and the 
innate immune signaling pathway was slightly elevated in our exhaustive 2- and 3-way 
interactions.  In particular, our exploratory analysis revealed a synergistic relationship 
between IRAK4 and TLR2 as significant PCA markers among men of African descent in 
the U.S. (Table 10b).  We speculate genetic variations in TLR-related genes may 
influence the PCA risk by modulating cell survival, proliferation and/or inflammation. To 




on PCA development, we plan to overexpress both IRAK4 and TLR2, individually and 
IRAK4-TLR2 in combination in PCA cell lines. Such studies may help us understand the 
role of the IRAK4-TLR2 axis in the PCA phenotype, including cell death, proliferation, 
migration, colony formation and invasion. In addition, these modified cell lines could be 
implanted into mice to observe their effect on PCA tumor growth and metastasis. The 
combination of our genetic variation analysis of TLR-related polymorphisms with 
biological studies will aid in the accurate prediction and eventual offset of genetic risk 





CHEMOKINE LIGAND 5 (CCL5) AND CHEMOKINE RECEPTOR(CCR5) GENETIC 
VARIANTS AND PROSTATE CANCER RISK AMONG MEN OF AFRICAN  
 Chemokine and chemokine receptors play an essential role in tumorigenesis. 
Chemokine-associated single nucleotide polymorphisms (SNPs) are associated with 
various cancers. However, their impact on prostate cancer (PCA) among men of African 
descent is unknown. Consequently, we evaluated main and combined effects of 43 
chemokine-associated SNPs in germ-line DNA samples from 814 African-American and 
Jamaican men (279 PCA cases and 535 controls) in relation to PCA risk using the 
Illumina’s Goldengate genotyping system, multivariate logistic regression and entropy-
based MDR. We hypothesized that inheritance of variant chemokine-associated alleles 
may lead to alterations in PCA susceptibility, presumably due to variations in antitumor 
immune responses. For the total population, inheritance of CCL5 rs2107538 (AA, 
GA+AA) and rs3817655 (AA, AG, AG+AA) genotypes were linked with a 34-48% 
reduction in PCA risk [35]. The recessive and dominant models for CCR5 rs1799988 and 
CCR7 rs3136685 were associated with a 1.52-1.73 fold increase in PCA risk. Upon 
stratification, only CCL5 rs3817655 and CCR7 rs3136685 remained significant for the 
Jamaican and U.S. subgroups, respectively [35]. In summary, CCL5 (rs2107538, 
rs3817655) and CCR5 rs1799988 sequence variants significantly modified PCA 





comparisons. Our findings require further evaluation and validation in relation to 
prostate cancer risk and ultimately disease progression, biochemical/disease recurrence 
and mortality in larger high-risk subgroups. Such efforts will help to identify genetic 
markers capable of explaining disproportionately high prostate cancer incidence, 
mortality, and morbidity rates among men of African descent. 
Results 
Prevalence of minor alleles/genotype frequency comparing men of African Descent 
from the U.S. and Jamaica 
 Overall, the chemokine-related SNPs were fairly common among disease-free 
individuals from the entire sub-population of U.S. and Jamaica, with average minor 
frequencies of 26-27% and a standard deviation of 14%, respectively (data not shown).  
Thirty-eight SNPs had minor allele frequencies ≥ 5%.  For exploratory purposes, five rare 
SNPs (CCR9 rs12721497, CCL17 rs11076191, CCL11 rs4795896, CCL21 rs11574916, 
CXCL12 rs1801157) were analyzed with minor allele frequencies ranging between 
0.015-0.490.  The minor allele frequency comparing controls from the U.S. and Jamaica 
were strongly correlated (R
2
 = 0.957).  Only 5 out of the 43 SNPs analyzed were 
discordant comparing men of African descent from the U.S. to men from Jamaica (p-
value ≤ 0.0487), namely CCL17 rs11076191, CCL21 rs11574916, CCR7 rs3136685, 
CCR7 rs3136687, and CCR9 rs12721497 [35]. 
Relationship between chemokine sequence variants and prostate cancer risk 
Among all men of African descent, five sequence variants were significantly 
associated with the risk of developing prostate cancer, as summarized in Table 11a.  




CCL5 rs3817655 GA+AA (ORunadjusted = 0.54; 95%CI = 0.40, 0.74) genotype was linked 
with a 41-46% reduction in PCA risk in the unadjusted LR models.  These effects 
remained significant for both CCL5 SNPs after adjusting for age. The recessive genetic 
model for CCR5 rs1799988 (ORage-adjusted = 1.52; 95%CI = 1.02, 2.26) as well as the 
dominant models for CCR7 rs3136685 (ORage-adjusted = 1.66; 95%CI = 1.09, 2.54) and 
CCR7 rs3136687 (ORage-adjusted =1.14; 95%CI = 1.12, 1.16), respectively, were associated 
with a significant 1.14-1.66 fold increase in PCA risk within the age adjusted LR models. 
After controlling for multiple comparisons, the dominant genetic models for the two 
CCL5 SNPs (rs2107538, rs3817655) remained significant with false-discovery rates 
(FDR) ≤ 0.015; whereas, the recessive model for CCR5 rs1799988 was statistically 
















Genotype Cases         
n (%) 











CCR5 AA 85 (30.7) 194 (36.7)   1.00 (referent)   1.00 (referent) 0.0050 0.004 0.068 
rs1799988 AG 107 (38.6) 227 (43.9) 1.08 (0.76, 1.52) 0.83 (0.55, 1.25) 0.6760 
  
5’UTR GG 85 (30.7) 108 (20.4) 1.80 (1.23, 2.63) 1.38 (0.87, 2.17) 0.0030 
  




GG vs (AA+AG) 
  
1.73 (1.24, 2.40) 1.52 (1.02, 2.26) 0.0013 
 
0.049 
CCL5 GG 111 (39.8) 150 (28.1)    1.00 (referent)   1.00 (referent) 0.0020 0.001 0.049 
rs2107538 GA 124 (44.4) 270 (50.6) 0.62 (0.45, 0.86) 0.72 (0.49, 1.06) 0.0040 
 
 
5' near gene AA 44 (15.8) 114 (21.4) 0.52 (0.34, 0.80) 0.53 (0.32, 0.89) 0.0030 
 
 




AA vs (GG+GA) 
 
 
0.83 (0.57, 1.20) 0.74 (0.47, 1.16) 0.0570 
 
0.474 
CCL5 GG 114 (41.0) 147 (27.5)   1.00 (referent)   1.00 (referent) 0.0040 0.002 0.019 
rs3817655 GA 115 (41.4) 278 (52.0) 0.53 (0.38, 0.74) 0.57 (0.38, 0.84) 0.0002 
 
 
Intron 2 AA 49 (17.6) 110 (20.5) 0.57 (0.38, 0.87) 0.54 (0.32, 0.89) 0.0009 
 
 




AA vs (GG+GA) 
  
0.83 (0.57, 1.20) 0.74 (0.47, 1.16) 0.3170 
 
1.000 
CCR7 AA 55 (19.7) 151 (28.3)    1.00 (referent)  1.00 (referent) 0.0290 0.031 0.308 
rs3136685 AG 139 (49.8) 237 (44.4) 1.61 (1.11, 2.34) 1.86 (1.18, 2.92) 0.0120 
 
 








GG vs (AA+AG) 
 
 
1.16 (0.85, 1.60) 0.92 (0.62, 1.35) 0.3480 
 
0.161 
CCR7 GG 84 (30.1) 173 (32.4)   1.00 (referent)  1.00 (referent) 0.0410 0.458 0.352 
rs3136687 GA 153 (54.8) 249 (46.5) 1.26 (0.91, 1.76) 1.45 (0.97, 2.16) 0.1611 
 
 








AA vs (GG+GA) 
  
0.66 (0.45, 0.98) 0.76 (0.49, 1.20) 0.0372 
 
0.509 
          
The chi-square (χ2) test p-values were used to determine the difference in the genotype frequencies between cases and controls. 
*Fisher’s p-values were calculated when expected genotype counts were <5 for either cases and controls. Significant odd ratios 
(ORs) and 95% confidence interval (CI) are indicated in boldface. Abbreviations: TFBS, transcription factor binding site; FDR, 




In an exploratory analysis, we evaluated risk estimates for all 43 chemokine 
targets for each racial/ethnic group, as depicted in Table 11b.  Among U.S. men, CCR5 
rs1799988, CCL5 (rs2107538, rs2280789, rs3817655), CCL25 rs2032887, and CXCR7 
rs1045879 were associated with PCA risk. Inheritance of the CCL25 rs2032887 AG+GG 
(ORunadjusted = 0.66; 95%CI = 0.46, 0.96), CCL5 rs2107538 GA+AA (ORunadjusted = 0.52; 
95%CI = 0.36, 0.76), CCL5 rs2280789 AG+GG (ORunadjusted = 0.60; 95%CI = 0.41, 
0.89), and CCL5 rs3817655 GA+AA (ORunadjusted = 0.46; 95%CI = 0.32, 0.68) genotypes 
were significantly associated with a 34-54% reduction in the risk of developing PCA with 
chi-square p-values ranging from 0.0001-0.027.  Although the magnitude of the reduction 
in PCA risk for CCL5 rs2107538 GA+AA, CCL5 rs3817655 GA+AA and CCL25 
rs2032887 AG+GG genotypes remained practically unchanged after adjusting for age, 
the findings only remained significant for CCL5 rs3817655 SNP after the adjustment 
(ORunadjusted = 0.46, ORage-adjusted = 0.51).  The 1.5-1.6 fold increase in PCA susceptibility 
was associated with the CCR5 rs1799988 recessive model (ORunadjusted =1.62; 
95%CI=1.08, 2.42) and the CXCR7 rs1045879 AG+GG genotype (ORunadjusted = 1.54; 
95%CI = 1.07, 2.22; P = 0.02) was lost in the age adjusted risk models. 
For the Jamaican population, there was a two-fold increase in PCA susceptibility 
associated with the CCR5 rs1799987 AA (ORunadjusted = 2.18; 95% CI=1.04, 4.58), CCR5 
rs1799988 GG (ORunadjusted =2.25; 95% CI = 1.08, 4.71), and CCR7 rs3136685 AG+GG 
(ORunadjusted = 2.3; 95% CI = 1.05, 5.07) genotypes, with corresponding chi-square P-
values ranging from 0.02-0.037.  Additionally, a 54% reduction in PCA risk was 
observed for individuals who possessed the CCR9 rs1488371 CA+AA genotype 




SNP remained significant after adjusting for age. Notably, the magnitude of PCA risk 
estimates did not change for the CCR5, CCL5, and CCR9 SNPs, comparing the adjusted 
and unadjusted risk models. However, only CCL5 (rs2107538, rs3817655) sequence 
variants survived multiple hypothesis testing among U.S. men of African descent 











 Gene (Allele, 
position, function) 
Genotype Unadjusted        
OR (95%CI)            
US Men 
Unadjusted    
OR (95%CI)  
Jamaican Men 
Age-Adjusted 
OR (95%CI)   
US Men 
Age-Adjusted 












CCR5 AA 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.063 0.076 0.085 0.034 
rs1799988 AG 0.95 (0.62, 1.44) 1.26 (0.66, 2.40) 0.68 (0.42, 1.12) 1.23 (0.60, 2.52) 0.808   0.484   
5’UTR GG 1.58 (0.99, 2.49) 2.25 (1.08, 4.71) 1.06 (0.60, 1.85) 2.23 (0.99, 5.00) 0.053   0.031   
TFBS AG+GG 1.15 (0.79, 1.68) 1.56 (0.86, 2.82) 0.80 (0.52, 1.26) 1.55 (0.81, 2.98) 0.453   0.142   
  GG vs (AA+AG) 1.62 (1.08, 2.42) 1.96 (1.04, 3.70) 1.28 (0.78, 2.12) 1.98 (0.98, 3.98) 0.020   0.037   
CCL5 GG 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.003 0.002 0.286 0.116 
rs2107538 GA 0.54 (0.36, 0.80) 0.75 (0.40, 1.40) 0.67 (0.42, 1.08) 0.82 (0.40, 1.64) 0.003   0.375   
5' near gene AA 0.48 (0.28, 0.82) 0.53 (0.24, 1.16) 0.53 (0.28, 1.01) 0.52 (0.22, 1.22) 0.007   0.116   
TFBS GA+AA 0.52 (0.36, 0.76) 0.68 (0.38, 1.23) 0.63 (0.40, 0.99) 0.72 (0.37, 1.40) 0.001   0.204   
  AA vs (GG+AG) 0.68 (0.42, 1.11) 0.64 (0.32, 1.26) 0.66 (0.37, 1.20) 0.58 (0.28, 1.24) 0.125   0.192   
CCL5 AA 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.039 0.018 0.508 0.823 
rs2280789 AG 0.60 (0.40, 0.90) 1.20 (0.66, 2.18) 0.60 (0.37, 0.97) 1.48 (0.76, 2.89) 0.015   0.549   
Intron 1 GG 0.62 (0.24, 1.56) 0.59 (0.18, 1.89) 1.00 (0.34, 2.99) 0.42 (0.12, 1.46) 0.309   0.373   
TFBS AG+GG 0.60 (0.41, 0.89) 1.06 (0.61, 1.86) 0.64 (0.40, 1.01) 1.18 (0.63, 2.20) 0.011   0.82   
  GG vs (AA+AG) 0.72 (0.28, 1.82) 0.55 (0.18, 1.80) 1.14 (1.12, 1.18) 0.36 (0.10, 1.27) 0.488   0.313   
CCL5 GG 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.0002 0.003 0.275 0.11 
rs3817655 GA 0.44 (0.29, 0.65) 0.72 (0.38, 1.34) 0.49 (0.30, 0.80) 0.74 (0.36, 1.50) <0.0001   0.302   
Intron 2 AA 0.56 (0.34, 0.92) 0.53 (0.24, 1.16) 0.54 (0.29, 1.02) 0.50 (0.22, 1.20) 0.022   0.115   
TFBS GA+AA 0.46 (0.32, 0.68) 0.66 (0.36, 1.20) 0.51 (0.32, 0.80) 0.66 (0.34, 1.28) <0.0001   0.167   
  AA vs (GG+GA) 0.88 (0.55, 1.40) 0.66 (0.34, 1.28) 0.80 (0.46, 1.42) 0.61 (0.28, 1.27) 0.577   0.22   
CCL25 AA 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.084 0.034 0.474 0.379 
rs2032887 AG 0.67 (0.46, 0.99) 1.42 (0.80, 2.48) 0.70 (0.44, 1.11) 1.54 (0.82, 2.88) 0.404 0.225   
Exon 3 GG 0.61 (0.29, 1.28) 1.10 (0.36, 3.38) 0.57 (0.22, 1.42) 0.84 (0.24, 2.88) 0.196 0.86   
ESE/ESS, nsSNP AG+GG 0.66 (0.46, 0.96) 1.37 (0.80, 2.36) 0.68 (0.44, 1.05) 1.42 (0.78, 2.60) 0.027 0.253   
probably damaging 
missense R>H 
GG vs (AA+AG) 0.71 (0.34, 1.47) 0.93 (0.32, 2.75) 0.65 (0.26, 1.60) 0.68 (0.20, 2.24) 0.357 0.898   
CCR5 GG 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.197 0.951 0.107 0.041 
rs1799987 GA 1.29 (0.88, 1.92) 1.28 (0.68, 2.44) 0.89 (0.56, 1.44) 1.25 (0.61, 2.56) 0.191   0.442   
Intron 1 AA 0.84 (0.48, 1.48) 2.18 (1.04, 4.58) 0.58 (0.29, 1.14) 2.20 (0.98, 4.94) 0.558   0.039   
TFBS GA+AA 1.18 (0.80, 1.70) 1.56 (0.86, 2.82) 0.81 (0.52, 1.26) 1.55 (0.81, 2.98) 0.399   0.142   
  AA vs (GG+GA) 0.72 (0.44, 1.21) 1.88 (0.99, 3.56) 0.61 (0.32, 1.15) 1.92 (0.96, 3.88) 0.222   0.051   
CCR7 AA 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.381 0.731 0.103 0.086 
rs3136685 AG 1.32 (0.86, 2.02) 2.24 (0.98, 5.16) 1.58 (0.94, 2.66) 2.78 (1.09, 7.08) 0.197   0.056   
Intron 1 GG 1.07 (0.65, 1.76) 2.38 (1.02, 5.58) 1.02 (0.56, 1.86) 2.52 (0.97, 6.52) 0.778   0.045   
  AG+GG 1.23 (0.82, 1.84) 2.30 (1.05, 5.07) 1.36 (0.83, 2.21) 2.66 (1.10, 6.42) 0.305   0.037   
  GG vs (AA+AG) 0.90 (0.59, 1.36) 1.28 (0.74, 2.25) 0.76 (0.46, 1.26) 1.16 (0.62, 2.15) 0.622   0.372   
CCR7 GG 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.022 0.294 0.229 0.218 
rs3136687 GA 1.81 (1.16, 2.80) 0.98 (0.55, 1.75) 1.73 (1.03, 2.93) 1.13 (0.60, 2.14) 0.008   0.459   








 Intron 1 AA 1.27 (0.74, 2.18) 0.46 (0.18, 1.18) 1.18 (0.63, 2.20) 0.74 (0.25, 2.17) 0.380   0.106   
  GA+AA 1.63 (1.07, 2.49) 0.85 (0.49, 1.48) 1.53 (0.96, 2.53) 1.06 (0.57, 1.95) 0.023   0.573   
  AA vs (GG+GA) 0.86 (0.55, 1.32) 0.46 (0.19, 1.14) 1.15 (1.12, 1.18) 0.69 (0.25, 1.91) 0.482   0.092   
CCR9 CC 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.013 0.902 0.003 0.018 
rs1488371 CA 0.94 (0.62, 1.40) 0.52 (0.26, 1.08) 0.88 (0.54, 1.42) 0.60 (0.26, 1.31) 0.747   0.08   
Intron 2 AA 1.57 (0.50, 4.90) 
 
0.92 (0.22, 3.80) 
 
0.435   0.984   
  CA+AA 0.98 (0.66, 1.44) 0.46 (0.23, 0.94) 0.88 (0.54, 1.40) 0.48 (0.22, 1.04) 0.901   0.034   
  AA vs (AA+CA) 1.60 (0.52, 4.97) 
 
0.95 (0.23, 4.00) 
 
0.414   0.984   
CXCR7 AA 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.065 0.038 0.459 0.762 
rs1045879 AG 1.54 (1.06, 2.26) 1.38 (0.77, 2.48) 1.30 (0.82, 2.04) 1.30 (0.68, 2.50) 0.025   0.279   
Exon 1 GG 1.53 (0.84, 2.79) 0.86 (0.34, 2.16) 1.02 (0.47, 2.20) 0.74 (0.27, 2.04) 0.166   0.756   
synSNP AG+GG 1.54 (1.07, 2.22) 1.24 (0.72, 2.14) 1.24 (0.80, 1.93) 1.15 (0.62, 2.10) 0.02   0.431   
L>L GG vs (AA+AG) 1.21 (0.69, 2.13) 0.76 (0.31, 1.84) 0.88 (0.42, 1.84) 0.67 (0.25, 1.80) 0.499   0.538   
The chi-square (
χ2)
 test p-values were used to determine the difference in the genotype frequencies between cases and controls. 
*Fisher’s p-values were calculated when expected genotype counts were <5 for either cases and controls. Significant associations are 
indicated in boldface. Abbreviations: UTR, untranslated region; TFBS, transcription factor binding site; ESE exonic splicing enhancer; 




Analysis of gene-gene interactions using Multi-factor Dimensionality Reduction  
               MDR modeling was utilized to evaluate and validate gene-gene interactions 
among 43 chemokine-associated sequence variants in relation to PCA risk. The top age-
adjusted one-, two- and three-factor gene-gene interaction models for the total 
population, including men of African descent from Jamaica and the U.S., were 
statistically significant with 100% cross validation consistency (CVC), 59-67% average 
testing accuracy (ATA) and permutation testing p-values of 0.001, as shown in Table 
12a. The three-factor interaction model consisting of CCR7 rs3136685, CCL5 
rs3817655, and CCR9 rs41289608 was the best predictor of PCA risk among men of 
African descent, based upon the highest ATA value of 66.5%.  This three-factor 
interaction model was driven by theThe mutual information gain score  of CCL5 
rs3817655 (IG = 2.8%) (Figure 10).   However, none of the pairwise interactions of the 
three-factor interaction model yielded more information than each SNP considered alone.   
              Analysis of age-adjusted gene-gene interactions among U.S. men of African 
descent yielded statistically significant one-, two- and three-factor interaction models 
with 100% CVC, 58-68% ATA values, and permutation testing p-values of 0.001-0.003 
(Table 12b). In addition, the best one-factor MDR model (CCL5 rs3817655) was a 
persistent predictor of PCA risk in the total population and U.S. men, as shown in Tables 
12a and 12b, respectively. Yet, the three-factor gene-gene interaction model (CCR6 
rs3093024-CCL5 rs3817655-CCR9 rs41289608) was selected as the best predictor of 
PCA risk among U.S. men based upon its high ATA value of 68.7% (Permutation testing 
p-value = 0.001).  However, this 3-way interaction was dominated by CCL5 rs3817655   




            Upon stratification of age-adjusted MDR analyses for Jamaican men, the three-
factor gene-gene interaction model of CCR6 rs3093024, CCR4 rs6550178 and CXCR7 
rs7559855 was statistically significant and the overall best predictor of PCA 
susceptibility (Permutation testing p-value = 0.017) (Table 12c). The three-factor model 
was selected as the best predictor of risk due to its association with an extremely high 
ATA score of 70% among Jamaican men. This interaction model was moderately 
synergistic (orange line) and primarily driven the main effect of CCR4 rs6550178 (IG = 
8.2%) and the pairwise interaction between CCR6 and CXCR7 (IG = 3.41%) (Figure 
11). Thus far, CCR4 rs6550178 had the highest individual information gain score among 

















Table 12a. Interactions and main effects of Chemokine-associated SNPs as predictors of 
PCA using age-adjusted MDR among men of African Descent. 
Best Model 
(dbSNPID#)  













      
CCL5 rs3817655 43 10/10 0.595 0.001 
Two Factor 
 
      
CCL5 rs3817655 903 10/10 0.628 0.001 
CCR4 rs6550178         
Three Factor 
 
      
CCR7 rs3136685 12,341 10/10 0.665 0.001 
CCL5 rs3817655          








*Analysis was restricted to 279 cases and 535 controls. Interaction models were 














Figure 10. Entropy graph of Chemokine gene-gene interactions among U.S. and 
Jamaican men of African Descent.   The mutual gain scores for all the pairwise 
combinations for the best 2- and 3-factor MDR models did not exceed the 
information gain scores of the individual loci.  Consequently the selected gene-
gene interaction models were not informative and predominantly driven by a strong 




Table 12b. Interactions and main effects of Chemokine-associated SNPs as predictors of 
















      
CCL5 rs3817655 43 10/10 0.584 0.001 
Two Factor         
CCL5 rs3817655 903 10/10 0.619 0.003 
CCR5 rs1799988         
Three Factor         
CCR6 rs3093024  12,341 10/10 0.687 0.001 
CCL5 rs3817655         




















*Analysis was restricted to 279 cases and 535 controls. Interaction models were 




Table 12c. Interactions and main effects of Chemokine-associated SNPs as predictors of 
PCA using age-adjusted MDR among Jamaican men of African Descent. 
Best Model 
(dbSNPID #)  













      
CCR9 rs2286486 43 10/10 0.606 0.061 
Two Factor         
CCR9 rs2286486 903 10/10 0.637 0.329 
CCR7 rs3136687         
Three Factor         
CCR6 rs3093024 12,341 9/10 0.704 0.017 
CCR4 rs6550178         













*Analysis was restricted to 279 cases and 535 controls. Interaction models were 












Figure 11. Entropy graph of Chemokine gene-gene interactions among 
Jamaican men of African Descent. MDR analysis revealed that only the three-
factor (CCR6 rs3093024-CXCR7 rs7559855-CCR4 rs6550178) survived 
multiple hypothesis testing with 90% CVC and 70.4% ATA values 
(Permutation p-value=0.017). However, a moderately synergistic (orange line) 
interaction between CCR6 and CXCR7 associated with a pairwise mutual 
information gain score of 3.41%, which is higher than the mutual information 
gain scores of each SNP. In addition, the three-factor interaction model was 






Chemotaxis is an important process required for tumor growth and metastasis 
[179, 180].  It is regulated by a complex network of chemokines, chemokine receptors 
and downstream targets that synergistically regulate immune and inflammatory responses 
[180].  Recent molecular studies have demonstrated that over expression of selected 
chemokines and chemokine receptors are related to aggressive cancer phenotypes, 
including lung, breast and prostate cancer [181-185].  Some observational studies suggest 
inheritance of susceptibilities detected in chemokine-associated genes may alter the risk 
of developing cancer [116-120].  However, to our knowledge, there are no published 
reports on the impact of inheriting multiple functional variants in relation to prostate 
cancer among men of African Descent.  Therefore, the current study evaluated the 
individual and combined effects of 43 chemokine associated sequence variants on PCA 
risk among 279 cases and 535 disease-free men of African descent from the U.S and 
Jamaica using LR and MDR modeling.  Five SNPs detected in CCL5, CCR5 and CCR7 
were significantly associated with prostate cancer risk among all study participants; 
however, only three markers survived adjustments for potential confounders and multiple 
hypothesis testing [35].  Notably, inheritance of at least one CCL5 rs3817655 A or CCL5 
rs2107538 A loci was linked with a 34-44% decrease in PCA susceptibility among all 
men of African Descent.  In addition, the recessive genetic model for CCR5 rs1799988 
was associated with a 52-73% increase in PCA risk.  We also observed significant main 
effects for the CCL5 rs3817655 and CCR7 rs3136685 SNPs among U.S. and Jamaican 




MDR analysis revealed several significant chemokine-associated gene-gene 
interactions among men of African descent. In the total population, a three factor model 
interaction model  was selected as the best prostate cancer predictor for the total 
population (CCR7 rs3136685-CCL5 rs3817655-CCR9 rs41289608) as well as the 
African-Americans from the U.S. (CCR6 rs3093024- CCL5 rs3817655-CCR9 
rs41289608) with CVC = 100% ATA = 66.5-68.7 and  Permutation-testing p-value = 
0.001.  (CVC = 100%; ATA = 66.5% value; Permutation testing p-value = 0.001). 
However, upon closer inspection, these 3-way  interactions were primarily driven by 
CCL5 rs3817655  none of the interactions within the three-factor model were 
informative. Interestingly, a significant three-factor interaction model (CCR6 rs3093024-
CCR4 rs6550178- CXCR7 rs7559855) for Jamaican men had the highest ATA value 
(70.4%) compared to the total population and U.S men interaction models (Permutation 
p-value = 0.017). This interaction model was moderately synergistic due to the major 
main effect of CCR4 rs6550178 (IG = 8.2%) and a pairwise interaction between CCR6 
rs3093024 and CXCR7 rs7559855 (IG = 3.41%). In fact, the pairwise mutual information 
gain score of CCR6 rs3093024 and CXCR7 rs7559855 was higher than information gain 
scores of the individual variants. However, the other interaction models among Jamaican 
men did not survive multiple hypothesis testing.  
Several cancer cells, including PCA cells, express chemokines and their cell 
surface bound receptors.  Chemokine ligand 5 (RANTES) is a small molecule with a 
strong capacity to induce cellular migration of inflammatory cells and production of its 
receptor (CCR5) in human PCA cell lines [73, 75].  The CCL5/CCR5 axis induces PCA 




serves as an autocrine factor and activates cellular responses involved in cancer 
progression [73].  In the current study, possession of the CCL5 rs3817655 A or CCL5 
rs2107538 A loci was linked with a protective effect in relation to prostate cancer risk 
among all men of African descent from the U.S. and Jamaica combined. The 
directionality of the risk estimates persisted when we stratified by racial/ethnic group; 
however, the findings were only statistical significant for the U.S. men.  In addition, 
findings for the total and U.S. subgroups remained significant even after adjusting for age 
and multiple hypothesis testing.  The observed protective effects associated with the two 
aforementioned CCL5 SNPs (rs3817655, rs2107538) may be attributed to a reduction in 
transcriptional activation, reduced protein levels, and ultimately reduced tumorigenic 
capacity. To our knowledge, there are no published reports on the impact of the CCL5 
rs3817655 SNP on prostate cancer susceptibility or its functional consequence on 
genes/proteins.  On the other hand, the CCL5 rs2107538 G-403A promoter SNP is 
associated with a decrease in protein expression detected in serum collected from Type II 
diabetic and disease-free subjects [186].  In addition, this locus has been evaluated in two 
independent prostate cancer studies.  In a study involving 607 Caucasian male residents 
of Spain (297 cases, 3011 controls), Saenz-Lopez and co-workers (2008) observed a 
1.44-fold increase in PCA risk among carriers of the CCL5 rs2107538 GA+AA genotype 
(p-value = 0.039) [116].  However, this finding did not corroborate with a larger null 
report consisting of 1553 Caucasian men (i.e., 815 PCA cases, 738 controls) from 
Australia [187].  Our findings of a protective effect against PCA among our study 
participants is consistent with other published reports that reveal a decrease in the risk of 




multi-ethnic pancreatic case-control study, the prevalence of the “A” allele was more 
frequent among disease-free Asian and African-Americans relative to pancreatic cases 
[118]; however, this allele was more prevalent among Caucasian pancreatic cases relative 
to controls. Collectively, these findings may suggest inheritance of genetic 
susceptibilities detected in the CCL5 gene may vary across different racial/ethnic groups.  
The functional impact of CCL5 sequence variants is complicated by the high 
degree of linkage disequilibrium within both the promoter and intron 1 region. An and 
co-workers (2006), evaluated the impact of three SNPs detected in the promoter region 
(rs2280788 -28C/G, rs2107538 -405 G/A) and intron 1 of CCL5 rs2280789 [189]. They 
demonstrated that transcriptional regulation of CCL5 was primarily governed by an 
intron 1.1 A/G SNP (rs2280789).  Intron 1.1 G allele corresponded with a strong 
decrease in transcriptional activity of RANTES; whereas, the -28G allele had a modest 
up-regulation in human cell lines.  In our stratified analysis, the intron 1.1 CCL5 
rs2280789 AG or AG+GG genotypes were associated with a marginal 36-41% decrease 
in PCA risk among men of African descent from the U.S.; however, these findings 
require further evaluation in a larger study set.  The CCL5 rs2280788 -28C/G was not 
evaluated in the current study, since the C allele frequency is 0% for African-American 
men, as reported in NCBI.  The functional consequence of SNPs detected in CCL5 is 
further perplexed by their interaction with downstream receptors. 
The biological activity mediated by CCL5 is facilitated through its interaction 
with chemokine receptors (CCR1, CCR2, CCR3, and CCR5).  However, relative to 
CCR1-3, CCR5 plays a more important role in CCL5-mediated cell migration [190]. 




protein, which is expressed by T cells and macrophages.  Over expression of CCR5 has 
been detected in aggressive prostate cancer tissue relative to benign prostatic hyperplasia 
[75].  The CCR5 rs1799988 C allele is significantly associated with viral load set point 
(i.e., decreased time from asymptomatic HIV
+
 to AIDS and increased infectiousness) and 
AIDS progression [191]; however, there are no published reports for this 5’UTR SNP in 
relation to prostate cancer or other inflammatory/immune response-related diseases.  In 
the current study, we observed a 1.52-1.75 fold increase in the risk of developing prostate 
cancer among all men of African descent who possessed the CCR5 rs1799988 CC 
genotype.  However, the impact of this SNP in relation to PCA risk was more 
pronounced among men of African descent from Jamaica relative to U.S. men.  This 
increased risk may have an impact on transcriptional activity, which may result in 
increased protein levels of CCR5; however, this requires confirmation using ex vivo, in 
vitro, and micro-dissected tumor tissue-based assays.  
 The functional consequence of intronic sequence variants, CCR6 rs3093024, 
CCR4 rs6550178 and CXCR7 rs7559855, is unknown for any cancer. However, our lab 
observed a significant 3-factor gene-gene interaction (CCR6 rs3093024-CCR4 
rs6550178-CXCR7 rs7559855) model, which was the best predictor of PCA risk among 
Jamaican men (Permutation testing p-value = 0.017) .  Although these chemokine 
sequence variants have not been studied in relation to PCA in the literature, the genes in 
which these variants reside are associated with PCA. Several published reports have 
implicated that the expression of CCR6, CCR4 and CXCR7 plays a role in prostate 
cancer progression. Ghadjar and co-workers (2008) showed the CCR6 protein was 




prostate cancer, according to gleason score (p-value = 0.003) and tumor stage (p < 
0.0005) [192].  For CXCR7, Wang and associates (2008) demonstrated that 
CXCR7/RDC1 protein expression increases gradually from PIN to localized and 
metastatic PCA [86]. CXCR7/RDC1 targets cadherin-11 and influences the expression of 
pro-angiogenic VEGF and IL8 in prostate cancer, which may contribute to tumor growth. 
In addition, CXCR7 is a direct target of hypermethylated in cancer 1 (HIC1), a gene that 
regulates proliferation migration and invasion [193]. The promoter of HIC1 is 
hypermethylated in prostate cancer cells. Restoration of HIC1 in prostate cancer cell 
lines, PC3 and C4-2B, inhibited cellular proliferation, migration and invasion via down 
regulation of MMP2/3 protein expression. A study by Derhovanessian and colleagues 
(2009) observed that hormone-resistant prostate cancer patients with IL17+ T cells 
lacking the expression of CCR4 were strongly associated with a poor prognosis [194]. 
CCR4 expression may have a protective effect against prostate cancer progression.  
The strengths, limitations and future directions were considered in relation to our 
findings on PCA susceptibility among men of African descent.  Forty-three sequence 
variants were evaluated in relation to prostate cancer risk among men of African descent 
from the U.S. and Jamaica [35].  A strong correlation between the minor allele 
frequencies between these two study populations enabled us to pool genetic data to 
identify relationships that would have remained undetected if we evaluated the 
populations separately.  As a result of pooling, we identified three SNPs (i.e., CCL5 
rs3817655, CCL5 rs2107538, CCR5 rs1799988) that were significantly associated with 
prostate cancer in the total population even after adjusting for age and multiple 




that race/ethnic specific sequence variants may track with disease progression or 
prognosis.  Consequently, future targeted sequencing will allow us to identify, evaluate 
and validate novel and commonly reported chemokine-associated SNPs as tumor 
classification and prognostication tools among African-American, Caribbean, African 
and European men.  Such efforts will require pooled data from multi-center studies that 
seek to identify the genetic signatures related to prostate cancer health disparities 
domestically and globally.  In addition, molecular biological studies are needed to 
understand the functional consequence of the CCL5 and CCR5 sequence variants on:  
mRNA expression/stability, or protein expression, structure and/or function.  This will 
require observational studies that allow us to consider lifestyle, geographical, 
environmental, or cultural differences that may interact with genetic susceptibilities and 
subsequently modify PCA outcomes.  In future studies, we will evaluate the mRNA and 
protein expression of CCL5 and CCR5 in metastatic and non-metastatic prostate cancer 
cell lines compared to normal prostate cells using qRT-PCR and western blot analysis. 
We will also examine the impact of coding and non-coding SNPs in CCL5 and CCR5 on 
cellular migration, proliferation and invasion in selected prostate cancer cell lines to 
determine the functional mechanism of selected SNPs. We will also evaluate the protein 
expression of CCL5 and CCR5 in tumor tissue collected from men of African and 
European descent to determine any unique expression profiles between ethnic groups.  
Lastly, study participants self-identified themselves as African-American, Caribbean, 
African, or Jamaican.  Population admixture, which commonly occurs among men of 
African descent, may bias risk estimates.  After adjusting risk estimates for West African 




models (data not shown).  Statistical power greater than 80% was used to observe effect 
sizes of ≥ 1.5 (or ≤ 0.67) and 1.55 (or ≤ 0.64) for the total and U.S. populations, 
respectively.  All p-values were adjusted for multiple hypotheses testing to minimize 
false positive results using the false discovery rate and Bonferroni Correction. Despite 
these efforts, we cannot rule out the possibility that the significant relationships observed 
for the U.S. (CCL5 rs3817655) and total populations (CCL5 rs2107538, CCL5 
rs3817655, CCR5 rs1799988) are suggestive and warrant further validation in larger 
studies.  Future studies in our laboratory will focus on high-throughput targeted 
sequencing to evaluate the impact of novel and commonly reported CCL5 (rs2107538, 
rs3817655) and CCR5 (rs1799988) sequence variants on PCA susceptibility and disease 
prognosis among men of African descent.  Even modest variations in genotype allele 
frequencies among men of African descent can reduce the chances of replicating single 
SNP effects within and between independent and validation study sets.  To ensure 
reproducibility within future and ongoing studies, extreme care is needed to select study 








THE IMPACT OF GENETIC VARIANTS IN INFLAMMATORY-RELATED GENES 
ON PROSTATE CANCER RISK AMONG MEN OF AFRICAN DESCENT 
 
 Although case–control studies have evaluated the role of variant inflammatory-
related loci in prostate cancer, their impact is virtually unknown among men of African 
descent. To address this, we evaluated the impact of inflammatory cytokine single 
nucleotide polymorphisms (SNPs) on prostate cancer risk for men of African descent. 
Forty-four SNPs in inflammatory cytokine-associated genes in germ-line DNA were 
evaluated among 814 African-American and Jamaican men (279 prostate cancer cases 
and 535 controls) using Illumina’s Golden gate genotyping system, logistic regression 
and entropy-based MDR. Four SNPs were modestly associated with prostate cancer after 
adjusting for age. In the total population, inheritance of the IL1R2 rs11886877 AA, 
IL8RB rs11574752 AA, TNF rs1800629 GA + AA, and TNF rs673 GA genotypes 
modestly increased prostate cancer risk by 1.45 to 11.7-fold relative to the referent 
genotype. Among U.S. men, age-adjusted dominant, recessive and additive genetic 
models for the IL1R2 rs11886877 locus were linked to an increase in prostate cancer 
susceptibility. However, these main effects did not persist after adjusting for multiple 
hypothesis testing. Our preliminary data does not strongly support the hypothesis that 
inflammatory-related sequence variants influence prostate cancer risk among men of 
African descent. However, further evaluation is needed to assess whether other variant 




progression in larger and ethnically diverse multi-center studies. Findings from our study 
will help to fill in the gaps in information pertinent to prostate cancer among men of 
African descent.  
Results 
Prevalence of inflammatory-associated sequence variants among men of African 
Descent  
 Inheritance of variant inflammatory-related loci was fairly common among 
African-American men in the current study.  Specifically, the minor allele frequencies of 
44 sequence variants ranged from 3% to 48%, as depicted in Table 8.  Notably, the 
observed genotype frequency distribution among controls did not significantly deviate 
from expected counts according to the Hardy Weinberg equilibrium. With the exception 
of three loci (IL1RN rs4251961, IL10RB rs999788, and TNF rs673), the observed 
genotype frequencies in the current study corroborated with values for individuals of 
African-American/African ancestry, reported in the NCBI’s SNP entrez Table 8 (p-value 
= 0.081-0.975).   
Relationship between inflammatory sequence variants and prostate cancer risk 
 Seven out of 44 sequence variants detected in inflammatory-related genes were 
modestly associated with prostate cancer risk among 814 men of African descent (279 
cases and 535 controls) [36].  For unadjusted risk models, elevations in prostate cancer 
susceptibility were observed among carriers of IL1R2 rs1188687 (AA, GA+AA), IL8RB 
rs11574752 (AA, GA+AA), TNF rs1800629 (GA, GA+AA), TNF rs673 (GA), IL1A 
(rs17561 AA, rs2856836 GG) and IL10RA rs4252243 AA genotypes with risk estimates 




significant after adjusting for age, namely the IL1R2 rs1188687 (AA, GA+AA), IL8RB 
rs11574752AA, and TNF rs673GA markers (Table 13a). Inheritance of IL1R2 
rs1188687 [AA (ORage-adjusted = 1.92; 95% CI = 1.11-3.32), GA+AA (ORage-adjusted = 1.46; 
95% CI = 1.01-2.10)], IL8RB rs11574752 [AA (ORage-adjusted = 38.4; 95% CI = 3.86-
382.8), recessive genetic model (ORage-adjusted = 39.2; 95% CI = 3.94-390)], TNF 
rs1800629 [GA (ORage-adjusted = 1.54; 95% CI = 1.06-2.24), GA+AA (ORage-adjusted = 1.53; 
95% CI = 1.06-2.20)] and TNF rs673 [GA (ORage-adjusted = 1.50; 95% CI = 1.04-2.16)] 
genotypes were associated with an increase in PCA risk among men of African descent 
(Table 13a). However, IL1R2 rs11886877 marker was the only genetic susceptibility 
factor that was significant under the additive genetic model, indicative of a significant 
dose-response effect in relation to the number of inherited minor allele (P-trend = 0.010). 
The aforementioned markers were not classified as important prostate cancer predictors 
after adjusting for multiple comparisons bias using the Bonferroni correction, with a 














Genotype Cases  
n (%) 












IL1R2 GG 87 (31.2) 211 (39.4)     1.00 (referent)      1.00 (referent) 0.034 0.01 NS 
rs11886877 GA 149 (53.4) 265 (49.5) 1.36 (0.99, 1.88) 1.35 (0.92,1.98) 0.058 
  
Intron 1 AA 43 (15.4) 59 (11.1) 1.77 (1.11, 2.82) 1.92 (1.11, 3.32) 0.017 
  
 
GA+AA 192 (68.8) 324 (60.6) 1.44 (1.06, 1.95) 1.46 (1.01, 2.10) 0.021 
  
 
AA vs (GG+GA) 
  
1.47 (0.96,2.24) 1.61 (0.98,2.63) 0.074 
  
IL1A CC 195 (69.9) 358 (66.9) 1.00 (referent)      1.00 (referent) 0.025 0.108 NS 
rs17561 CA 82 (29.4) 155 (29.0) 0.97 (0.70,1.34) 1.01 (0.68,1.48) 0.858 
  
Exon 4 AA 2 (0.70) 22 (4.10) 0.17 (0.04,0.72) 0.40 (0.08,1.83) 0.016 
  
Splicing CA+AA 84 (30.1) 177 (33.1) 0.87 (0.64,1.20) 0.96 (0.66,1.40) 0.388 
  
nsSNP, benign AA vs (CC+CA) 
  
0.17 (0.04,0.72) 0.40 (0.09,1.82) 0.016 
  
IL8RB GG 230 (82.4) 435 (81.3)     1.00 (referent)      1.00 (referent) 0.011 0.784 NS 
rs11574752 GA 43 (15.4) 99 (18.5) 0.82 (0.55,1.21) 0.90 (0.56,1.40) 0.326 
  




GA+AA 49 (17.6) 100 (18.7) 0.93 (0.64,1.35) 1.08 (0.69,1.70) 0.693 
  
Sanger) AA vs (GG+GA) 
  
11.7 (1.40, 98.0) 39.2 (3.94, 390) 0.008 
  
TNF GG 171 (61.2) 368 (68.8)     1.00 (referent)      1.00 (referent) 0.047 0.087 NS 
rs1800629 GA 103 (37.0) 153 (28.6) 1.45 (1.06, 1.97) 1.54 (1.06,2.24) 0.019 
  
5' near gene AA 5 (1.80) 14 (2.60) 0.77 (0.27, 2.16) 1.30 (0.37,4.60) 0.619 
  
TFBS GA+AA 108 (38.8) 167 (31.2) 1.39 (1.03,1.90) 1.53 (1.06,2.20) 0.032 
  
 
AA vs (GG+GA) 
  
0.68 (0.24,1.91) 1.13 (0.32,3.90) 0.462 
  
TNF GG 171 (61.3) 364 (68.0)     1.00 (referent)      1.00 (referent) 0.009 0.228 NS 
rs673 GA 106 (38.0) 156 (29.2) 1.45 (1.06, 2.00) 1.50 (1.04,2.16) 0.018 
  
5' near gene AA 2 (0.70) 15 (2.80) 0.28 (0.06, 1.26) 0.47 (0.09,2.40) 0.097 
  
TFBS GA+AA 108 (39.1) 171 (32.0) 1.34 (0.99, 1.82) 1.43 (1.00, 2.05) 0.055 
  
 
AA vs (GG+GA) 
  
0.25 (0.06,1.10) 0.41 (0.08,2.07) 0.067 
  
IL1A AA 196 (70.3) 358 (66.9)     1.00 (referent)      1.00 (referent) 0.024 0.089 NS 
rs2856836 AG 81 (29.0) 155 (29.0) 0.96 (0.69,1.32) 0.99 (0.67,1.45) 0.776 
  




AG+GG 83 (29.7) 177 (33.1) 0.86 (0.63,1.17) 0.94 (0.65,1.36) 0.333 
  
Sanger) GG vs (AA+AG) 
  
0.17 (0.04, 0.72) 0.40 (0.09,1.82) 0.016 
  
IL10RA GG 134 (48.4) 268 (50.4)     1.00 (referent)      1.00 (referent) 0.066 0.168 NS 
rs4252243 GA 115 (41.5) 234 (44.0) 0.98 (0.72,1.32) 0.83 (0.58,1.18) 0.893 
  
5' near gene AA 28 (10.1) 30 (5.60) 1.86 (1.07, 3.24) 1.62 (0.82, 3.21) 0.028 
  
TFBS GA+AA 143 (51.6) 264 (49.6) 1.08 (0.81,1.44) 0.91 (0.64,1.28) 0.605 
  










AA vs (GG+GA) 
  
1.88 (1.10, 3.21) 1.77 (0.91, 3.43) 0.021 
  
.
The chi-square (χ2) test p-values were used to determine the difference in the genotype frequencies between cases and controls. 
*Fisher’s p-values were calculated when expected genotype counts were <5 for either cases and controls. Significant odd ratios 
(ORs) and 95% confidence interval (CI) are indicated in boldface. Abbreviations: UTR, untranslated region; TFBS, transcription 
factor binding site; ESE exonic splicing enhancer; ESS, exonic splicing silencers; nsSNP, non-synonymous coding SNP; miRNA, 




 Upon stratification by sub-population, modestly significant prostate cancer 
predictors varied by racial/ethnic group in the unadjusted and adjusted risk models. 
Possession of the RNASEL rs1213524 AG (ORage-adjusted = 2.10; 95% CI = 1.04-4.24) 
genotype was associated with a 2.10-fold increase in the risk of developing prostate 
cancer among Jamaican men (Table 13b). However, this loci was not significant in the 
dominant, recessive or additive genetic models. Similar to the total population, 
inheritance of sequence variants in IL1R2, IL10RA and TNF among U.S. men were linked 
with an increase in prostate cancer risk. Among U.S. men, four inflammatory-related 
sequence variants, IL1R2 rs11886877 (GA, GA+AA, AA), TNF rs673 GA, TNF 
rs1800629 (GA, GA+AA), IL10RA rs4252243 AA were associated with 1.4-2.34 fold 
increase in prostate cancer risk; whereas, reductions were observed among carriers of 
IL1B rs1071676 GC+CC, IL1B rs1143634 GA+AA, and IL1A rs1800587 AA genotypes 
within unadjusted risk estimate models (p-value ≥ 0.028). Out of these 7 markers, most of 
the genetic models for the IL1R2 loci remained significant after adjusting for age. 
Possession of IL1R2 rs11886877 variant alleles under the dominant/co-dominant [AA 
(ORage-adjusted = 2.75; 95% CI = 1.38-5.50), GA+AA (ORage-adjusted = 1.82; 95% CI = 1.82-
2.88), IL1R2 rs11886877 recessive genetic (ORage-adjusted = 2.05; 95% CI = 1.10-3.80)] 
and IL10RA rs4252243 recessive genetic (ORage-adjusted = 2.49; 95% CI = 1.08-5.72) 
models were associated with an elevation in PCA susceptibility among U.S. men of 
African descent. In the stratified analysis, none of the aforementioned markers survived 
correction for multiple hypothesis testing according to the new significance level among 












Genotype Unadjusted      
OR (95%CI)          
US men 
Age-Adjusted 
OR (95%CI)          
US men 
Unadjusted      
OR (95%CI)       
Jam men 
Age-Adjusted OR 
(95%CI)          
Jam men  
χ2          
 p-value* 
US men   
χ2           
p-value*  
Jam men 




IL1B GG  1.00 (referent)  1.00 (referent)  1.00 (referent) 1.00 (referent) 0.050 0.550 0.022 0.276 
rs1071676 GC 0.72 (0.48, 1.10) 0.70 (0.42, 1.14) 1.39 (0.71, 2.70) 1.28 (0.62, 2.64) 0.124 0.338     
UTR'3 CC 0.16 (0.02, 1.25) 0.19 (0.02, 2.00) 2.02 (0.18, 22.8) 1.15 (0.10, 14.6) 0.081 0.568     
miRNA 
(miRanda,  
GC+CC 0.66 (0.44, 1.00) 0.66 (0.40, 1.10) 1.42 (0.74, 2.72) 1.26 (0.62, 2.60) 0.050 0.294     
 Sanger)  CC vs (GG+GC) 0.18 (0.02, 1.36) 0.21 (0.02, 2.18) 1.89 (0.16, 21.1) 1.10 (0.08, 13.7) 0.096 0.606     
IL1B GG 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.051 0.447 0.016 0.203 
rs1143634 GA 0.67 (0.44, 1.01) 0.65 (0.40, 1.06) 1.51 (0.76, 3.00) 1.37 (0.64, 2.90) 0.058 0.243     
Exon 4 AA 0.21 (0.02, 1.60) 0.24 (0.02, 2.86) 2.05 (0.18, 23.0) 1.16 (0.10, 14.6) 0.131 0.561     
Splicing 
(ESE/ ESS)  
GA+AA 0.63 (0.42, 0.95) 0.62 (0.38, 1.02) 1.54 (0.78, 3.00) 1.36 (0.65, 2.82) 0.028 0.208     
cds-
synonmous 
AA vs(GG+GA) 0.23 (0.02, 1.80) 0.27 (0.02, 3.20) 1.89 (0.16, 21.1) 1.10 (0.08, 13.7) 0.157 0.606     
IL1R2 GG  1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.007 0.889 0.002 0.631 
rs11886877 GA 1.60 (1.08, 2.40) 1.63 (1.00, 2.64) 0.92 (0.50, 1.68) 0.94 (0.48, 1.80) 0.020 0.782     
Intron 1 AA 2.34 (1.31, 4.16) 2.75 (1.38, 5.50) 0.82 (0.36, 1.86) 0.94 (0.38, 2.30) 0.004 0.633     
  GA+AA 1.72 (1.18, 2.52) 1.82 (1.14, 2.88) 0.89 (0.50, 1.58) 0.94 (0.50, 1.74) 0.005 0.700     
  AA vs (GG+GA) 1.76 (1.04, 2.96) 2.05 (1.10, 3.80) 0.86 (0.40, 1.80) 0.97 (0.43, 2.20) 0.033 0.691     
RNASEL AA  1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.820 0.025 0.909 0.216 
rs12135247 AG 1.06 (0.72, 1.58) 1.14 (0.71, 1.84) 2.17 (1.14, 4.12) 2.10 (1.04, 4.24) 0.756 0.018     
UTR'3 GG 0.77 (0.30, 1.96) 0.70 (0.24, 2.10) 0.45 (0.08, 2.40) 0.28 (0.04, 1.70) 0.570 0.344     
TFBS, 
miRNA  
AG+GG 1.02 (0.70, 1.50) 1.07 (0.68, 1.68) 1.81 (0.99, 3.30) 1.68 (0.88, 3.24) 0.906 0.053     
 
GG vs (AG+AA) 0.76 (0.30, 1.92) 0.67 (0.22, 1.97) 0.36 (0.06, 1.91) 0.22 (0.04, 1.35) 0.555 0.232     
TNF GG  1.00 (referent) 1.00 (referent)  1.00 (referent) 1.00 (referent) 0.101 0.782 0.113 0.549 
rs1800629 GA 1.50 (1.03, 2.20) 1.52 (0.96, 2.42) 1.21 (0.68, 2.12) 1.41 (0.78, 2.63) 0.034 0.518     
5' near gene AA 0.90 (0.28, 2.80) 1.51 (0.36, 6.24) 1.00 (0.06, 16.3) 1.00 (0.06, 17.2) 0.842 1.000     
TFBS GA+AA 1.44 (0.99, 2.10) 1.53 (0.97, 2.40) 1.20 (0.68, 2.10) 1.40 (0.75, 2.60) 0.050 0.525     
  AA vs (GG+GA) 0.78 (0.25, 2.42) 1.32 (0.32, 5.40) 0.94 (0.06, 15.2) 0.88 (0.05, 15.0) 0.666 0.962     
IL1A GG  1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.088 0.450 0.028 0.224 
rs1800587 GA 0.75 (0.50, 1.10) 0.68 (0.42, 1.08) 1.38 (0.76, 2.50) 1.42 (0.74, 2.72) 0.119 0.297     
UTR'5 AA 0.56 (0.32, 0.96) 0.78 (0.40, 1.53) 1.56 (0.69, 3.50) 1.64 (0.70, 4.00) 0.038 0.279     
TFBS, 
Splicing  
GA+AA 0.70 (0.48, 1.00) 0.70 (0.45, 1.10) 1.42 (0.80, 2.50) 1.47 (0.80, 2.72) 0.053 0.222     
(ESE or ESS) AA vs (GG+GA) 0.66 (0.40, 1.10) 0.96 (0.52, 1.80) 1.30 (0.62, 2.70) 1.34 (0.60, 3.00) 0.105 0.478     
IL10RA GG 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.062 0.632 0.275 0.329 
rs4252243 GA 0.92 (0.63, 1.33) 0.70 (0.44, 1.10) 1.24 (0.70, 2.20) 1.21 (0.64, 2.28) 0.648 0.448     
5' near gene AA 2.02 (1.04, 3.95) 2.10 (0.90, 4.98) 1.50 (0.54, 4.26) 1.04 (0.34, 3.20) 0.038 0.436     
TFBS GA+AA 1.03 (0.72, 1.50) 0.81 (0.52, 1.30) 1.28 (0.74, 2.21) 1.15 (0.64, 2.10) 0.863 0.328     
  AA vs (GG+GA) 2.11 (1.10, 4.02) 2.49 (1.08, 5.72) 1.37 (0.50, 3.74) 1.02 (0.40, 2.98) 0.023 0.539     
TNF GG 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.027 0.452 0.279 0.874 
rs673 GA 1.50 (1.02, 2.20) 1.46 (0.92, 2.30) 1.22 (0.70, 2.14) 1.41 (0.76, 2.62) 0.025 0.498     









5' near gene AA 0.24 (0.03, 1.84) 0.54 (0.06, 4.44) 0.33 (0.03, 3.24) 0.40 (0.03, 4.70) 0.178 0.340     
TFBS GA+AA 1.38 (0.95, 2.00) 1.40 (0.88, 2.20) 1.14 (0.66, 2.00) 1.33 (0.72, 2.46) 0.087 0.635     
  AA vs (GG+GA) 0.21 (0.02, 1.60) 0.47 (0.06, 3.91) 0.31 (0.03, 2.98) 0.35 (0.03, 4.08) 0.132 0.308     
The chi-square (χ
2)
 test p-values were used to determine the difference in the genotype frequencies between cases and controls.  
*Fisher’s p-values were calculated when expected genotype counts were <5 for either cases and controls. Significant odd ratios (ORs) and 95% 
confidence interval (CI) are indicated in boldface. Abbreviations: UTR, untranslated region; TFBS, transcription factor binding site; ESE exonic 




Analysis of gene-gene interactions using Multi-factor Dimensionality Reduction 
                MDR analyses revealed that the one-, two- and three-factor interaction models 
survived multiple hypothesis testing with a 90-100% CVC and a 58-61% ATA values 
among men of African descent, as shown in Table 14a (Permutation p-value=0.001-
0.013). TNF rs673 was selected as the best one-factor model among men of African 
descent, based on the highest information gain score relative to the other cytokine-
associated sequence variants (IG = 2.08%)  (Figure 12). For the two-factor interaction 
model (IL10RA rs4252243, IL10RB rs8178433), the MDR entropy-based graph revealed 
no informative pairwise mutual information gain score for the interaction (Figure 12). 
The three-factor gene-gene interaction model (IL1R2 rs11886877, IL10 rs1800896, 
IL10RA rs4252243) was selected as the best predictor of PCA susceptibility among men 
of African descent based on its association with the highest ATA value (ATA = 61%). 
This three-factor interaction model was primarily driven by a highly synergistic (red line) 
pairwise interaction between IL10 and IL1R2 associated with a mutual information gain 
score of 0.86%.  This pairwise interaction was more informative than each individual 
SNP when considered alone  (Figure 12).  
Upon stratification by ethnic group, the one- and three-factor interaction models 
were statistically significant with 100% CVC and 60-67% ATA values among U.S. men 
(Permutation testing p-value = 0.001-0.005) (Table 14b).  IL10 rs4252243 was selected 
as the best one-factor predictor of prostate cancer, based on a 100% CVC and 59.7% 
ATA.  Perhaps MDR allows us to detect important prostate cancer predictors that we 
were unable to observe under the Bonferroni adjusted LR models.  The three-factor 




the best predictor of PCA risk due to its high CVC value of 100% and ATA score of 67% 
among U.S. men (Permutation testing p-value = 0.001). The synergy of this interaction 
model was driven by a highly synergistic interaction between IL1B rs1143627 and IL1A 
rs1800587 with an informative IG score of 1.93% (Data not shown). Among Jamaican 
men, the two-factor (IL1RN rs315951 and IL1R1 rs949963) interaction model associated 
with a 100% CVC value and 65% ATA score remained significant after adjustment for 
multiple hypothesis testing (Permutation testing p-value = 0.008).  This two-factor 
interaction model was highly synergistic due to its informative pairwise mutual 



















Table 14a. Interactions and main effects of Inflammatory-associated SNPs as predictors 
of PCA using age-adjusted MDR among men of African Descent. 
Best Model 










Testing               
p –value 
One Factor        
TNF rs673 44 10/10 0.580 0.001 
Two Factor        
IL10RA rs4252243  946 9/10 0.598 0.013 
IL10RB rs8178433        
Three Factor        
IL1R2 rs11886877  13,244 9/10 0.610 0.003 
IL10 rs1800896        














*Analysis was restricted to 279 cases and 535 controls. Interaction models were adjusted 













Figure 12. Entropy graph of Cytokine gene-gene interactions among U.S. and 
Jamaican men of African Descent. MDR analysis revealed that 1-, 2- and 3-factor 
interaction models survived multiple hypothesis testing with a 90-100% CVC and 
58-61% ATA values (Permutation p-value=0.001-0.013). The three-factor gene-
gene interaction model (IL1R2 rs11886877, IL10 rs1800896, IL10RA rs4252243) 
was the best predictor of PCA risk among men of African descent. The synergy of 
this model was based on interaction information gain score of 0.86% for IL10 and 




Table 14b. Interactions and main effects of Inflammatory-associated SNPs as predictors 
of PCA using age-adjusted MDR among U.S. men of African Descent. 
Best Model 










Testing                
p-value 
One Factor        
IL10RA rs4252243 44 10/10 0.597 0.005 
Two Factor        
IL10RA rs4252243  946 10/10 0.627 0.084 
IL10RB rs8178433        
Three Factor        
IL1B rs1143627 13,244 10/10 0.665 0.001 
IL1A rs1800587        
















*Analysis was restricted to 279 cases and 535 controls. Interaction models were 




Table 14c. Interactions and main effects of Inflammatory-associated SNPs as predictors 
of PCA using age-adjusted MDR among Jamaican men of African Descent. 
Best Model 










Testing               
p-value 
One Factor        
IL1R2 rs4141134 44 10/10 0.577 0.243 
Two Factor        
IL1RN rs315951  946 10/10 0.653 0.008 
IL1R1 rs949963         
Three Factor        
IL1A rs1304037  13,244 10/10 0.657 0.060 
IL10 rs1800872        

















*Analysis was restricted to 279 cases and 535 controls. Interaction models were 





Chronic inflammation has been associated with tumor development and 
metastasis in cancer progression.  Inflammatory response is regulated through a complex 
network of cytokines, cytokine receptors and downstream targets that synergistically 
regulate innate/humoral immune and inflammatory processes. Recent molecular and 
genetic epidemiology studies have demonstrated that chronic inflammation and 
susceptibilities in inflammatory-associated genes are related to aggressive cancer 
phenotypes, including lymphoma, and gastric and prostate cancer [101, 122, 195-197]. 
However, to our knowledge, there are limited published reports on the impact of 
inheriting multiple cytokine-related functional sequence variants in relation to prostate 
cancer among men of African Descent.  Therefore, our current study evaluated the 
individual and combined effects of 44 inflammatory associated sequence variants on 
prostate cancer risk among 279 cases and 535 disease-free men of African descent from 
the U.S and Jamaica [36]. Cytokine-associated sequence variants (IL1R2 rs11886877 
AA, IL10RA rs4252243 AA) were associated with a 2.11-2.34-fold increase in risk of 
developing prostate cancer among men of Descent from the U.S. However, these 
sequence variants did not survive multiple hypothesis testing. MDR analysis revealed 
significant and highly synergistic age adjusted two-factor (IL10RB rs8178433 and 
IL10RA rs4252243) pairwise and three-factor (IL1R2 rs11886877, IL10 rs1800896, 
IL10RA rs4252243) interaction models  associated with prostate cancer risk among  men 
of African descent. Nevertheless, the three-factor interaction was selected as the overall 
best predictor of prostate cancer susceptibility among men of African based upon an 




 Our findings show a modest increase in prostate cancer risk for unadjusted and 
adjusted logistic regression models for IL1R2 rs11886877 among men of African descent. 
Although this sequence variant did not survive multiple hypothesis testing, the additive, 
dominant and recessive genetic models of this variant were significant. The IL1R2 
rs11886877 SNP is located 2415 base pairs from the transcription start site. Its close 
proximity to the regulatory region of the IL1R2 gene suggests it may have a high 
likelihood of regulating IL1R2 gene expression. Currently, there are no published reports 
on the relationship between IL1R2 rs11886877 and prostate cancer for any population. 
Although there is no evidence of the impact of this sequence variant on prostate cancer 
risk among European- and African-American men, the relationship between the IL1R2 
gene expression and prostate cancer has been demonstrated through published reports 
[140, 198, 199].  However, Ricote and colleagues (2004) observed high protein 
expression of IL1R2 in high and low gleason score prostatic tumor tissue compared to 
normal prostatic tissue [140]. The study findings suggest that high expression of IL1R2 is 
in result of the absence of IL1Ra (antagonist of IL1) to mute the pro-inflammatory effect 
of IL1α in prostate cancer. However, IL1α does not have a high affinity to bind to IL1R2. 
Additionally, other studies also suggest that IL1R2 may function as a decoy receptor or 
natural inhibitor of IL1 [139, 140].  Moreover, Leshem and colleagues found that the 
promoter region of IL1R2 possesses putative binding motifs for the TMPRSS2/ERG 
fusion gene, which is highly expressed in aggressive prostate cancer [198]. When the 
expression of IL1R2 was knocked down using small interfering RNAs, it resulted in the 
reduction of ZEB2 mRNA expression in hTERT/shp53/CyclinD-CDK4 overexpressing 




regulates ZEB2, a facilitator of the epithelial to mesechymal transition (EMT), by binding 
to IL1R2 to increase prostate cancer tumorigenesis [200]. Further investigation of IL1R2 
in relation to PCA risk is needed to determine the effect of IL1R2 expression on prostate 
cancer tumorigenesis. 
 Additionally, MDR analyses revealed other inflammatory-related sequence 
variants associated with PCA susceptibility. Within a three-factor interaction model, the 
inheritance of IL1R2 rs11886877 combined with IL10 rs1800896 and IL10RA rs4252243 
was significantly associated with PCA susceptibility based upon an informative IG of 
0.86% for the pairwise interaction (IL1R2 rs11886877, IL10 rs1800896), individual IG 
score of 1.26% (IL10RA rs4252243) and ATA score of 61% among men of African 
descent. IL10 is a major anti-inflammatory cytokine and IL10RA (interleukin 10 receptor 
alpha) is a known mediator of its signaling in immunosuppression. For instance, Stearns 
and associates (2003) observed that IL10 treatment down-regulates the gene and protein 
expression of MMP2 and membrane type 1 MMP in non-immortalized primary prostate 
cancer cells (HPCA-10c) via its receptor IL10R [201]. Moreover, Cardillo and colleagues 
(2006) observed an increase in the protein expression of IL10 in the epithelium of 
prostatic tissue compared to normal prostatic tissue [202]. Based upon LR modeling, the 
inheritance of IL10 rs1800896 and IL10RA rs425224 was associated with a marginal 
increase in PCA susceptibility among men of African from the U.S. men. This increase in 
PCA risk may be attributed to these genetic alterations within these genes (IL10 and 
IL10RA), which can impair gene function of these anti-inflammatory cytokines.  
Out of 44 inflammatory-related sequence variants, 7 SNPs included in our study 




observational studies [121, 122, 125, 126]. Commensurate with our findings, two 
observational studies demonstrated that sequence variants detected in IL10 (rs1800871, 
rs1800872) and IL8 rs4073 were not significantly related to prostate cancer risk [122, 
126]. Inheritance of TNF rs1800629 AA genotype was associated with a significant 1.8 
fold increase in prostate cancer risk among North Indian men in a small study (150 cases, 
150 controls); however, this marker resulted in null findings in a larger study (484 cases, 
484 controls) [121, 122]. In our preliminary analyses inheritance of one or more TNF 
rs1800629 A alleles was marginally associated with a 1.5-fold increase in prostate risk; 
however, this relationship did not survive adjustment after multiple hypothesis testing. 
Lastly, IL10 rs1800896 G and IL1B rs1143627 C alleles had protective effects in two 
separate Caucasian sub-populations. However, neither of these markers served as 
important prostate cancer predictors among African American men in the current study. 
Casey and colleagues (2002) showed a 2-fold increase in prostate cancer susceptibility 
linked to inheritance of the RNASEL rs486907 AA genotype among men of European 
descent [125]. However, this loci was not related to prostate cancer risk among African 
Americans in the current study. This may be due to differences in minor allele 
frequencies, prevalence of the sequence variants, environment exposures, failure to adjust 
findings for multiple hypothesis testing or inadequate sample size.  
We considered the strengths, limitations and future directions of our study. Forty-
four sequence variants were evaluated in relation to prostate cancer risk among men of 
African descent from the U.S. and Jamaica. Upon stratification by study center, we 
identified race/ethnicity specific inflammatory-associated sequence variants associated 




not show a robust relationship with prostate cancer susceptibility. Population admixture, 
which commonly occurs among men of African descent, may bias risk estimates. 
However, adjustment of risk estimates by West African Ancestry and/or age did not 
modify the directionality of observed risk estimates among men from the U.S. (Data not 
shown). Although, the sample statistical size of this study population is small, we ensured 
that we had ample power to accurately detect risk estimates. Our findings do not support 
the hypothesis that inflammatory related sequence variants are associated with prostate 
cancer among men of African descent. However, we cannot eliminate the possibility that 
IL1R2 and other inflammatory-related sequence variants not included in this study may 
influence the risk of prostate cancer development or aggressive tumor behavior. In larger 
studies, the impact of individual or interaction between inflammatory cytokine-associated 
SNPs in relation to prostate cancer tumor grade, biochemical or disease recurrence, and 
mortality will undergo evaluation using targeted sequencing, in vitro studies, in silico and 
bioinformatics tools.  Such efforts will help to identify genetic markers linked to 
disproportionately high prostate cancer incidence, mortality, and morbidity rates among 







CONCLUSION AND SUMMARY  
The literature on the contribution of chronic inflammation to prostate cancer 
(PCA) development and progression has increasingly grown over the past decade. Many 
reports discuss how inflammatory-related genes (e.g., TLRs, chemokines, cytokines) and 
genetic alterations of these genes play a pivotal role in PCA pathogenesis.  Toll-like 
receptors (TLRs), which are major mediators in innate immunity serve as a surveillance 
system. In the presence of pathogens, TLRs are activated and trigger the inflammatory 
response via innate immunity. Inflammation is a critical response in innate immunity that 
leads to tissue repair and attracts innate immune cells via production of 
cytokines/chemokines. Repetitive damage to prostatic tissue leads to chronic 
inflammation in the prostate. Genetic polymorphisms within the inflammatory and 
immune response pathway may lead to an imbalance in pro-and anti- inflammatory 
signals and result in prolonged chronic inflammation. Some inflammatory and immune 
response related sequence variants have been previously studied in relation to PCA risk; 
however, most of these studies focus on European and Asian sub-populations. 
Furthermore, the contribution of gene-gene interactions on PCA susceptibility has not 
been well studied. Failure to include gene-gene interactions may greatly limit the 
detection of markers that influence PCA susceptibility. 
To address these gaps in the literature, we evaluated 119 single nucleotide 




TLRs, chemokines and cytokines) among men of African descent [31, 35, 36 ].  
Logistic regression (LR) analyses did not reveal any significant associations with PCA 
susceptibility that survived multiple hypothesis testing among toll-like receptor -related 
sequence variants. Interestingly after adjustment for multiple hypothesis testing of LR 
models, possession of CCL5 (rs2107538, rs3817655), CCR5 rs1799988 and IL1R2 
rs11886877 sequence variants were strongly and/or marginally associated with PCA 
susceptibility among men of African descent. CCL5 [(rs2107538 (GA, AA), rs3817655 
(GA, AA)] genotypes showed a decrease in PCA risk, primarily driven by the U.S. 
population. However, the variant alleles of IL1R2 rs11886877 A and CCR5 rs1799988 G 
were associated with an increase in PCA susceptibility among men of African descent. 
Among the inflammatory and immune response associated gene-gene 
interactions, we observed several highly synergistic interactions. A highly synergistic 
three-factor (TLR10 rs11096957, TLR6 rs2381289 and IRF3 rs2304206) interaction 
model was observed with a high CVC value and ATA score among men of African 
descent from the U.S. and Jamaica (Permutation testing p-value = 0.001).  Additionally, 
this three-factor interaction model was the best predictor of PCA risk was primarily 
driven by pairwise interaction between TLR10 rs11096957 and IRF3 rs2304206 (IG = 
1.32%) and the main effect of TLR6 rs2381289 (IG = 1.71%) .  Among U.S. men, the 
two-factor (TLR2 rs1898830, IRAK4 rs4251545) interaction model was selected as the 
best predictor of PCA risk, based on an informative pairwise mutual  IG score (IG =  
2.33%) that exceeded main effects (Permutation testing p-value = 0.001). Chemokine 
associated interactions resulted in a three-factor (CCR6 rs3093024, CXCR7 rs7559855, 




Jamaican men (ATA = 70.4%; Permutation testing p-value = 0.017). The synergy of this 
interaction model was primarily based upon the informative pairwise mutual interaction 
information gain score between CCR6 rs309302 and CXCR7 rs7559855 (IG = 3.41%) 
and the main effect of CCR4 rs6550178 (IG = 8.2%) . Lastly, cytokine-associated 
interaction models yielded a highly synergistic three-factor (IL1R2 rs11886877, IL10 
rs1800896, IL10RA rs4252243) interaction model, primarily driven by IL10RA 
rs4252243 (IG = 1.26%) coupled with the IL1R2 rs11886877 -IL10 rs1800896  axis (IG 
= 0.86%) among men of African (ATA = 61% ; Permutation testing p-value = 0.003).  
Collectively, our findings suggest that the inheritance of main  [CCL5 (rs2107538, 
rs3817655), IL1R2 rs11886877] and joint [(TLR10 rs11096957, TLR6 rs2381289, and  
IRF3 rs2304206),  (TLR2 rs1898830, IRAK4 rs4251545), (CCR6 rs3093024, CXCR7 
rs7559855, and CCR4 rs6550178)] effects  modify the PCA susceptibility  among men of 
African descent.   
Further investigation of these sequence variants will further elucidate the role of 
inflammatory and immune response-related genes on PCA development and aggressive 
phenotype associated with men of African descent. Future studies will evaluate the 
following:  (1) the impact of CCL5, CCR5 and IL1R2 expression on prostate cancer 
tumorigenesis via knockout and/or knockin in vitro and in vivo models; and (2) the 
association of inflammatory and immune response-associated sequence variants  in 
relation to PCA tumor grade, biochemical or disease recurrence, and  mortality among 





In the U.S., 17% of men will develop PCA in their lifetime. Once PCA 
metastasizes, it is associated with a 5 year survival rate of 29%. Current conventional 
therapies are not very effective against PCA metastatic disease. Moreover, African-
American and Caribbean men are disproportionately affected by this disease compared to 
their European-American counterparts. Therefore, it is imperative that we study the 
biological underpinnings responsible for PCA development and progression.  Our 
published reports evaluated the contribution of genetic alterations in the inflammatory 
and immune response pathway to PCA development. The investigation of sequence 
variants within inflammatory and immune response-associated genes involved in prostate 
cancer will help to improve the overall detection, prognosis, diagnosis, and clinical 
management of PCA among men. For clinicians and physicians, the prostate serum 
antigen (PSA) test and DRE (digital rectum exam) are unreliable PCA screening 
prognostication tools. Infact, the U.S. Preventive Services Task Force (USPSTF) and 
American Urological Association (AUA) highly recommend against the use of the PSA 
test for PCA detection due to its lack of specificity and sensitivity. Moreover, PCA 
detection cannot solely depend on DRE findings, since this test must always be 
performed in combination with another test. Consequently, clinicians and physicians are 
unable to make reliable PCA prognostic and diagnostic decisions for patients without the 
use of invasive procedures such as prostate biopsies.  Even after dozens of painful needle 
core biopsies, tumors may still remain undetected.  As a result of the USPSTF’s and 
AUA’s recommendations, many clinicians and urologists have experienced a significant 
loss financially due to their inability to highly recommend the PSA test to their patients. 




aggressive phenotype may serve as a potential solution to the issues associated the PSA 
test. These genetic alterations will help in the design of PCA specific genetic marker 
(SNP) panels and therapeutic agents against PCA metastatic disease. Clinicians and 
physicians may use these panels as non-invasive PCA prognostic and/or diagnostic tools 
to determine disk risk due to the high detectability of SNPs in DNA isolated from human 
blood specimens. Sequence may replace the PSA test and DRE as robust and reliable 
screening tools for PCA detection.  Ultimately, genetic markers may improve personalize 
medicine and explain the disproportionate effect on prostate cancer incidence, mortality, 
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